Document:

Form of Developement, License and Commercialization Agreement

 EXHIBIT 10.219 
 EXECUTION COPY 
 September 25, 2008 
 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION 
 DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT 
 by and between 

INDEVUS PHARMACEUTICALS, INC. 
 and

 TEVA PHARMACEUTICAL INDUSTRIES LTD. 

 TABLE OF CONTENTS 
  

			
	 	  	Page
	 ARTICLE 1 DEFINITIONS
	  	1
		
	 ARTICLE 2 GRANT OF RIGHTS
	  	19
		
	 ARTICLE 3 GOVERNANCE
	  	22
		
	 ARTICLE 4 TRANSITION; DEVELOPMENT AND COMMERCIALIZATION
	  	25
		
	 ARTICLE 5 PAYMENTS AND STATEMENTS
	  	37
		
	 ARTICLE 6 REPRESENTATIONS AND WARRANTIES
	  	46
		
	 ARTICLE 7 PATENT MATTERS
	  	49
		
	 ARTICLE 8 CONFIDENTIALITY AND PUBLICITY
	  	55
		
	 ARTICLE 9 TERM AND TERMINATION
	  	58
		
	 ARTICLE 10 INDEMNIFICATION AND INSURANCE
	  	64
		
	 ARTICLE 11 MISCELLANEOUS
	  	68

 THIS DEVELOPMENT, LICENSE AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is made as of
September 25, 2008 (“Agreement Date”), by and between INDEVUS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware and having its principal office at 33 Hayden Avenue, Lexington,
MA 02421, United States (“Indevus”) and TEVA PHARMACEUTICAL INDUSTRIES LTD., a limited liability company existing under the laws of Israel and having its principal office at Petah Tiqva 49131, Israel (“Teva”). 

B A C K G R O U N D: 
 Indevus owns
or Controls the Indevus Intellectual Property relating to Compound for the treatment of stuttering; 
 Teva and its Affiliates have
significant experience in the development, marketing, promotion and sale of pharmaceutical products, and Teva desires to obtain on the Effective Date the exclusive worldwide right and license in the Territory under the Indevus Intellectual Property
to further develop and thereafter Commercialize the Product for all possible indications in the Field (including for stuttering) and Indevus desires to grant to Teva on the Effective Date such exclusive worldwide right and license, on and subject to
the terms and conditions set forth herein; and 
 Indevus and Teva desire to conduct certain Development for the U.S. market, all on and
subject to the terms and conditions set forth below. 
 NOW, THEREFORE, in consideration of the mutual representations, warranties and
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 Unless specifically set forth to the contrary herein, the following terms, where used in the singular or plural, shall have the respective meanings set
forth below: 
 1.1 “Act” means the United States Food, Drug, and Cosmetic Act of 1938, as amended, and the rules and
regulations promulgated thereunder, or any successor act, as the same shall be in effect from time to time. 
  

 1 

 1.2 “Affiliate” means with respect to a Party (i) any corporation or business
entity of which more than fifty percent (50%) of the securities or other ownership interests representing the equity, the voting stock or general partnership interest are owned, controlled or held, directly or indirectly, by such Party;
(ii) any corporation or business entity which, directly or indirectly, owns, controls or holds more than fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing
the equity, voting stock or general partnership interest of such Party; (iii) any corporation or business entity of which, directly or indirectly, an entity described in the immediately preceding subsection (ii) controls or holds more than
fifty percent (50%) (or the maximum ownership interest permitted by law) of the securities or other ownership interests representing the equity, voting stock or general partnership interest of such corporation or entity; or (iv) any
corporation or business entity of which such Party has the right to acquire, directly or indirectly, more than fifty percent (50%) of the securities or other ownership interests representing the equity, voting stock or general partnership
interest thereof. 
 1.3 “Agreement Date” has the meaning set forth in the preamble hereof. 
 1.4 “Agreement Term” has the meaning set forth in Section 9.1(a). 
 1.5 “Authorized Generic Product” has the meaning set forth in Section 2.4. 
 1.6 “Authorized Generic Royalty Term” means, in each country in the Territory, the period commencing on the date of First Commercial
Sale of an Authorized Generic Product in the applicable country and expiring on the date of First Commercial Sale of the [***] Generic Product in such country. 
 1.7 “Bankruptcy Code” has the meaning set forth in Section 9.3. 
 1.8
“Breaching Party” has the meaning set forth in Section 9.2(b)(i). 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 2 

 1.9 “Business Day” means any calendar day, except that if an activity to be performed or
an event to occur falls on a Friday, Saturday, Sunday or a day which is recognized as a national holiday in the place of performance of an applicable activity or occurrence of an applicable event, then the activity may be performed or the event may
occur on the next day that is not a Friday, Saturday, Sunday or nationally recognized holiday. 
 1.10 “Calendar Quarter”
means for each Calendar Year, each of the three month periods ending March 31, June 30, September 30 and December 31; provided, however, that (a) the last Calendar Quarter of the U.S. Collaboration
Period shall commence on the first day of the Calendar Quarter in which the U.S. Collaboration Period terminated and expire on the effective date of termination of the U.S. Collaboration Period, (b) the first Calendar Quarter of the Royalty
Term for the United States shall commence on the first day of the U.S. License Period and expire at the end of the Calendar Quarter in which the U.S License Period commenced, (c) the first Calendar Quarter of any other period specified under
this Agreement shall extend from the commencement of such period to the end of the first complete Calendar Quarter thereafter; and (d) the last Calendar Quarter shall end upon the expiration or termination of this Agreement. 
 1.11 “Calendar Year” means, for the first Calendar Year, the period commencing on the Effective Date and ending on December 31,
2008, and for each year thereafter, each successive period beginning on January 1 and ending twelve (12) consecutive calendar months later on December 31. 
 1.12 “C.F.R.” means the United States Code of Federal Regulations, as amended from time to time. 
 1.13 “Change of Control” means with respect to a Party, the occurrence of any of the following: 
 (a) any Third
Party that was not, on the Effective Date, the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the voting equity of such Party becomes (after the Effective Date) the beneficial owner, directly or indirectly, of
more than fifty percent (50%) of the voting equity of such Party whether as a result of issuances, redemptions, repurchases or transfers of voting equity or otherwise; or 
  

 3 

 (b) such Party consolidates with, or merges with or into, a Third Party or sells, assigns, conveys,
transfers, leases or otherwise disposes of all, or substantially all, of its assets to a Third Party, or a Third Party consolidates with, or merges with or into, such Party, in any such event pursuant to a transaction in which the outstanding voting
equity of such Party is converted into or exchanged for cash, securities, equity interests or other property and immediately after such transaction the persons who were the beneficial owners of the outstanding voting equity of such Party immediately
prior to the transaction are not the beneficial owners, directly or indirectly, of more than fifty percent (50%) of the total voting equity of the surviving or transferee entity. 
 For purposes of this Agreement, any such Third Party or surviving or transferee entity resulting from any of the foregoing is referred to as a “Successor Entity” of the applicable Party. 

1.14 “Claims” has the meaning set forth in Section 10.2. 
 1.15 “Clinical Data Review” has the meaning set forth in Schedule 1.64(a). 
 1.16 “Clinical Studies” means any clinical studies of Product conducted on humans. 
 1.17 “Commercialization” and “Commercialize” means those activities undertaken with respect to the commercialization of
Product, including promotion, marketing, sale, supply, manufacturing, purchasing, procurement, warehousing, import, export, distribution, educational activities, post-approval Clinical Study activities and pre-launch activities. 
 1.18 “Commercially Reasonable Efforts” means exerting such efforts and employing such resources as would normally be exerted or employed
by the applicable Party for its other drug candidates and pharmaceutical products of a comparable stage of development and commercial potential, taking into account the cost effectiveness of efforts or resources, the competitiveness of alternative
compounds or products that are or are expected to be in the marketplace, the patent and other proprietary position of the compound or product, the profitability of the compound or product and alternative compounds or products and other relevant
commercial factors. 
  

 4 

 1.19 “Competing Product” means any pharmaceutical product that is approved by the
applicable Regulatory Authority with a labeled indication for stuttering. 
 1.20 “Compound” means [***] or
pagoclone, as diagrammed on Schedule 1.20 and any pharmaceutically acceptable salts, hydrates, solvates, metabolites, enantiomers, amides, prodrugs and esters of the foregoing, or mixtures thereof. 
 1.21 “Control” means possession of the ability to grant a license or sublicense as provided for herein without violating the terms of
any agreement or arrangement with any Third Party. 
 1.22 “CSC” means the Central Steering Committee formed by the Parties
in accordance with Article 3. 
 1.23 “Data” means any and all research data, pharmacology data, preclinical data, clinical
data, Chemistry, Manufacturing and Control (“CMC”) data and/or all other similar documentation generated in connection with the Compound or Product. 
 1.24 “Data Management Plan” has the meaning set forth in Schedule 1.64(a). 
 1.25
“Database Lock” means, with respect to the Next Trial, the stage in which the clinical trial database is ready for code opening and analysis of the trial results, as described in Schedule 1.64(a). 
 1.26 “Decision Point” means any date on which the following events occur during the U.S. Collaboration Period: 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 5 

 [***] 
 1.27 “Development” means those activities undertaken with respect to the Compound or Product which are devoted to the exploration of a potential pharmaceutical product, including Clinical Studies and
any other activities directed toward quality issues, publication, or as part of the process of obtaining Regulatory Approval of such Compound or Product. 
 1.28 “Disputed Claim” has the meaning set forth in Section 10.4(b). 
 1.29
“Dollar” or “$” means the lawful currency of the United States. 
 1.30 “Drug Approval
Application” means an application for Regulatory Approval required before commercial sale or use of a Product as a pharmaceutical product in a regulatory jurisdiction. 
 1.31 “Effective Date” means the date on which the waiting period, if any, under the HSR Act with respect to the transactions
contemplated hereunder has expired or has been terminated. 
 1.32 “EMEA” means the European Medicines Agency and any
successor agency thereof having substantially the same functions or, if the mutual recognition procedure is used for the Product in the EU, any governmental authority having the authority to regulate the sale of medicinal or pharmaceutical products
in any country in the EU. 
 1.33 “End-of-Phase II Meeting” means Teva’s meeting with the FDA consistent with 21 C.F.R.
Section 312.47(b)(1). 
 1.34 “EU” means all countries that are member states of the European Union at any time during
the Agreement Term. 
 1.35 “EU Major Market” means any one of the following countries: United Kingdom, France, Germany,
Italy or Spain. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 6 

 1.36 “FDA” means the Food and Drug Administration of the United States Department of
Health and Human Services and any successor agency having substantially the same functions. 
 1.37 “FDA Approval” means all
authorizations by the FDA which are required for the marketing of a Product in the United States as defined in 21 C.F.R. Section 314.105. 
 1.38 “Field” means the prevention, diagnosis or treatment of any disease or medical condition in humans. 
 1.39
“First Commercial Sale” means the first sale to a Third Party for end use or consumption of an applicable product in a country after receipt of Regulatory Approval in such country or, where Regulatory Approval is not required, then
the first sale for end use or consumption of a product to a Third Party in that country in connection with the nationwide introduction of such product. 
 1.40 “First Period Plan and Budget” means the plan setting forth (a) activities and estimated timelines relating to Development and Commercialization throughout the Territory, including a
description of activities designed to generate clinical, manufacturing and regulatory information required for filing the first NDA in the United States, and (b) the budget setting forth costs estimated to be incurred in performing such
activities (the “First Period Budget Costs”), both in the aggregate and by Calendar Year, for the period commencing on the date Teva issues the Go Decision and ending on the date that is forecasted therein for the submission of the
first NDA for the initial indication of Product (the “First Period Plan and Budget Period”), submitted by Teva to Indevus pursuant to Section 4.4(c)(i), and all revisions, amendments or updates thereto submitted by Teva to
Indevus pursuant to Section 4.4(c)(ii). First Period Budget Costs shall include the external out-of-pocket costs and expenses incurred by and on behalf of Teva and its Affiliates and the costs of such activities performed by Teva’s FTEs,
valued at the then current Teva FTE reimbursement rate, and consistent with Schedule 1.40, but shall exclude any costs and expenses incurred for (x) Development activities conducted solely for Regulatory Approval outside the United
States, and (y) Commercialization activities conducted solely for markets outside the United States. 
  

 7 

 1.41 “GAAP” means generally accepted accounting principles in the United States,
consistently applied. 
 1.42 “Generic Competition” shall be deemed to exist in a particular country as of any date if,
during the [***] immediately preceding Calendar Quarters, (a) Generic Products have a market share in the applicable country of at least [***] of the then combined unit volume of Product and Generic Products, or (b) after the
introduction of a Generic Product, Net Sales of Product decrease by at least [***], provided that each of (a) and (b) herein shall be measured as an average taken over such [***] Calendar Quarters. If such
market share or such decrease in Net Sales of Product is greater than [***] during the [***] immediately preceding Calendar Quarters in any country, similarly measured as an average taken over such [***] Calendar Quarters, then
“Substantial Level Generic Competition” shall be deemed to exist in such country as of such date. 
 1.43 “Generic
Product” means any product containing the Compound as an active ingredient sold by a Third Party (excluding, for these purposes, sublicensees of Teva). 
 1.44 “Go Decision” has the meaning set forth in Section 4.4(b). 
 1.45 “HSR
Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time. 
 1.46 “HSR
Filing” has the meaning set forth in Section 11.6(a). 
 1.47 “Improvements” means all inventions and
Know-How, patentable or otherwise, made, created, developed, conceived or reduced to practice by or on behalf of a Party and/or any of its Affiliates pursuant to activities relating to or contemplated by this Agreement during the Agreement Term,
that have application or relate to Compound or Product for use in the Field including developments in the manufacture, formulation, ingredients, preparation, presentation, means of delivery or administration, dosage, indication, methods of use or
packaging and/or sale of Product. 
 1.48 “IND” means an Investigational New Drug application, as described in 21 C.F.R.
Section 312.23, obtained for purposes of conducting clinical trials in accordance with the 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 8 

 
requirements of the Act and the regulations promulgated thereunder, including all supplements and amendments thereto relating to the use of Compound or
Product in the Field, including IND Number [***]. 
 1.49 “IND Transfer Date” has the meaning set forth in
Section 4.3. 
 1.50 “Indevus Indemnified Parties” has the meaning set forth in Section 10.1. 
 1.51 “Indevus Intellectual Property” means the Indevus Patent Rights and the Indevus Know-How. 
 1.52 “Indevus Know-How” means all Know-How that are as of the Agreement Date or become as a result of the Next Trial owned or Controlled
by Indevus. 
 1.53 “Indevus Patent Rights” means all Patent Rights (a) that are owned or Controlled by Indevus as of
the Agreement Date, and/or (b) which arise from inventions made, conceived, discovered, reduced to practice or generated during Development activities conducted by Indevus prior to the Go Decision, in each case including (i) any and all
Indevus Patent Rights that are not SA Patents (the “Assignable Patents”), including the Patent Rights listed in Schedule 1.53(A); and (ii) any and all Patent Rights that are licensed to Indevus pursuant to the SA
Agreement (the “SA Patents”), including the Compound Patent Rights listed in Schedule 1.53(B) and the Patent Rights listed in Schedule 1.53(C) (as each of such terms is defined in the SA Agreement), which schedule
shall be updated as necessary from time to time. 
 1.54 “Indevus Transition Team” has the meaning set forth in
Section 4.2(b). 
 1.55 “Insurance” has the meaning set forth in Section 10.6(a). 
 1.56 “Intellectual Property” means Patent Rights and Know-How, collectively. 
 1.57 “Know-How” means all proprietary information and technology, including trade secret information, developments, discoveries,
methods, techniques, formulations, data, and other information, whether or not patentable, that relate to the Compound, Product or any Improvement, including methods relating to their development, manufacture or use and which are not disclosed or
covered in Patent Rights. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 9 

 1.58 “Law(s)” means all laws, statutes, rules, regulations, ordinances and other
pronouncements having the binding effect of law of any governmental authority. 
 1.59 “Losses” means any and all damages,
awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties (including penalties imposed by any governmental authority), costs, fees, liabilities, obligations, taxes, liens, losses, lost profits and expenses (including
court costs, interest and reasonable fees of attorneys, accountants and other experts) awarded or otherwise paid or payable to Third Parties. 
 1.60 “NDA” means a new drug application submitted to the FDA to obtain approval for the marketing of the Product in the United States, together with all subsequent submissions, supplements and amendments thereto.

 1.61 “Net Sales” means the gross sales amount of Products (or, in the case of Sections 5.3(a)(v), 5.4(d), 5.5(c), 5.5(d)
and 5.6, of Authorized Generic Products) invoiced to Third Parties by Teva, its Affiliates and sublicensees, less the following deductions only if recorded by Teva, its Affiliates and sublicensees as a reduction from gross to net sales and
calculated in accordance with GAAP, except with respect to item (g) below, or to the extent included in such gross invoiced amount: 
 (a) quantity and/or cash discounts allocated to the applicable Product; 
 (b) customs, duties, sales and similar taxes; 

(c) amounts allowed or credited by reason of rejections, return of goods (including as a result of recalls, market withdrawals and other corrective
actions), and retroactive price reductions or allowances specifically identifiable as related to the sale of the Product; 
 (d) allowances
and credits related to inventory management or similar agreements with wholesalers allocated to the applicable Product; 
 (e) amounts
incurred resulting from government (or any agency thereof) mandated rebate programs in the Territory specifically identifiable as related to the sale of Product; 
  

 10 

 (f) Third Party rebates, patient discount programs, administrative fees and chargebacks or similar price
concessions specifically identifiable as related to the sale of the Product; 
 (g) bad debt recognized by Teva for accounting purposes as
not collectible, adjusted for changes to reserve for bad debts; 
 (h) freight, packing, shipping or insurance; 
 (i) usual and customary commissions paid to agents or distributors to secure tender offers or other purchases by local authorities, to the extent
specifically identifiable as related to the sale of Product; and 
 (j) as agreed by the Parties, such agreement not to be unreasonably
withheld, any other specifically identifiable amounts included in a Product’s gross sales amount that were or ultimately will be credited and that are substantially similar to those listed above. 
 To the extent that such discounts, allowances, credits, rebates and other deductions are not specifically identifiable as related to Product, they shall be fairly and
equitably allocated to the applicable Product and, to the extent applicable, other products or services of Teva or its Affiliates such that the Products do not bear a disproportionate portion of such deductions. For the avoidance of doubt, Net Sales
shall not include sales by Teva to its Affiliates or sublicensees for resale; provided that, if Teva sells the Product to an Affiliate or sublicensee for resale, then the Net Sales calculation shall include the amounts invoiced by such
Affiliate or sublicensee to Third Parties on the resale of the Product. For purposes of this Agreement, “sale” shall not include transfers or other distributions or dispositions of the Product, at no charge, for regulatory purposes,
clinical trials, samples, free products or in connection with patient assistance programs or other charitable purposes or to physicians or hospitals for promotional purposes. The Product shall be considered “sold” only when billed or
invoiced. 
 No amount included in subsections (a)-(j) above shall be included in the costs used by Teva under Section 1.91 in the calculation of
the U.S. Gross Margin. 
  

 11 

 1.62 “Next Trial” means the Phase II Clinical Study relating to Product, the protocol
for which shall be agreed upon by the Parties as promptly as practicable but not later than [***] before the commencement of the Next Trial, which protocol shall be consistent with the budget setting forth costs associated with the Next Trial
(the “Next Trial Costs”), as described in detail in Schedule 4.4(b) (the “Next Trial Budget”), the synopsis attached hereto as Schedule 1.62, and the draft of which has been delivered by Indevus to
Teva for its review and final comments (the “Next Trial Protocol”). 
 1.63 “Next Trial Completion” means
the date of the Database Lock. 
 1.64 “Next Trial Report” has the meaning set forth in Section 4.4(b). 
 1.65 “No Go Decision” has the meaning set forth in Section 9.2(a)(i). 
 1.66 “Party” means Indevus or Teva. 
 1.67 “Parties’ Patent Rights” has the meaning set forth in Section 7.3(a). 
 1.68
“Patent Rights” means any patents, patent applications, certificates of invention, or applications for certificates of invention and any supplemental protection certificates, together with any extensions, registrations,
confirmations, reissues, substitutions, divisions, continuations or continuations-in-part, reexaminations or renewals thereof that relate to the Compound, Product or any Improvement, including methods of development, manufacture or use invented
pursuant to this Agreement and relating solely to the Compound or Product. 
 1.69 “Primary Endpoint” [***]

 1.70 “Product” means any pharmaceutical preparation in final form (or, where the context so indicates, the form under
development) containing the Compound as a primary active therapeutic ingredient, which requires a prescription from a physician or other health care professional, for use in the Territory. For purposes of clarity, “Product” does not
include “Authorized Generic Product”. 
 1.71 “Product Label(ing)” shall have the same meaning as defined in the
Act and as interpreted by the FDA. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 12 

 1.72 “Proprietary Information” means any and all scientific, clinical, regulatory,
marketing, financial and commercial information or data, whether communicated in writing, orally or by any other means, which is owned and under the protection of one Party and is provided by that Party to the other Party in connection with this
Agreement, and shall include Indevus Know-How and Teva Know-How, as applicable. 
 1.73 “Regulatory Approval” means approval
by the relevant Regulatory Authority of an NDA or other Drug Approval Application, notice of compliance and any other license or permit required to be approved for the manufacture, use, storage, import, export, transport and sale of Product in a
regulatory jurisdiction. 
 1.74 “Regulatory Authority” means any governmental or other competent authority in a country,
region or other regulatory jurisdiction, including the FDA and the EMEA, that regulates the manufacture, use, storage, import, export, transport and sale of any Product. 
 1.75 “Regulatory Documents” has the meaning set forth in Section 4.3. 
 1.76
“Royalty Conversion Event” has the meaning set forth in Section 5.3(b). 
 1.77 “Royalty Term” means
the period (a) commencing (i) in the United States, on the first day of the U.S. License Period, and (ii) in each country in the Territory other than the United States [***] , on the date of First Commercial Sale of Product by
Teva, its Affiliates or sublicensees in the applicable country; and (b) expiring on the later of either (i) the expiration or invalidation of the last Valid Claim in the applicable country in the Territory or (ii) twelve
(12) years from the date of First Commercial Sale of Product by Teva, its Affiliates or sublicensees in such country, subject in either case to early termination in the event of Substantial Level Generic Competition in the applicable country in
the Territory. 
 1.78 “SA Agreement” means the License Agreement dated as of February 18, 1994 by and between Indevus
(f/k/a Interneuron Pharmaceuticals, Inc.) and Sanofi-Aventis, SA (as successor to Rhone-Poulenc Rorer S.A.) (“SA”), as amended on October 29, 2001 and on March 27, 2008, a true and correct copy of which has been delivered
to Teva concurrently with the execution of this Agreement. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 13 

 1.79 “SEC” means the United States Securities and Exchange Commission and any successor
agency having substantially the same functions. 
 1.80 “Second Period Plan and Budget” means the plan setting forth
(a) activities and estimated timelines relating to Development and Commercialization, including a description of the planned launch, educational, marketing and promotional activities related to Product for the initial indication in the United
States, and (b) the budget setting forth costs estimated to be incurred in performing such activities (the “Second Period Budget Costs”), both in the aggregate and by Calendar Year, for the period commencing on the date of the
submission of the first NDA for the initial indication of the Product and ending on the date that is forecasted therein to be twelve (12) months after the First Commercial Sale of Product in the United States by Teva, its Affiliates or
sublicensees (the “Second Period Plan and Budget Period”), submitted by Teva to Indevus pursuant to Section 4.7(d)(i), and all revisions, amendments or updates thereto submitted by Teva to Indevus pursuant to
Section 4.7(d)(ii). Second Period Budget Costs shall include the external out-of-pocket costs and expenses incurred by and on behalf of Teva and its Affiliates and the costs of such activities performed by Teva’s FTEs, valued at the then
current Teva FTE reimbursement rate, and consistent with Schedule 1.40, but shall exclude any costs and expenses incurred for (x) Development activities conducted solely for Regulatory Approval outside the United States, and
(y) Commercialization activities conducted solely for markets outside the United States. 
 1.81 “Significant Plan
Amendment” means: 
 (a) as used in Section 4.4(c), any revision, amendment or update to the First Period Plan and Budget that:

 (i) for the period beginning on the date of the Go Decision and ending on and including the date of completion of the
End-of-Phase II Meeting, would have the effect of increasing the First Period Budget Costs during any Calendar Year within the First Period Plan and Budget Period or the total aggregate First Period Budget Costs by an amount greater than
[***]; 
 and 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 14 

 (ii) for the period beginning on the date immediately following the date of completion of
the End-of-Phase II Meeting, would have the effect of increasing First Period Budget Costs by either: 
 (A) during any
Calendar Year within the First Period Plan and Budget Period, the lesser of 
 1. an amount greater than a [***]
increase of the First Period Budget Costs projected for such Calendar Year, 
 or 
 2. [***]; 
 or 
 (B) an amount greater than a [***] increase from the total aggregate First Period Budget Costs included
in the initial First Period Plan and Budget delivered to the CSC under Section 4.4(c)(i); 
 provided, however, that
following the delivery by Teva of a revised First Period Plan and Budget pursuant to Section 4.4(c)(ii)(A), if such revision does not constitute a Significant Plan Amendment under Section 1.81(a)(ii)(A) or 1.81(a)(ii)(B) or it does
constitute such a Significant Plan Amendment but Indevus does not deem the Decision Point set forth in Section 1.26(c) a Royalty Conversion Event pursuant to Section 5.3(b), then the First Period Budget Costs set forth in such revised
First Period Plan and Budget delivered pursuant to Section 4.4(c)(ii)(A) will become the baseline for the determination of a Significant Plan Amendment under Section 1.81(a)(ii)(A) and 1.81(a)(ii)(B) for the remainder of the First Period
Plan and Budget Period; and 
 (b) as used in Section 4.7(d) any revision, amendment or update to the Second Period Plan and Budget that:

 (i) for the period beginning on the date of the submission of the first NDA for the initial indication of Product and
ending on and including the date of FDA Approval of 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 15 

 
such NDA, would have the effect of increasing either the Second Period Budget Costs during any Calendar Year within the Second Period Plan and Budget Period
or the total aggregate Second Period Budget Costs by the lesser of 
 (A) an amount greater than a [***] increase of
such budget costs, 
 or 
 (B) $[***]; 
 and 
 (ii) for the period beginning the day immediately following the date of FDA Approval of the first NDA for the initial indication of
Product and ending on and including the date forecasted to be twelve (12) months after the First Commercial Sale of Product by Teva, its Affiliates or sublicensees in the United States, would have the effect of increasing Second Period Budget
Costs by either: 
 (A) during any Calendar Year within the Second Period Plan and Budget Period by the lesser of 

1. an amount greater than a[***] increase of the Second Period Budget Costs projected for such Calendar Year, 
 or 
 2.
[***]; 
 or 
 (B) an amount greater than a [***] increase from the total aggregate Second Period Budget Costs included in the initial Second Period Plan and Budget delivered to the CSC under Section 4.7(d)(i);

 provided, however, that following the delivery by Teva of a revised Second Period Plan and Budget pursuant to
Section 4.7(d)(ii)(A), if such revision does not constitute a 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 16 

 
Significant Plan Amendment under Section 1.81(b)(ii)(A) or 1.81(b)(ii)(B) or it does constitute such a Significant Plan Amendment but Indevus does not
deem the Decision Point set forth in Section 1.26(c) a Royalty Conversion Event pursuant to Section 5.3(b), then the Second Period Budget Costs set forth in such revised Second Period Plan and Budget delivered pursuant to
Section 4.7(d)(ii)(A) will become the baseline for determination of a Significant Plan Amendment under Section 1.81(b)(ii)(A) and 1.81(b)(ii)(B) for the remainder of the Second Period Plan and Budget Period. 
 1.82 “Successor Entity” has the meaning set forth in Section 1.13. 
 1.83 “Territory” means the entire world. 
 1.84 “Teva Indemnified Parties” has the meaning set forth in Section 10.1. 
 1.85
“Teva Know-How” means all Know-How that becomes during the Agreement Term and pursuant to the terms of this Agreement owned or Controlled by Teva. 
 1.86 “Teva Patent Rights” means any Patent Right that becomes during the Agreement Term and pursuant to the terms of this Agreement owned or Controlled by Teva, which Patent Right discloses or claims
subject matter resulting or derived from Development from and after the Go Decision. 
 1.87 “Third Party(ies)” means a
person or entity who or which is neither a Party nor an Affiliate of a Party. 
 1.88 “Third Party Agreements” has the
meaning set forth in Section 6.2(d). 
 1.89 “Transition Period” has the meaning set forth in Section 4.2(b).

 1.90 “U.S. Collaboration Period” means, with respect to the United States, the period commencing on the Effective Date
and, unless terminated earlier upon the occurrence of a Royalty Conversion Event pursuant to Section 5.3(b), expiring on the later of either (a) the expiration or invalidation of the last Valid Claim in the United States or (b) twelve
(12) years from the date of First Commercial Sale of Product by Teva, its Affiliates or sublicensees in the United States. 
  

 17 

 1.91 “U.S. Gross Margin” means, for a particular Calendar Quarter during the U.S.
Collaboration Period, an amount equal to (a) Net Sales of Product in the United States for such Calendar Quarter, minus (b) either (i) during the Second Period Plan and Budget Period, the actual costs associated with activities set
forth in the Second Period Plan and Budget or (ii) after the Second Period Plan and Budget Period, the actual costs associated with Commercialization and Development incurred by Teva consistent with Schedule 1.40, in either case for such
Calendar Quarter. Notwithstanding the foregoing, costs that would constitute a Significant Plan Amendment (whether incurred prior to or after delivery to Indevus of the Significant Plan Amendment) shall not be deemed costs included in the
calculation of the U.S. Gross Margin hereunder if, within [***] after receipt of the required Significant Plan Amendment, Indevus deems such Significant Plan Amendment a Royalty Conversion Event pursuant to Section 5.3(b),
provided, however, that all other costs incurred from and after Indevus’ receipt of such Significant Plan Amendment up to and including the date of a Royalty Conversion Event, if any, shall be included in the calculation of the
U.S. Gross Margin. 
 1.92 “U.S. License Period” means, if the U.S. Collaboration Period is terminated upon the occurrence
of a Royalty Conversion Event pursuant to Section 5.3(b), the period commencing on the day immediately following the effective date of such termination and continuing in effect until expiration or earlier termination of the Royalty Term.

 1.93 “Valid Claim” means any claim issued in an unexpired Indevus Patent Right or Teva Patent Right which has not been
held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction following exhaustion of all possible appeal processes, and which has not been admitted to be invalid or unenforceable through
reissue, reexamination or disclaimer and has not been terminated for failure to pay maintenance fees. 
 1.94 “Warner Assignment and
License” means the Assignment and License Agreement by and between Indevus and Warner Lambert Company LLC dated as of February 9, 2004, a true and correct copy of which has been delivered to Teva concurrently with the execution of this
Agreement. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 18 

 1.95 “Warner Know-How” means the Warner Know-How, as such term is defined in the Warner
Assignment and License. 
 ARTICLE 2 
 GRANT OF RIGHTS 
 2.1 Grants by Indevus. 
 (a) Subject to the terms and conditions of this Agreement, beginning on the Effective Date and ending upon the termination of this Agreement, Indevus
hereby grants to Teva an exclusive (even as to Indevus) right and license throughout the Territory (with the right to grant sublicenses, subject to the provisions of Section 2.5) to practice under the Indevus Intellectual Property, to develop,
make, have made, use, sell, have sold, offer for sale, import, export, register, market, promote and otherwise Commercialize the Compound and Products in the Field for all indications; provided, however, that the license granted under
this Section 2.1 is expressly subject to the retained rights of Indevus to practice under the Indevus Intellectual Property solely to the extent necessary to carry out its express obligations under this Agreement. During the period beginning on
the Agreement Date and ending on the Effective Date, Indevus shall take no action that adversely impacts or is otherwise inconsistent with the rights being granted to Teva hereunder. 
 (b) Teva does not expect or anticipate receiving any additional Indevus Intellectual Property created subsequent to the Next Trial Completion and through
the Agreement Term, as Indevus has represented to Teva that it believes that it is remote that after the Next Trial Completion Indevus will be performing any research or development activities which would generate any additional Indevus Intellectual
Property related to the license granted hereunder. 
 2.2 Sublicenses of Third Party Rights. The license granted to Teva under
Section 2.1 includes exclusive sublicenses by Indevus in the Field (a) of certain Indevus Patent Rights and Indevus Know-How under the [***], and (b) of certain Indevus Know-How under the [***]. Teva acknowledges that it
is a sublicensee under the [***] and the [***] to the extent stated in the foregoing sentence and agrees to be bound (and that any sublicensee hereunder shall be bound) by the 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 19 

 
respective terms of such agreements, to the same extent as Indevus is bound by such terms, to the extent applicable to the sublicense granted to Teva
hereunder. Provided that Teva has not materially breached this Agreement and has failed to cure such material breach pursuant to Section 9.2(b)(i), Indevus shall pay all amounts which Indevus shall owe pursuant to the [***] by virtue of
this Agreement and shall perform in all material respects its obligations under the [***] that are required to enable Teva to perform its obligations and exercise its rights under this Agreement. In the event that Indevus receives notice of a
breach of the [***], which breach gives rise to a right to terminate the [***] in a way that would terminate or materially adversely affect Teva’s ability to perform its obligations or exercise its rights under this Agreement,
Indevus shall notify Teva of such situation as soon as practicable, and use commercially reasonable efforts to promptly cure such breach. However, if Indevus is unable to cure such breach, Indevus shall, to the fullest extent possible, permit Teva
to cure such breach, provided that Indevus shall reimburse Teva for any costs associated with curing such breach, or Teva shall be permitted to set off such costs against any amounts owed by Teva to Indevus hereunder. Without limiting
the foregoing obligation of Indevus, Indevus shall use Commercially Reasonable Efforts to obtain within [***] of the Effective Date an agreement from [***] that, provided that Teva has not breached its obligations under
this Agreement, in the event that the [***] is terminated for any reason, [***] agrees to grant Teva substantially equivalent rights on substantially equivalent terms as those granted to Indevus pursuant to the [***] as are
necessary for Teva to exercise its rights and perform its obligations under this Agreement. 
 2.3 Retained Rights; No Implied
Licenses. All rights not specifically granted to Teva under this Agreement are reserved and retained by Indevus. Nothing in this Agreement shall be deemed to constitute the grant of any license or other right to either Party, to or in respect of
any product, patent, trademark, Proprietary Information, trade secret or other data or any other intellectual property of the other Party, except as set forth under this Agreement. 
 2.4 Competition. During the Agreement Term, neither Party will directly or indirectly distribute, promote, market or sell any Competing Product in
the Territory; provided, however, that if during the Agreement Term a Party believes in good faith that at any time a launch of a Generic Product is imminent in any country, Teva shall have the right (but not the 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 20 

 
obligation) to launch a Generic Product of its own (an “Authorized Generic Product”) in such country, subject to the provisions of
Section 5.3(a)(v). Notwithstanding the foregoing to the contrary, subject to the provisions of Section 11.2, in the event that Teva acquires a Third Party, or is acquired or becomes controlled by a Third Party, which is distributing,
promoting, marketing or selling a Competing Product in a country in the Territory, Teva shall continue to use Commercially Reasonable Efforts to Develop and/or Commercialize the Product. Notwithstanding the foregoing, in the event that a Third Party
is commercializing a pharmaceutical product with the same or similar labeling as Product but that does not contain the Compound as an active ingredient, nothing in this Agreement shall prohibit Teva from manufacturing, distributing, promoting,
marketing or selling a generic version of such product, provided that the provisions under this Agreement regarding the use of Proprietary Information shall apply to such Third Party. 
 2.5 Proposed Sublicense by Teva. In the event Teva proposes to sublicense any of the rights or licenses granted to it by Indevus hereunder, the
provisions of this Section 2.5 shall be applicable. Teva shall advise Indevus in advance of any proposed sublicense and give due consideration to Indevus’ comments thereto; provided, however that if any such proposed
sublicense of a Product is with respect to [***], then such sublicense shall be subject to the [***]. Any sublicense shall be subject to the terms and conditions of this Agreement, and the grant of any sublicense by Teva shall not
relieve Teva of any of its obligations under this Agreement. 
 2.6 Third Party Agreements. Within [***] after the Go Decision,
Indevus shall assign to Teva and Teva shall assume the Third Party Agreements listed in Schedule 2.6(a), including all obligations thereunder (subject to the other provisions of this Agreement). Indevus shall use its Commercially Reasonable
Efforts to modify such provisions of the Third Party Agreements listed in Schedule 2.6(a) as Teva shall reasonably request. Within [***] after the Next Trial Completion, Indevus shall provide to Teva a Schedule 2.6(b) setting forth
therein all Third Party Agreements entered into subsequent to the Agreement Date in connection with the Next Trial and consistent with the Next Trial Budget. Indevus shall assign to Teva and Teva shall assume the Third Party Agreements listed in
Schedule 2.6(b) 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 21 

 
which Teva shall specifically request, including all obligations thereunder (subject to the other provisions of this Agreement), or terminate such
Third Party Agreements as Teva shall request. Indevus shall provide Teva with a reasonable opportunity to review and comment upon any such Third Party Agreements that Indevus believes in good faith would reasonably affect the Indevus Intellectual
Property prior to execution by Indevus. Upon assignment to Teva, (a) all such Third Party Agreements shall be in full force and effect in accordance with their terms, (b) neither Indevus nor any other party thereto shall be in default or
breach in any material respect of such Third Party Agreements, and (c) Indevus shall not have received any notice of any defaults, breaches or violation thereunder. Subject to the foregoing, Indevus shall have no further obligations under any
Third Party Agreements assigned to Teva. Without Teva’s prior written consent, Indevus shall not modify, assign, amend or terminate any Third Party Agreement (as well as the SA Agreement and the Warner Assignment and License) and Indevus shall
not enter into any other agreements regarding the Compound or the Products. 
 ARTICLE 3 
 GOVERNANCE 
 3.1 Central Steering
Committee. 
 (a) Members. As of the Effective Date, the Parties shall establish a central steering committee (the
“CSC”), which shall consist of four (4) members, two (2) of whom shall be designated by Teva, and two (2) of whom shall be designated by Indevus. The initial members of the CSC are set forth on Schedule 3.1.
Teva and Indevus may replace any or all of its representatives on the CSC at any time upon written notice to the other Party. A Party may designate a substitute to temporarily attend and perform the functions of such Party’s designee at any
meeting of the CSC; provided, however, that such designee shall have appropriate expertise. The CSC shall be chaired by a representative of Teva. 
 (b) Responsibilities. The CSC shall have as its overall purpose the supervision of Development and Commercialization in the United States. From time to time during the U.S. Collaboration Period, the CSC shall
(i) review Development and Commercialization, as well as the First Period Plan and Budget and Second Period Plan and Budget and all revisions, updates or amendments thereto, and (ii) establish any additional committees deemed necessary or

  

 22 

 
desirable to address other issues associated with the implementation of this Agreement. Indevus shall have the right, but not the obligation, to review and
provide its comments to the First Period Plan and Budget and Second Period Plan and Budget, and all revisions, updates or amendments thereto, submitted by Teva to the CSC. The CSC shall have subordinate to it and shall oversee and supervise any such
other committees as are formed by it from time to time and shall be responsible for ensuring that there is an alignment between the objectives of all such subordinate committees. The activities of such subordinate committees shall be responsive to,
consistent with the decisions and direction of, and implement the policies of, the CSC. 
 (c) Decision Making. The CSC may make
decisions with respect to any subject matter that is subject to the CSC’s decision-making authority and responsibilities as set forth in Section 3.1(b). Regardless of the number of individuals attending any CSC meeting, Teva and Indevus
shall have a single vote each. The CSC shall attempt in good faith to reach unanimity with respect to matters that come before it for decision and shall give consideration to the views, positions and recommendations of each Party on such matters. If
the CSC is unable to reach unanimity upon any issue or matter that is brought before it for decision within [***] after consideration by the CSC then, and in each such event, Teva shall be entitled to make the final decision for the CSC with
respect to such issue or matter, which decision shall be binding upon the Parties; provided, however, that in case of a dispute regarding [***], if such a dispute has not been resolved within [***] after presentation to
the CSC, then the dispute shall be referred to the Chief Executive Officer of Indevus and an Executive Vice President of Teva for resolution. If the Parties’ respective officers are unable to resolve such dispute within [***] after
presentation of the dispute to them for resolution, the dispute shall be resolved pursuant to Section 11.8. 
 3.2 Meetings. The
chairperson of the CSC shall call meetings as reasonably requested during the U.S. Collaboration Period by one of the Parties; provided, however, that the CSC shall meet at least on a semi-annual basis during the U.S. Collaboration
Period unless otherwise required by this Agreement or agreed to between the Parties, and that the first meeting of the CSC shall be held as soon as practicable, but no later than [***] after the Effective Date[***]. The chairperson
shall establish the timing and agenda of all CSC meetings 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 23 

 
and shall transmit notice of such meetings, including the agenda therefor, to all CSC members; provided, however, either Party may request that
specific items be included on the applicable agenda and may request that additional meetings be scheduled as needed. Meetings may be held in person, by telephone, or by video conference call and, except as set forth above, the location of each
meeting shall alternate between the Parties’ selected locations in Israel or Massachusetts or such other location as may be mutually agreed upon by the Parties. On advance written notice to the other Party, additional participants may be
invited by any representative to attend meetings where appropriate. Each Party shall be responsible for all travel and related costs and expenses for its members and other representatives to participate in or attend committee meetings. Any
Proprietary Information disclosed in any meeting of the CSC or its subcommittees shall remain Proprietary Information of such Party. 
 3.3
Minutes of CSC and Subcommittee Meetings. Minutes of each CSC and CSC subcommittee meeting shall be transcribed and issued by a representative of Indevus within thirty (30) days after each meeting (or in any event at least ten
(10) Business Days prior to the date of the next scheduled meeting of such committee) and shall be approved within thirty (30) days after each such meeting. Such minutes shall include only key discussion points and decisions made and
provide a list of any identified issues yet to be resolved, either within such committee or through the relevant resolution process, if any. 
 3.4 Disbanding of CSC. The Parties shall have the right to disband the CSC upon mutual agreement. Teva shall have the right, in its sole discretion, to disband the CSC upon a Change of Control of Indevus. Additionally, if the CSC is
not disbanded pursuant to the preceding sentences, and absent a mutual written agreement by the Parties to continue the CSC, the CSC shall be automatically disbanded effective on the earliest of (a) the termination of the U.S. Collaboration
Period, (b) the [***] anniversary of the Effective Date or (c) the date of the first FDA Approval. 
 3.5 No
Amendment. The CSC shall have only the powers assigned to it in this Article 3. All activities conducted by and decisions taken by the CSC shall be consistent with and subject to the provisions of this Agreement, and the CSC shall not have any
power to take any action that conflicts with the terms of this Agreement or to amend, modify or waive compliance with any of the terms of this Agreement. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 24 

 ARTICLE 4 
 TRANSITION; DEVELOPMENT AND COMMERCIALIZATION 
 4.1 Information. Within [***] of the
Effective Date, Indevus shall disclose and deliver to Teva electronic, where reasonably available, and hard copies (or, upon Teva’s request, originals) of all Data, all existing Indevus Intellectual Property, and any other documents regarding
the Compound that may be necessary or useful for regulatory submissions (other than the IND). Without limiting the generality of the foregoing, Indevus shall deliver to Teva those items that were disclosed to Teva during the due diligence meetings
held at Indevus’ offices on May 12-15, 2008, including all Data generated by any Third Party (including by SA (as successor to Rhone-Poulenc Rorer S.A.) and Warner Lambert Company LLC). 
 4.2 Transfer of Materials and Technical Assistance. 
 (a) Transfer of Materials. Within [***] after the Go Decision, Indevus shall deliver to Teva any Compound, analytical standards or markers for the Compound, intermediates, Product and any related
substances that it owns or Controls and which are necessary or useful for the continued Development, Commercialization and research regarding the Compound and Products. 
 (b) Technical Assistance. Beginning on the date Teva issues the Go Decision and continuing for [***] thereafter (the “Transition Period”), Indevus shall provide for an orderly transition
to Teva of the development, testing and regulatory activities performed by or on behalf of Indevus with respect to Compound and/or Product, subject to and in accordance with this Section 4.2. During the Transition Period, Indevus shall make
available to Teva at Indevus’ facility in the United States, no fewer than [***] knowledgeable Indevus personnel familiar with the Indevus Know-How and clinical, regulatory, biostatistical, and chemistry, manufacturing and control (CMC)
issues relating to Compound and/or Product (the “Indevus Transition Team”), to provide reasonable training and assistance to Teva with respect to the Indevus Know-How and such related issues, upon Teva’s reasonable request and
at such times and places during normal 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 25 

 
business hours as may be mutually agreed to. After the expiration of the Transition Period, for a period not to exceed [***], if Teva requests
additional training or assistance, Teva shall pay Indevus, at Indevus’ then current FTE reimbursement rate, and bear all Indevus’ reasonable out of pocket expenses, in connection with such assistance, provided that Indevus
shall not be required to provide in excess of [***] during such [***] period for such services. 
 4.3 Regulatory Filings,
Approvals and Applications. As soon as reasonably practicable, but in any event within [***] after the Go Decision, Indevus shall submit to the FDA a letter authorizing the transfer of ownership from Indevus to Teva, and shall otherwise
take action within its control to transfer to Teva, all regulatory filings, approvals and applications relating to the Compound or the Products, including all INDs and all Regulatory Approvals, Drug Approval Applications and all related
documentation and information (the “Regulatory Documents”). Teva shall execute and submit to the FDA a letter, accompanied by the transfer letter referred to in the preceding sentence, acknowledging Teva’s assumption of
ownership of and responsibility for the Regulatory Documents. The effective date of the transfer of ownership of the Regulatory Documents to Teva is referred to as the “IND Transfer Date.” 
 4.4 Development. 
 (a) General.
Except as specifically set forth in Section 4.4(b) with respect to the Next Trial, Development shall be conducted by Teva from and after the Go Decision with review by the CSC during the U.S. Collaboration Period, and Teva shall exercise
Commercially Reasonable Efforts in doing so. Not less than [***] per Calendar Year, Teva shall provide to the CSC or, if the CSC has been disbanded, Teva shall provide to Indevus (i) a copy of the annual report that it submits to the FDA
in connection with the periodic reporting requirement for the IND, and (ii) a written report summarizing the progress, status, and results of all Development and regulatory activities of Teva, its Affiliates and sublicensees relating to the
Compound or Product, consistent with written reports issued by Teva in the ordinary course of its business. In addition, no more than [***] per Calendar Year, in addition to any meetings of the CSC, Indevus may request a meeting with Teva to
discuss such written report at dates and locations to which the Parties mutually agree. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 26 

 (b) Next Trial. Commencing on the Effective Date, Indevus shall use Commercially Reasonable
Efforts to conduct the Next Trial in accordance with the Next Trial Protocol and Next Trial Budget. No later than [***] following the Next Trial Completion, Indevus shall provide to Teva, in electronic format, the clinical trial database at
Database Lock and all other information set forth on Schedule 1.64(a). Next Trial Costs shall be funded in the manner set forth in Sections 5.2(a) and 5.4(a). Any revisions to the Next Trial Protocol and Next Trial Budget that would,
individually or in the aggregate, have the effect of increasing by more than [***] the costs set forth in the original Next Trial Budget shall be subject to mutual agreement by the Parties and, if so agreed, shall be set forth in an amendment
to Schedule 4.4(b). Not later than [***] after the Next Trial Completion, Indevus shall deliver to Teva a report which shall be substantially similar in form to Schedule 1.64(b) (the “Next Trial Report”). Not
later than [***] after the Next Trial Completion, Teva shall notify Indevus in writing of its decision in its sole discretion, either (i) to proceed with a Phase III clinical trial of the Compound for any indication, including stuttering
(a “Go Decision”) or (ii) to terminate this Agreement pursuant to Section 9.2(a)(i). 
 (c) First Period Plan
and Budget. 
 (i) First Period Plan and Budget. Not later than [***] after the Next Trial Completion, but
in any event at least [***] prior to commencing any further Development under this Agreement, Teva shall prepare and deliver to the CSC the First Period Plan and Budget, which plan shall be consistent with plans employed by Teva in connection
with pharmaceutical product projects of a comparable stage of development and similar market potential. Within [***] of receipt of the First Period Plan and Budget in accordance with this Section 4.4(c)(i), Indevus shall notify Teva of
its decision, pursuant to the Decision Point set forth in Section 1.26(a), whether to continue the U.S. Collaboration Period or to deem such Decision Point a Royalty Conversion Event pursuant to Section 5.3(b). 
 (ii) Revisions, Amendments and Updates. 
 Teva shall: 
 (A) prepare and deliver to the CSC a revised First Period Plan and Budget within [***] following the date of completion of the End-of-Phase II Meeting; and 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 27 

 (B) prepare and deliver to the CSC an update of its then outstanding First Period Plan
and Budget on or before [***] during the U.S. Collaboration Period. 
 (iii) In addition to any other reporting
obligations hereunder, Teva shall deliver to the CSC not later than [***] prior to any implementation thereof by Teva any Significant Plan Amendment to the First Period Plan and Budget. Within [***] of receipt of such Significant Plan
Amendment, Indevus shall notify Teva of its decision, pursuant to the Decision Point set forth in Section 1.26(c), whether to continue the U.S. Collaboration Period or to deem such Decision Point a Royalty Conversion Event pursuant to
Section 5.3(b). 
 (d) Additional Development. Either Party may at any time submit to the CSC a written proposal for additional
development, including development of additional indications or Improvements. Such proposal shall contain, at a minimum, commercially reasonable information supporting the rationale for such development from a scientific, regulatory and commercial
standpoint, as well as an estimated developmental critical path and an estimate of the time, cost and economic or other benefit of such efforts. In considering whether to recommend to the CSC approval of such proposal for additional development, the
CSC shall evaluate whether the proposed program has scientific and technical merit and is likely to result in the approval of a new indication or dosage amount of Product, or is advisable to address safety or efficacy issues and/or whether the
commercial return from sales of Product that may result from such development can reasonably be expected to offset the cost of development within a reasonable period of time. If any such additional development is approved by the CSC pursuant to
Section 3.1, Teva shall promptly determine a development plan and budget for such development including the estimated cost and scope of work necessary for obtaining desired Regulatory Approval. If such budget for additional development contains
costs that constitute a Significant Plan Amendment, then within [***] of receipt of such Significant Plan Amendment, 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 28 

 
Indevus shall notify Teva of its decision, pursuant to the Decision Point set forth in Section 1.26(c), whether to continue the U.S. Collaboration
Period or to deem such Decision Point a Royalty Conversion Event pursuant to Section 5.3(b). 
 (e) Records. Any Party conducting
Development activities under this Agreement shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes and in accordance with good industry practice, which shall be complete and accurate
in all material respects and shall fully and properly reflect all work done and results achieved, including all Know-How and including individual case report forms, in the performance of the Next Trial or Development activities, as applicable, in
the form required under applicable Laws. 
 4.5 Regulatory Matters. 
 (a) Responsibility Before IND Transfer Date. 
 Prior to the IND Transfer Date: 
 (i) Indevus shall own and control all Regulatory Documents
relating to a Product in the Field in the Territory and shall have sole authority and responsibility for the timely preparation, filing, prosecution and maintenance of all Regulatory Documents relating to a Product in the Territory, including any
reports or amendments to such Regulatory Documents. 
 (ii) Indevus shall remain the primary contact with the FDA and shall be
solely responsible for all communications with the FDA that relate to any Regulatory Document. 
 (iii) Teva shall have the
right, but not the obligation, to assist and consult with Indevus with respect to all Regulatory Documents prior to Indevus’ making any submissions thereof. Notwithstanding anything contained in the foregoing to the contrary, Indevus shall
provide Teva with copies of all such Regulatory Documents no less than [***] (except if a shorter period is required for such submission by the FDA or applicable laws) prior to filing or submission of the foregoing and shall consider in good
faith any comments of Teva with respect to the same. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 29 

 (iv) Indevus shall provide advance notice to Teva of any planned meetings, discussions or
other communications with the FDA relating to Products. Teva shall have the right, but not the obligation, to participate with respect to such meetings, discussions, or other communications; provided that, in providing any such
assistance, Teva shall not contact the FDA without the prior approval of Indevus, which approval shall not be unreasonably withheld or delayed, and, if contacted by the FDA with respect to Product, shall refer such contact to Indevus. 
 (v) If contacted by the FDA with respect to a Product, Indevus shall notify Teva within [***] of such contact, and provide Teva with any
related official correspondence received from the FDA, including as applicable minutes of any meetings or telephone conferences and/or discussions between Indevus and the FDA. Teva shall have a right to participate in and provide comments with
respect to any subsequent meetings, discussions or other communications with respect to such contact. 
 (vi) To the extent
Teva reasonably believes that a filing or submission relating to Products in the Territory is required by Law, Teva shall notify Indevus. If Indevus decides not to prepare such filing or submission, Indevus shall promptly notify Teva, but in no
event later than [***] after Teva’s notification of Indevus, unless notified by Teva that a shorter period of review is mandated by the FDA or Law, and Teva shall be entitled to prepare such filing or submission, to be filed or submitted
by Indevus; provided that, Teva shall use good faith efforts to include any comments of Indevus in such filing or submission. 
 (vii) Indevus shall promptly provide Teva with copies of all filings and submissions made by Indevus with any Regulatory Authorities with respect to Product. 
 (b) Responsibility After IND Transfer Date. 
 From and after the IND Transfer Date: 
 (i) Teva shall have sole authority and responsibility
for the timely preparation, filing and prosecution of all filings, submissions, authorizations or approvals with Regulatory Authorities, and shall own and control all such filings, submissions, authorizations and approvals, including any IND, NDA or
other Drug Approval Application. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 30 

 (ii) Teva shall be the primary contact with each Regulatory Authority and shall be solely
responsible for all communications with each Regulatory Authority that relate to any IND, NDA, or other Drug Approval Application, provided, however, that upon the reasonable request of Teva, during the Transition Period, Indevus shall
provide appropriate personnel to participate in discussions with a Regulatory Authority regarding the regulatory review process and shall assist and consult with Teva in applying for Regulatory Approval in accordance with the terms of
Section 4.2. In providing such assistance, Indevus shall not contact the Regulatory Authorities without the prior written approval of Teva and, if contacted by a Regulatory Authority with respect to Product, shall refer such contact to Teva.
Each Party shall inform the other Party within [***] as to the status of its efforts and activities under this Section 4.5(b)(ii). 
 (iii) Teva shall promptly provide Indevus with copies of all filings and submissions and of any minutes of meetings or telephone conferences and/or discussions between Teva and Regulatory Authorities with respect to
Product. 
 (iv) From and after receipt of each Regulatory Approval, Teva shall have exclusive authority and responsibility to
submit all reports or amendments necessary to maintain Regulatory Approvals and to seek revisions of the conditions of each such Regulatory Approval and shall keep Indevus promptly informed of any such actions. No less than [***] (except if a
shorter period is required for such submission by the FDA or applicable laws) prior to planned submission to the FDA, Teva shall provide Indevus with drafts of submissions that are intended to change or modify the Product Label or FDA-approved
prescribing information for, or the indications of, Product and give prompt and reasonable consideration to any comments Indevus may have. Teva shall also provide Indevus with final copies of such submissions as soon as practicable 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 31 

 
after filing with the FDA. Teva shall have sole authority and responsibility to seek and/or obtain any necessary FDA approvals of any Product Label, or
FDA-approved prescribing information, package inserts, monographs and packaging used in connection with Product, as well as promotional material used in connection with Product, and for determining whether the same requires Regulatory Approval.

 (c) Regulatory Cooperation. The Parties’ responsibilities concerning adverse drug reactions, safety information and compliance
with regulatory requirements with respect thereto will be detailed in a separate agreement (the “Pharmacovigilance Agreement”) to be mutually agreed as soon as practicable after the Effective Date. Each Party shall inform the other
in writing of any information coming to its attention concerning Product quality and Product complaints, with such detail and within such time frames as are set forth in the Pharmacovigilance Agreement. 
 (d) Recalls and Other Corrective Action. Teva shall make all final decisions with respect to any recall, market withdrawal or any other corrective
action related to Product, and nothing herein shall prohibit Teva from initiating or conducting any recall or other corrective action mandated by a Regulatory Authority or applicable Law. Teva shall conduct any recall, market withdrawals, or other
corrective action related to Product. At Teva’s request, during the U.S. Collaboration Period, Indevus shall provide reasonable assistance in conducting such recall, market withdrawal or other corrective action, including providing all
pertinent records that Teva may reasonably request to assist in effecting such action. With respect to any recall, market withdrawal or any corrective action related to Product that occurs during the U.S. Collaboration Period and that arises from a
defect in the design of the Compound or Product, the Parties agree that they will share equally all documented, direct, out-of-pocket costs and expenses incurred in connection with such recall, market withdrawal or corrective action. With respect to
any such recall, market withdrawal or any corrective action related to Product that occurs during the U.S. License Period, or any recall, market withdrawal or any corrective action related to Product at any time that arises from a failure of the
Product to meet specifications required by an applicable Regulatory Authority, as between Teva and Indevus, Teva shall be responsible for all direct costs and expenses associated with such recall, market withdrawal or corrective action;
provided, however, that if such recall, market withdrawal or corrective action occurs during the U.S. 

  

 32 

 
Collaboration Period and is caused by a Product defect or failure to conform to applicable specifications attributable to manufacturing by a Third Party, and
Teva, notwithstanding its compliance with pharmaceutical manufacturing industry-appropriate quality assurance and quality control practices and testing standards, failed to detect such Product defect or failure to conform to applicable
specifications, then the Parties agree that they will share equally all documented, direct out-of-pocket costs and expenses incurred in connection with such recall, market withdrawal or corrective action. In case of a dispute between the Parties as
to whether Teva complied with such industry-appropriate quality assurance and quality control practices and testing standards, the Parties agree to submit any such dispute to a mutually acceptable independent expert for final binding resolution.
Except as set forth in this Section 4.5(d) or pursuant to the Parties’ indemnification obligations under this Agreement, neither Party shall have any obligation to reimburse or otherwise compensate the other Party or its Affiliates for any
consequential damages, lost profits or income that may arise in connection with any recall, market withdrawal or corrective action with respect to Product. 
 4.6 Diligence Obligations. 
 In addition to and not in lieu of Teva’s obligations hereunder to exercise
Commercially Reasonable Efforts, Teva shall: 
 (a) enroll the first patient in a Phase III Clinical Study of Product within [***]:

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 33 

 and 
 (b)
launch Product in [***] within [***]. 
 4.7 Commercialization. 
 (a) Control and Authority. Subject to the terms and conditions of this Agreement, from and after the Go Decision, Teva shall control and be solely
responsible for Commercialization, and shall exercise Commercially Reasonable Efforts in doing so. 
 (b) Promotional Materials and
Activities. Teva shall create and develop the promotional materials for the Products. As holder of the Regulatory Approvals for Product in the Territory, Teva shall be responsible for all submissions and interactions with the Regulatory
Authorities regarding approval of all Product-related promotional materials that require Regulatory Approval. 
 (c) Ownership of
Copyrights and Trademarks. Teva shall own all right, title and interest in and to the copyrights, trademarks, service marks and trade dress used in connection with Commercialization. Indevus shall execute all documents and take all actions as
are reasonably requested by Teva to vest title in Teva to all such copyrights, trademarks, service marks and trade dress. Teva shall be responsible, at its expense, for searching, clearing and filing applications for registration of all such
copyrights, trademarks, service marks and trade dress. 
 (d) Second Period Plan and Budget. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 34 

 (i) Second Period Plan and Budget. Not later than [***] before submission
of the first NDA for the initial indication of Product, Teva shall prepare and deliver to the CSC the Second Period Plan and Budget, which plan shall be consistent with plans employed by Teva in connection with pharmaceutical product projects of
similar market potential. Within [***] of both (A) Indevus’ receipt of the Second Period Plan and Budget in accordance with this Section 4.7(d)(i) and (B) achievement of the milestone event set forth in
Section 5.1(a), Indevus shall notify Teva of its decision, pursuant to the Decision Point set forth in Section 1.26(b), whether to continue the U.S. Collaboration Period or to deem such Decision Point a Royalty Conversion Event pursuant to
Section 5.3(b). 
 (ii) Revisions, Amendments and Updates. 
 Teva shall: 
 (A) prepare and deliver to Indevus a revised Second Period Plan and Budget within [***] following FDA Approval; and 
 (B) prepare and deliver to Indevus an update of its then outstanding Second Period Plan and Budget on or before [***] during the Second Period Plan and Budget Period. 
 (iii) In addition to any other reporting obligations hereunder, Teva shall deliver to the CSC or Indevus, as applicable, not later than
[***] prior to any implementation thereof by Teva any Significant Plan Amendment to the Second Period Plan and Budget. Within [***] of receipt of any Significant Plan Amendment, Indevus shall notify Teva of its decision, pursuant to
the Decision Point set forth in Section 1.26(c), whether to continue the U.S. Collaboration Period or to deem such Decision Point a Royalty Conversion Event pursuant to Section 5.3(b). 
 (e) Annual Forecasts and Work Plans. During each Calendar Year of the U.S. Collaboration Period after First Commercial Sale of Product in the
United States, Teva shall prepare and deliver to Indevus: (i) on or before [***] of such Calendar Year, a forecast of the U.S. Gross Margin for the immediately following Calendar Year; and (ii) on or before 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 35 

 
[***] of such Calendar Year, a work plan setting forth Development and Commercialization activities, [***], provided that the
first such work plan delivered by Teva to Indevus following the First Commercial Sale of Product in the United States will cover the period following the end of the Second Period Plan and Budget Period and ending on December 31 of the first
year included in such work plan. With respect to any estimated amounts or forecasts provided by Teva to Indevus under this Section 4.7(e), Indevus acknowledges and agrees that (i) such estimates or forecasts may vary from the actual
amount, (ii) the magnitude of any such variance is unpredictable and may be material, (iii) Teva shall not have any liability for Claims of Third Parties arising from, related to or in connection with any such variance, and
(iv) Indevus shall indemnify and hold harmless Teva from any Claims of Third Parties arising from Indevus’ direct or indirect use of such estimates or forecasts, excluding the disclosure by Indevus of estimates or forecasts previously
disclosed publicly by Teva. 
 (f) Sales of Product. All sales of Products shall be made, recorded, invoiced and collected by Teva.
All terms regarding Product sales, including terms respecting credit, pricing, cash discounts, rebates, chargebacks, bad debt write-offs, and other fees and charges, and returns and allowances shall be set solely by Teva. 
 (g) [***]. From time to time, the Parties shall meet and discuss a mutually agreeable strategy for Development and Commercialization in
[***]. If the Parties desire to Develop and Commercialize Products in [***] , the Parties will [***]. 
 (h) Supply
of Product. Indevus shall supply, without charge, except as expressly set forth in the Next Trial Protocol and Next Trial Budget, such quantity of Product as is necessary for the Next Trial, which Product shall be in accordance with cGMP, all
agreed-upon specifications, and requirements of applicable Regulatory Authorities. From and after the issuance of the Go Decision, Teva shall use Commercially Reasonable Efforts to supply, or cause to be supplied, during the Agreement Term, in
accordance with cGMP, all agreed-upon 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 36 

 
specifications, and requirements of applicable Regulatory Authorities, all of the requirements for Product in the Territory. Teva shall use Commercially
Reasonable Efforts that any arrangement entered into between Teva and any Third Party with respect to the manufacturing of Compound, Product, or any portion thereof shall provide for the assignment of such arrangement to Indevus upon any termination
of this Agreement. 
 ARTICLE 5 
 PAYMENTS AND STATEMENTS 
 5.1 Milestone Payments. In consideration of the rights granted by Indevus hereunder, Teva
shall pay Indevus the following non-refundable milestone payments, contingent upon occurrence of the specified event, with each milestone payment to be made no more than once with respect to the achievement of such milestone event (but payable the
first time such milestone event is achieved), regardless of whether such achievement is by Teva or any Affiliate or sublicensee of Teva: 
  

					
		 	 [***]
	  	
			
		 		  	
			
		 		  	
			
		 		  	
			
		 		  	
			
		 		  	
			
		 		  	

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 37 

 Each milestone payment shall be deemed earned as of the achievement of the related milestone event. Teva shall notify
Indevus in writing of the achievement of the milestones set forth in Sections 5.1(a) through (f) within [***] after the achievement thereof, and of the achievement of the milestone set forth in Section 5.1(g) within [***]
after such milestone is achieved. On the date of such notice, the applicable milestone payment shall be paid by Teva. Notwithstanding the expiration of the Royalty Term in any country in the Territory, Net Sales of Product in any such country(ies)
shall continue to be included in Net Sales for the purposes of determining the achievement of the milestone set forth in Section 5.1(g). 
 5.2 Next Trial Costs and Costs Associated with Activities Set Forth in the First Period Plan and Budget. 
 (a) Next Trial
Costs. Indevus shall be responsible for the initial payment of Next Trial Costs; provided, however, that in consideration of Indevus’ performance of the Next Trial, Teva shall reimburse Indevus for Next Trial Costs in
accordance with Section 5.4(a). 
 (b) Reimbursement of Other Indevus Development Costs. Teva shall reimburse Indevus for certain
Development costs, such costs to include all external out-of-pocket costs and expenses for such Development and the costs of such Development activities performed by Indevus’ FTEs (valued at Indevus’ then current FTE reimbursement rate),
and incurred by Indevus prior to the Effective Date and, excluding the Next Trial Costs reimbursed by Teva pursuant to Section 5.2(a) and Section 5.4(a), after the Effective Date, subject to the following conditions: 
 (A) If the Primary Endpoint is achieved, Teva shall pay Indevus [***] as reimbursement of such other Development costs within
[***] after the Next Trial Completion; and 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 38 

 (B) if Teva, at its sole discretion, issues a Go Decision, Teva shall pay Indevus
[***] as reimbursement of such other Development costs within [***] after the issuance of such Go Decision. 
 (c) Payments
of Costs Associated with Activities Set Forth in the First Period Plan and Budget. Teva shall be responsible for initial payment of all costs associated with activities set forth in the First Period Plan and Budget; provided,
however, that Indevus shall reimburse Teva for fifty percent (50%) of all such costs, in accordance with Section 5.4(b). Notwithstanding the foregoing, any costs that would constitute a Significant Plan Amendment (regardless of
whether such costs are incurred prior to or after delivery to Indevus of such Significant Plan Amendment) shall not be deemed costs subject to reimbursement hereunder if, within [***] after receipt of the required Significant Plan Amendment,
Indevus deems such Significant Plan Amendment a Royalty Conversion Event pursuant to Section 5.3(b), provided, however, that all other costs associated with activities set forth in the First Period Plan and Budget that are
incurred from and after Indevus’ receipt of such Significant Plan Amendment up to and including the date of a Royalty Conversion Event, if any, shall be deemed costs subject to reimbursement hereunder. 
 5.3 Other Payments. 
 (a) Fee and
Royalty Payments. 
 (i) If, for any Calendar Quarter during the U.S. Collaboration Period, the U.S. Gross Margin is a
positive number, Teva shall, pursuant to the provisions of Section 5.4(c), pay to Indevus a fee in an amount equal to fifty percent (50%) of the U.S. Gross Margin. 
 (ii) If, for any Calendar Quarter during the U.S. Collaboration Period, the U.S. Gross Margin is a negative number, Indevus shall,
pursuant to the provisions of Section 5.4(c), pay to Teva a fee in an amount equal to fifty percent (50%) of the absolute value of the U.S. Gross Margin. 
 (iii) During the Royalty Term, Teva shall, pursuant to Section 5.4(d), pay to Indevus (A) with respect to each country outside
the United States other than [***], 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 39 

 
royalties in an amount equal to [***] of Net Sales of Product in such country, and (B) with respect to the United States, milestone payments and
royalties on Net Sales of Product within the United States as set forth on Schedule 5.3(a). 
 (iv) The percentage of
Net Sales of Product used for the calculation of royalty payments payable during the Royalty Term shall be reduced by [***] in each country in which Generic Competition exists; provided, however, that if Substantial Level
Generic Competition exists in a country, then the Royalty Term shall terminate with respect to such country, and no further royalties shall be payable by Teva to Indevus in the subject country. 
 (v) In the event of a launch by Teva of an Authorized Generic Product in a particular country in accordance with Section 2.4, Teva
shall, pursuant to Section 5.4(d), pay Indevus an amount equal to [***] of the Net Sales of such Authorized Generic Product in such country during the Authorized Generic Royalty Term. 
 (b) Termination of U.S. Collaboration Period. Upon the occurrence of the following events (each, a “Royalty Conversion Event”),
the applicable Party specified below may terminate the U.S. Collaboration Period: 
 (i) Teva, upon the occurrence of the
Decision Point set forth in Section 1.26 (d), may in its discretion provide Indevus with written notice within [***] of such Decision Point of its election to terminate the U.S. Collaboration Period. 
 (ii) Indevus, upon the occurrence of any of the Decision Points set forth in Section 1.26, may in its discretion provide Teva with
written notice within [***] of such Decision Point of its election to terminate the U.S. Collaboration Period. 
 If notice of termination is provided
in accordance with this Section 5.3(b), (i) the U.S. Collaboration Period shall terminate effective on the Business Day immediately following delivery of such notice, and (ii) the U.S. License Period shall commence on the Business Day
immediately following the effective date of such termination. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 40 

 5.4 Reports and Payments. 
 (a) Next Trial Costs. Teva shall make payments to Indevus as reimbursement of Next Trial
Costs as follows: Teva shall pay Indevus (i) within [***] after the Effective Date, [***]; and (ii) not later than the [***] commencing after the Effective Date, (A) [***] following the Effective Date, and
(B) [***] thereafter. Within [***] following the Go Decision or the No Go Decision, as applicable, Indevus shall submit to Teva a written report of the aggregate actual Next Trial Costs incurred by Indevus in a form reasonably
agreed by the Parties. If such aggregate actual Next Trial Costs are less than [***], such report shall be accompanied by payment from Indevus to Teva of an amount equal to the difference between [***] and such aggregate Next Trial
Costs. If such aggregate actual Next Trial Costs are greater than [***], within [***] following receipt by Teva of such report, Teva shall reimburse Indevus an amount equal to fifty percent (50%) of the difference between such
aggregate Next Trial Costs and [***], provided that any such reimbursement shall be subject to Section 4.4(b). 
 (b) Costs Associated with Activities Set Forth in the First Period Plan and Budget. Within [***] following the end of each Calendar Quarter during the U.S. Collaboration Period, Teva shall submit to Indevus, with respect to
such Calendar Quarter and for the then-current Calendar Year through the end of such Calendar Quarter, a written report of actual costs incurred in connection with activities set forth in the First Period Plan and Budget for such Calendar Quarter.
Within [***] following receipt by Indevus of such final written report, Indevus shall, subject to the provisions of Section 5.2(c), pay Teva fifty percent (50%) of such costs incurred during such Calendar Quarter. 
 (c) U.S. Gross Margin. Within [***] following the end of each Calendar Quarter during the U.S. Collaboration Period, Teva shall submit to
Indevus, with respect to such Calendar Quarter and for the then-current Calendar Year through the end of such Calendar Quarter, a written report of (i) the actual costs included in the calculation of the U.S. Gross Margin, and (ii) the
gross sales, Net Sales of Product and the calculation of the U.S. Gross Margin, including a breakdown of all deductions taken in any such calculations, in each case consistent with Section 1.91, for such Calendar Quarter. Each such written
report shall be accompanied by payment to Indevus, pursuant to Section 5.3(a)(i), of a fee in an amount equal to 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 41 

 
fifty percent (50%) of the U.S. Gross Margin if the U.S. Gross Margin is positive for such Calendar Quarter. If the U.S. Gross Margin is negative for
such Calendar Quarter, Indevus shall, pursuant to Section 5.3(a)(ii), pay to Teva a fee in an amount equal to fifty percent (50%) of the absolute value of the U.S. Gross Margin within [***] after receipt of such written report.

 (d) Royalty and Other Payments. Within [***] following the end of each Calendar Quarter beginning or ending during the
Royalty Term or Authorized Generic Royalty Term, Teva shall submit to Indevus a written report providing, with respect to Product or Authorized Generic Product, as applicable, for such Calendar Quarter and for the then-current Calendar Year through
the end of such Calendar Quarter, on a country-by-country basis, gross sales, Net Sales and the royalties and other amounts payable in accordance with Section 5.3(a)(iii) or Section 5.3(a)(v), as applicable, for such Calendar Quarter, with
a breakdown of all deductions taken in any such calculations, in accordance with this subsection (d), and stating (i) the total gross sales and Net Sales in each country in the Territory during such Calendar Quarter in each country’s
currency, and (ii) the applicable currency exchange rates used to convert from each country’s currency to United States Dollars. The conversion to United States Dollars shall be calculated in accordance with Section 5.5(c). In the
event of any royalty reduction during any Calendar Quarter due to Generic Competition in any country in the Territory, the written report for such Calendar Quarter shall also show the basis for the determination of such Generic Competition.
Royalties and other amounts shown to have accrued by each written report shall be due and payable on the date such written report is due. 
 (e) Teva shall also furnish Indevus a written report on a country-by-country basis for the first Calendar Quarter commencing after the expiration of the Royalty Term in any country setting forth the basis for Net Sales of Product then being
free of royalty obligations hereunder. Teva shall thereafter have no further obligation to include in a report the Net Sales of Product in such country for purposes of the royalty calculation for any Calendar Quarter, but until such time as the
milestone payment required by Section 5.1(g) has been paid, Teva shall continue to be required to include Net Sales of Product in such country in the portion of the report showing cumulative Net Sales of Product in the Territory for the
then-current Calendar Year through the end of the applicable Calendar Quarter. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 42 

 (f) In the event of a Change of Control of Indevus, notwithstanding anything to the contrary in this
Agreement, any information required to be provided by Teva under this Agreement shall be subject to this Section 5.4(f). With the exception of cost and royalty reports as required under this Section 5.4 and updates on Development progress
of the Product as reasonably required to meet the reporting requirements of Indevus under the [***] (as such provisions exist on the Agreement Date), any other information that would otherwise be required to be delivered by Teva under this
Agreement may be redacted by Teva to the extent Teva considers such information competitively sensitive or that sharing such information may be in violation of Law, provided that to the extent any such redacted information is financial
in nature, Teva will provide it to the independent auditor of the Successor Entity as reasonably required to carry out the provisions of Section 5.6. 
 (g) Each Party shall keep and shall require its Affiliates to keep complete and accurate records in sufficient detail to permit accurate determination of all amounts necessary for calculation and verification of all
payment obligations set forth in this Article 5. 
 5.5 General Payment Provisions. 
 (a) Payment Method. All payments under this Agreement shall be made in United States Dollars by bank wire transfer in immediately available funds
to an account designated by Indevus or Teva, as applicable. Any payment required to be made by Teva to Indevus hereunder may, upon Indevus’ request, be made to Indevus’ designee, provided, however, that such payment shall
not, as determined in Teva’s sole discretion, result in any adverse economic consequence to Teva. 
 (b) Withholding Taxes.
Teva may deduct the amount of any taxes imposed on Indevus which are required to be withheld or collected by Teva, its Affiliates or sublicensees under the laws, rules or regulations of any country on amounts required to be paid by Teva to
Indevus hereunder. To the extent Teva, its Affiliates or sublicensees pay such withholding taxes to the appropriate governmental authority on behalf of Indevus, Teva shall promptly deliver to Indevus proof of payment of such taxes. Teva shall
cooperate with reasonable requests by Indevus to claim legally available exemption from withholding taxes under any double taxation or similar treaty from time to time in force and, thus, minimizing the amount required to be withheld. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 43 

 (c) Currency Exchange. For purposes of computing royalties or other payments based on Net
Sales of Products or Authorized Generic Products, as applicable, in any country outside the United States, such Net Sales shall be converted to United States Dollars using the average relevant rate of exchange for United States Dollars throughout
the then Calendar Quarter used by Teva for its internal financial accounting purposes in preparing its audited financial statements; provided, however, that the rates of exchange shall be as reported by The Wall Street Journal,
and shall in any event be in accordance with GAAP. 
 (d) Restrictions on Payment. If at any time legal restrictions prevent the
prompt remittance of part or all of the royalties or other payments with respect to Net Sales of Products or Authorized Generic Products, as applicable, in any country, or if by law, regulations or fiscal policy of a particular country, remittance
of royalties in United States Dollars is restricted or forbidden, notice thereof will be promptly given to Indevus, and payment shall be made through such lawful means or methods as Teva may determine after consultation with Indevus. 
 (e) Reduction for Third Party Royalties. If Teva would be prevented from selling Product in a country of the Territory on the grounds that by
doing so Teva would infringe a patent owned by a Third Party in said country (other than a patent subject to the SA Agreement), and Teva obtains a license to such patent in said country, Teva may deduct from any royalties or fees payable for a
Calendar Quarter to Indevus under this Agreement with respect to Net Sales of Product in such country, an amount equal to, at Teva’s sole discretion, (i) [***] of royalties or similar payments required to be made by Teva for such
Calendar Quarter to such Third Party, subject to Indevus’ prior approval not to be unreasonably withheld, or (ii) [***] of such royalties or payments if Indevus’ prior approval is not requested by Teva. 
 (f) Late Payments. Without limiting any Party’s remedies hereunder, in the event a payment required to be made under this Article 5 is not
made on or prior to the required payment date, and such payment is not being disputed in good faith, the amount of the late payment shall bear interest at the [***] commencing on the date such payment is due until such date as the payment is
made. [***]. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 44 

 (g) Except as otherwise defined herein, all financial calculations by either Party under this Agreement
shall be calculated in accordance with GAAP. In addition, all calculations shall give pro rata effect to and shall proportionally adjust (by giving effect to the number of applicable days in such Calendar Quarter) (i) for any Calendar
Quarter that is shorter than a standard Calendar Quarter or any Calendar Year that is shorter than four consecutive full Calendar Quarters, or (ii) as a result of a determination, in accordance with the terms of this Agreement, that the first
or last day of such Calendar Quarter (including as a result of termination of the U.S. Collaboration Period, commencement of the U.S. License Period, or termination of this Agreement) shall be deemed other than the actual first or last day of such
Calendar Quarter, or that the first or last day of such Calendar Year shall be deemed other than the actual first or last day of such Calendar Year. 
 5.6 Audits. Upon the written request of Indevus, Teva shall permit an independent certified public accounting firm of recognized standing, selected by Indevus and reasonably acceptable to Teva, provided
that such accounting firm shall not be retained or compensated on a contingency basis, to have access not more than once in any Calendar Year, during normal business hours, to such of the records of Teva as may be reasonably necessary to
verify the accuracy of the reports under Section 5.4 hereof for any year ending not more than [***] prior to the date of such request. The accounting firm shall disclose to Indevus whether the reports are correct or incorrect, the
specific details concerning any discrepancies (including the accuracy of the calculation of Net Sales of Products or Authorized Generic Products, as applicable, and the resulting effect of such calculations on the amounts payable by Teva under this
Agreement) and such other information that should properly be contained in a report required under this Agreement. Teva shall have reciprocal audit rights for reports to be provided by Indevus under this Agreement. 
 (a) If such accounting firm concludes that additional amounts were owed during such year, then the audited Party shall pay the additional payments,
together with interest at the [***] on the amount of such additional payments, within [***] of the date the auditing 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 45 

 
Party delivers to the audited Party such accounting firm’s written report so concluding. In the event such accounting firm concludes that amounts were
overpaid by the audited Party during such period, the auditing Party shall repay the audited Party the amount of such overpayment, together with interest at the [***] on the amount of such overpayment, within [***] of the date the
auditing Party delivers to the audited Party such accounting firm’s written report so concluding. The fees charged by such accounting firm shall be paid by the auditing Party; provided, however, that if an error in favor of the
auditing Party of more than [***] of the payments due hereunder for the period being reviewed is discovered, then the fees and expenses of the accounting firm shall be paid by the audited Party. 
 (b) Upon the expiration of [***] following the end of any year for which Teva or Indevus has made payment in full of amounts payable with respect
to such year, and in the absence of negligence or willful misconduct of Teva or Indevus or a contrary finding by an accounting firm pursuant to Section 5.6(a), such calculation shall be binding and conclusive upon Teva or Indevus, and Teva or
Indevus, as applicable, shall be released from any liability or accountability with respect to royalties or other payments for such year. 
 (c) Each Party shall treat all financial information subject to review under this Section 5.6 in accordance with the confidentiality provisions of this Agreement, subject to its existing agreements with Third Parties. 
 ARTICLE 6 
 REPRESENTATIONS AND
WARRANTIES 
 6.1 General Representations. Each Party hereby represents and warrants to the other Party as follows: 
 (a) Such Party is a corporation duly organized, validly existing and is in good standing under the laws of the jurisdiction of its incorporation, is
qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the conduct of its business or the ownership of its properties requires such qualification and failure to have such would prevent it from
performing its obligations under this Agreement; 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 46 

 (b) The execution, delivery and performance by such Party of this Agreement have been duly authorized by
all necessary corporate action and do not and will not (i) violate any provision of any law, rule, regulation, order, writ, judgment, injunction, decree, determination or award presently in effect having applicability to it or any provision of
its charter or bylaws; or (ii) conflict with or constitute a default under any other agreement to which such Party is a party; 
 (c)
This Agreement has been duly executed and is a legal, valid and binding obligation of such Party, enforceable against it in accordance with the terms and conditions hereof, except as enforceability may be limited by (i) any applicable
bankruptcy, insolvency, reorganization, moratorium or similar law affecting creditor’s rights generally, or (ii) general principles of equity, whether considered in a proceeding in equity or at law; 
 (d) Such Party is not under any obligation to any person or entity, contractual or otherwise, that is in conflict with the terms of this Agreement, nor
shall such Party undertake any such obligation during the Agreement Term; 
 (e) Except as set forth in Section 11.6, such Party has
obtained all authorizations, consents and approvals, governmental or otherwise, necessary for the execution and delivery of this Agreement, and to otherwise perform such Party’s obligations under this Agreement; 
 (f) Except for SA’s rights under the SA Agreement, neither Party, nor any of its Affiliates, is a party to, or is otherwise bound by, any oral or
written contract that will result in any person or entity obtaining any interest in, or that would give to any Third Party any right to assert any claim in or with respect to, any of such Party’s or the other Party’s rights under this
Agreement; and 
 (g) Such Party shall perform its obligations hereunder in accordance with all applicable Laws. 
 6.2 Additional Indevus Representations and Warranties. Indevus represents and warrants to Teva that: 
 (a) As of the Agreement Date, (i) Indevus has no reason to believe that any of the Indevus Intellectual Property is, or is likely to be held, invalid
or unenforceable; and (ii) to Indevus’ knowledge, the Indevus Intellectual Property is in full force and not subject to any pending or threatened re-examination, re-issue, opposition, interference or litigation proceedings; 
  

 47 

 (b) As of the Agreement Date in the Territory, except for SA’s rights under the SA Agreement,
(i) Indevus is the sole and exclusive owner of, or Controls and has the sole right to enforce and collect damages and/or royalties from the Indevus Intellectual Property and (ii) the Indevus Intellectual Property is not subject to any
encumbrance, lien, license to or claim of ownership by any Third Party; 
 (c) At no time during the Agreement Term shall Indevus assign,
transfer, encumber or grant rights in or with respect to the Indevus Intellectual Property inconsistent with the rights granted to Teva under this Agreement; 
 (d) (i) Schedule 2.6 sets forth a list of all contracts, agreements and other arrangements (in addition to the SA Agreement and the Warner Assignment and License) between Indevus and any and all Third Parties
relating to Development or Commercialization that will be in effect as of the Go Decision (“Third Party Agreements”). (ii) Except as set forth in Schedule 2.6, there are no contracts, agreements or other
arrangements between Indevus and any Third Parties relating to Development or Commercialization that could reasonably be anticipated to have an impact in any respect upon the rights granted to Teva or Indevus’ obligations under this Agreement
(excluding the SA Agreement and the Warner Assignment and License); 
 (e) The data and information provided in writing to Teva or its
Affiliates prior to the Agreement Date relating to pre-clinical and clinical studies related to Compound has been accurate in all material respects and Indevus has made no material misrepresentation or material omission in connection with such data
and information. Indevus has also provided Teva or its Affiliates with access to summaries of all material adverse events known to Indevus relating to the Compound; 
 (f) To Indevus’ knowledge, as of the Agreement Date, the manufacture, use importation and/or sale of the Product in the Territory as contemplated under this Agreement does not and would not infringe or
misappropriate any patents or other intellectual property right of any Third Party; 
  

 48 

 (g) All Product manufactured by Indevus, or manufactured by a Third Party on behalf of Indevus, and
delivered to Teva under this Agreement, shall be manufactured in compliance with cGMP and all other applicable Laws; and 
 (h) As of the
Agreement Date, the SA Agreement, the Warner Assignment and License and the Third Party Agreements are in full force and effect in accordance with its terms. As of the Agreement Date, Indevus is not in default or breach in any material respect of
the SA Agreement, the Warner Assignment and License or the Third Party Agreements, nor has it, as of the Agreement Date received any notice of any defaults, breaches or violation thereunder. To Indevus’ knowledge as of the Agreement Date, no
other party to the SA Agreement, the Warner Assignment and License or the Third Party Agreements is in default or breach of such agreement. Indevus has provided Teva with copies of the SA Agreement, Warner Assignment and License and Third Party
Agreements that are true, correct and complete as of the Agreement Date. 
 6.3 Disclaimer of Additional Warranties. EACH PARTY HEREBY
EXPRESSLY DISCLAIMS ANY OTHER WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR
PURPOSE, EVEN IF EITHER PARTY HAS BEEN ADVISED OF SUCH PURPOSE. 
 ARTICLE 7 
 PATENT MATTERS 
 7.1 Ownership of Inventions. 
 (a) Except as otherwise provided in and subject to the terms of this Agreement, as between the Parties: 
 (i) Indevus shall own and retain all right, title and interest in the Indevus Intellectual Property, subject to the provisions of
Section 7.7 and the licenses granted to Teva under this Agreement; and 
  

 49 

 (ii) Teva shall own and retain all right, title and interest in or Control over, as
applicable, all Teva Know-How and Teva Patent Rights, including all Intellectual Property which is made, conceived, discovered, reduced to practice or generated from and after the Go Decision, (A) solely by Indevus’ employees, agents, or
other persons acting under its authority, (B) solely by Teva’s employees, agents, or other persons acting under its authority, or (C) any combination of (A) or (B) hereof. 
 (b) Employees and Agents. Each of Indevus and Teva shall require all of its and its Affiliates’ employees to assign all inventions and
corresponding patent applications that are developed, made, or conceived by such employees during the Agreement Term to Indevus or Teva according to the ownership principles described in Section 7.1(a). Each Party shall use Commercially
Reasonable Efforts to require any Third Parties working on the Next Trial or any Development under this Agreement or who receive materials relating to Product or Know-How from a Party, to assign or grant a sublicenseable license on an exclusive,
fully paid-up, royalty-free basis to all inventions and corresponding Patent Rights that are developed, made or conceived by such Third Parties during the Agreement Term to Indevus or Teva according to the ownership principles described in
Section 7.1(a). 
 7.2 Maintenance and Prosecution. 
 (a) Assignable Patents. From and after the Go Decision, Teva shall have the first right to file, prosecute and maintain the Assignable Patents in Indevus’ name, using patent counsel selected by Teva, and
shall be responsible for the payment of all patent prosecution and maintenance costs. Teva agrees to keep Indevus fully informed of the course of patent prosecution or other proceedings, including by providing Indevus with copies of office actions
received by Teva from the United States Patent and Trademark Office concerning the Assignable Patents. If Teva elects not to file, prosecute or maintain a patent application or patent included in the Assignable Patents in the Territory, it shall
provide Indevus with no less than [***] written advance notice sufficient to avoid any loss or forfeiture, and Indevus shall have the right, but not the obligation, at its sole expense, to file, prosecute or maintain such Assignable Patent.

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 50 

 (b) [***]. Teva acknowledges and agrees that pursuant to the [***],
[***] has the first right to prosecute and maintain the [***]. Indevus shall provide all material information relating to the status and progress of the prosecution and maintenance of the [***], and copies of all materials
relating thereto, which Indevus receives from [***] within ten (10) Business Days after Indevus receives such information and materials from [***]. In the event [***] advises Indevus pursuant to the [***] that it
elects or has elected not to file, prosecute or maintain in any jurisdiction, patents or patent applications contained within the [***], and Indevus has the right to assume or has assumed such filing, prosecution or maintenance, Indevus shall
so notify Teva and the filing, prosecution and maintenance of such patents and patent applications shall thereafter be in accordance with the provisions of Section 7.2(a). 
 (c) Teva Patent Rights. Teva shall have the first right to file, prosecute and maintain the Teva Patent Rights in Teva’s name, using patent
counsel selected by Teva and shall be responsible for the payment of all patent prosecution and maintenance costs. Teva agrees to keep Indevus informed of the course of patent prosecution or other proceedings including by providing Indevus with
copies of office actions received by Teva from the United States Patent and Trademark Office concerning Teva Patent Rights. If Teva elects not to file, prosecute or maintain a patent application or patent included in the Teva Patent Rights, it shall
provide Indevus with no less than [***] written advance notice sufficient to avoid any loss or forfeiture, and subject to Teva’s prior written consent, Indevus shall then have the right, but not the obligation, at its sole expense, to
file, prosecute or maintain such Patent Right. 
 (d) The responsible Party under this Section 7.2 shall solicit the other Party’s
review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to the filing thereof, and the responsible Party shall take into account the other Party’s
reasonable comments related thereto. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 51 

 7.3 Third Party Infringement.  
 (a) Each Party shall promptly give the other Party notice of any actual or suspected infringement by a Third Party in the Territory of any patent included
in the Indevus Patent Rights or Teva Patent Rights (collectively, the “Parties’ Patent Rights”), which comes to such Party’s attention. The Parties shall thereafter consult and cooperate to determine a course of action,
including the commencement of legal action. 
 (b) Teva shall have the first right to initiate and prosecute such legal action at its own
expense and in the name of Indevus and/or Teva, or to control the defense of any declaratory judgment action relating to the Parties’ Patent Rights, and Teva shall provide Indevus with reasonable notice of any such action it commences and keep
Indevus reasonably informed of any significant developments in such action. Indevus shall render, at its expense, all assistance reasonably requested in connection with any action taken by Teva or to prevent such infringement. However, the control
of such action, including whether to initiate any legal proceeding and/or the settlement thereof, shall solely be under the control of Teva; provided that Teva shall not settle any such claim or proceeding in a manner that materially
adversely affects Indevus’ rights under this Agreement or which results in any material monetary payment by or financial loss to Indevus, without Indevus’ prior written consent, which consent, subject to the foregoing, shall not be
unreasonably withheld. 
 (c) If Teva elects not to initiate and prosecute an infringement or defend a declaratory judgment action in any
country in the Territory as provided in Section 7.3(b) within [***] after having become aware of such potential infringement, then Indevus may elect, which election shall be subject to the prior written consent of Teva, to take such
action that is reasonably necessary and appropriate to terminate or prevent such infringement, including instituting an infringement proceeding, provided, however, that Indevus shall not enter into any settlement or compromise of any
claim relating to the Parties’ Patent Rights licensed hereunder without the prior written consent of Teva, which consent shall not be unreasonably withheld. 
 (d) For any such legal action or defense, in the event that any Party is unable to initiate, prosecute, or defend such action solely in its own name, the other Party will join such action voluntarily and will execute
all documents necessary for the Party to prosecute, defend and maintain such action. In connection with any such action, the Parties will cooperate fully 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 52 

 
and will provide each other with any information or assistance that either reasonably may request. Any recovery or award obtained by either Party as a result
of any such action or settlement shall be shared as follows: 
 (i) the Party that initiated and prosecuted, or maintained the
defense of, the action shall recoup all of its reasonably documented costs and expenses (including reasonable outside attorneys’ fees) incurred in connection with the action, whether the recovery is by settlement or otherwise; 
 (ii) the other Party then shall, to the extent possible, recover its reasonably documented costs and expenses (including reasonable
outside attorneys’ fees) incurred in connection with the action; 
 (iii) if Indevus initiated and prosecuted, or
maintained the defense of, the action, the amount of any recovery remaining then shall be [***] by the Parties; and 
 (iv) if Teva initiated and prosecuted, or maintained the defense of, the action, the amount of any recovery remaining then shall be [***]. 
 7.4 Third Party Intellectual Property. 
 (a) In the event that a Party becomes aware of any claim that
the practice by either Party of Know-How or Patent Rights or manufacture, import, use or sale of Product hereunder infringes the intellectual property rights of any Third Party, such Party shall promptly notify the other Party. The Parties shall
thereafter discuss the situation, and to the extent reasonably necessary, attempt to agree on a course of action. 
 (b) If within
[***] the Parties fail to agree upon an appropriate course of action, Teva shall have the first right, but not the obligation, to defend any action related to the intellectual property rights of any Third Party or to initiate and prosecute
legal action related to the intellectual property rights of any Third Party in the name of Teva and/or 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 53 

 
Indevus. Teva shall keep Indevus reasonably informed as to the progress of any such action. Indevus shall render, at its expense, all assistance reasonably
requested in connection with any action taken by Teva. However, the control of such action, including whether to initiate any legal proceeding and/or the settlement thereof, shall solely be under the control of Teva; provided that Teva
shall not settle any such claim or proceeding in a manner that materially adversely affects Indevus’ rights under this Agreement or which results in any material monetary payment by or financial loss to Indevus, without Indevus’ written
consent, which consent, subject to the foregoing, shall not be unreasonably withheld. During the U.S. Collaboration Period, Indevus shall reimburse Teva for [***] of all Teva’s documented out of-pocket costs and expenses incurred in such
defense. 
 (c) If Teva elects not to defend an infringement action in any country in the Territory as provided in Section 7.4(b), and
Indevus elects to do so, which election shall be subject to the prior written consent of Teva, the cost of any agreed-upon course of action, including the costs of any legal action commenced or any infringement action defended, shall be borne solely
by Indevus, provided, however, that Indevus shall not enter into any settlement or compromise of any claim without the prior written consent of Teva, which consent shall not be unreasonably withheld. 
 (d) For any such legal action or defense, in the event that any Party is unable to initiate, prosecute, or defend such action solely in its own name, the
other Party will join such action voluntarily and will execute all documents necessary for the Party to prosecute, defend and maintain such action. In connection with any such action, the Parties will cooperate fully and will provide each other with
any information or assistance that either reasonably may request. 
 7.5 Patent Term Extensions. The Parties shall cooperate with each
other in obtaining patent term extensions or restorations or supplemental protection certificates or their equivalents in any country in the Territory where applicable and where desired by Teva. Elections with respect to obtaining such extension or
supplemental protection certificates shall be made in the same manner and with the same relative priorities between the Parties as is applicable to the prosecution and maintenance of Patent Rights pursuant to Section 7.2. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 54 

 7.6 Patent Marking. Teva shall mark, and shall require its Affiliates and sublicensees to mark,
all Products sold or distributed pursuant to this Agreement in accordance with the applicable patent statutes or regulations in the country or countries of manufacture and/or sale thereof. 
 7.7 Assignment of Assignable Patents. Following the first FDA Approval in the United States and Indevus’ receipt of the related milestone
payment required by Section 5.1(c), Indevus shall, at Teva’s sole cost and expense, assign to Teva Indevus’ entire right, title and interest in and to the Assignable Patents. In consideration thereof, Teva shall continue to make all
payments to Indevus set forth in this Agreement, including those set forth in and in accordance with the provisions of Article V. Such assignment shall not relieve Teva of its obligations with respect to such Assignable Patents under this Article 7,
nor shall it affect any of Teva’s other obligations hereunder. Notwithstanding such assignment to Teva, (a) the definition of “Indevus Patent Rights” shall continue to be interpreted to include the Assignable Patents;
(b) the definitions of “Valid Claim” and “Royalty Term” shall continue to be interpreted to include the Assignable Patents as Indevus Patent Rights; (c) the definition of “Teva Patent Rights” shall not be
interpreted to include the Assignable Patents; and (d) Teva shall not have the right to assign, transfer, pledge or grant to any Third Party any security interest in or lien on the Assignable Patents or Teva’s right, title or interest
therein. 
 ARTICLE 8 
 CONFIDENTIALITY AND PUBLICITY 
 8.1 Non-Disclosure and Non-Use Obligations. All Proprietary Information disclosed by
one Party to the other Party hereunder shall be maintained in confidence and shall not be disclosed to any Third Party or used for any purpose except as expressly permitted herein without the prior written consent of the Party that disclosed the
Proprietary Information to the other Party during the Agreement Term and for a period of [***] thereafter. The foregoing non-disclosure and non-use obligations shall not apply to the extent that such Proprietary Information: 
 (a) is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the disclosing Party, as documented by records;

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 55 

 (b) is or becomes properly in the public domain or knowledge without breach by either Party; 

(c) is subsequently disclosed to a receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the
disclosing Party; or 
 (d) is developed by the receiving Party independently of Proprietary Information received from the disclosing Party,
as documented by records. 
 8.2 Permitted Disclosure of Proprietary Information. Notwithstanding Section 8.1, a Party receiving
Proprietary Information of another Party may disclose such Proprietary Information: 
 (a) to governmental or other regulatory agencies in
order to obtain patents pursuant to this Agreement, or to gain approval to conduct clinical trials or to market Product, but such disclosure may be only to the extent reasonably necessary to obtain such patents or authorizations and in accordance
with the terms of this Agreement or as otherwise requested by the Regulatory Authorities; 
 (b) to its Affiliates, sublicensees, agents,
consultants or accountants in connection with Development or Commercialization, or to otherwise enable the receiving Party to fulfill its obligations and responsibilities under this Agreement, on the condition that prior to such disclosure such
entities agree to be bound by written obligations of confidentiality and non-use no less restrictive than the obligations set forth in this Article 8; or 
 (c) if required to be disclosed by law or court order, provided that notice is promptly delivered to the non-disclosing Party in order to provide an opportunity to challenge or limit the disclosure
obligations. 
 8.3 Certain Disclosures. Except as set forth in this Agreement or as required by law, neither Party shall make any
press release or other public announcement or other disclosure to a Third Party concerning the existence of or terms of this Agreement, the subject matter of this Agreement or the activities contemplated hereunder, without the prior written consent
of the other Party, which consent shall include agreement upon the nature and text of such release, 

  

 56 

 
announcement or other disclosure and shall not be unreasonably withheld or delayed. Each Party agrees to provide to the other Party a copy of any such press
release or other public announcement or disclosure as soon as reasonably practicable under the circumstances prior to its scheduled release. Each Party shall have the right to expeditiously (but in any event within [***] review and recommend
changes to any such press release or other public announcement or disclosure; provided, however, that such right of review and recommendation shall only apply for the first time that specific information is to be disclosed, and shall
not apply to the subsequent disclosure of substantially similar information that has previously been disclosed unless there have been material developments relating to Product since the date of the previous disclosure; provided,
further, that each Party shall provide to the other Party reasonable advance notice of any such subsequent disclosure; provided, however, that such advance notice shall not be required with respect to such subsequent disclosure
of this Agreement and the terms hereof by the Parties or their Affiliates in any filings required by the SEC, other governmental authority, or securities exchange, and that the Parties or their Affiliates may file this Agreement as an exhibit to any
filing with the SEC, other governmental authority, or securities exchange, and may distribute any such filing in the ordinary course of its business; provided, further, that to the maximum extent allowable by the rules and regulations
of the SEC, other governmental authority, or securities exchange, and except as required by applicable Laws, Indevus and Teva shall seek to redact any confidential information set forth in such filings, and each Party shall provide a draft of the
redacted version of this Agreement to the other Party no less than [***] prior to filing with the SEC, other governmental authority, or securities exchange, and give reasonable consideration to the other Party’s comments regarding any
proposed redaction.  
 8.4 Publications. Indevus shall not submit for written or oral publication any manuscript, abstract or
the like relating to the Compound or Product, without the prior written consent, which will not be unreasonably withheld or delayed, of Teva. If Indevus desires to submit such publication, it shall first deliver to Teva, for Teva’s prior
written consent, the proposed publication or an outline of the oral disclosure at least [***] prior to planned submission or presentation. Notwithstanding the generality of the foregoing, prior to the Go Decision, if either Party desires to
submit for written or oral publication any manuscript, abstract or the like relating to the Compound or Product, such Party shall first deliver to the other Party 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 57 

 
such proposed publication (or an outline of such proposed presentation) for such other Party’s prior written consent (which consent will not be
unreasonably withheld), and a definitive response shall be provided by such other Party as soon as reasonably practicable but in any event no later than [***] after its receipt. From and after the Go Decision, Teva shall provide Indevus from
time to time with copies of any of its publications relating to the Compound or Product. The contribution of each Party, if any, shall be noted in all publications or presentations by acknowledgment or co-authorship, whichever is appropriate.

 ARTICLE 9 
 TERM AND
TERMINATION 
 9.1 Term and Expiration. 
 (a) This Agreement shall be effective as of the Agreement Date and, unless terminated earlier pursuant to Section 9.2, shall extend for a period (the “Agreement Term”) which shall expire on a
country by country basis in each country in the Territory on the date that Teva is no longer obligated to pay any fees or royalties to Indevus hereunder. 
 (b) Upon expiration of this Agreement on a country by country basis, all rights and licenses granted to Teva hereunder with respect to the Indevus Intellectual Property in such country shall be deemed fully paid up
and shall survive such expiration and Teva shall be relieved of any obligation to pay Indevus any royalties or other fees hereunder with respect to such country except those accrued prior to the date of expiration. 
 9.2 Early Termination of Agreement Term. 
 (a) Termination by Teva. Teva may terminate this Agreement in its sole discretion 
 (i) by providing written
notice of termination (a “No Go Decision”) within [***] of the Next Trial Completion; or 
 (ii) upon not
less than [***] prior written notice of termination provided anytime after the issuance of the Go Decision, provided, however, that no such termination shall be effective until the completion of any then ongoing Clinical Study. If Teva
terminates this Agreement pursuant to this Section 9.2(a)(ii) after a Product has 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 58 

 
received Regulatory Approval in (A) the United States, Indevus shall pay Teva an amount equal to [***] of Indevus’ total revenues related to
the Product, or (B) an EU Major Market (but not the United States), Indevus shall pay Teva an amount equal to [***] of Indevus’ total revenues related to the Product, in each case on a country by country basis; provided,
however, that the aggregate amount payable to Teva shall not exceed [***]. 
 (b) Termination by Either Party.

 (i) Either Party may, without prejudice to any other remedies available to it under this Agreement or at law or in equity,
terminate this Agreement prior to expiration of the Agreement Term in the event that the other Party (as used in this subsection, the “Breaching Party”) shall have breached or defaulted in the performance of any of its material
obligations hereunder, and has not cured such breach within (i) [***] after notice of such breach is provided to the Breaching Party in case the breach is a non-payment of any amount due under this Agreement that is not being disputed in
good faith (which shall be deemed a breach of a material obligation) and (ii) [***] after notice of such breach is provided to the Breaching Party for other cases of breach (or, if such default cannot be cured within such [***],
if the Breaching Party does not commence and diligently continue actions to cure such default during such [***]). The termination shall become effective at the end of the (i) [***] in case the breach is a non-payment of any amount
due under this Agreement that is not being disputed in good faith if the Breaching Party has not cured such breach by such date, or (ii) for other cases of breach, [***] unless (a) the Breaching Party cures such breach during such
[***], or (b) if such breach is not susceptible to cure within such [***], the Breaching Party has commenced and is diligently pursuing a cure (unless such breach, by its nature, is incurable, in which case this Agreement may not
be terminated unless the Breaching Party fails to use its best commercially reasonable efforts to prevent a similar subsequent breach). The right of either Indevus or Teva to terminate this Agreement as provided in this Section 9.2(b)(i) shall
not be affected in any way by such Party’s waiver or failure to take action with respect to any previous breach or default. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 59 

 (ii) Either Party may, without prejudice to any other remedies available to it under this
Agreement or at law or in equity, terminate this Agreement upon the filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of
creditors by the other Party; provided, however, in the case of any involuntary bankruptcy, reorganization, liquidation, receivership or assignment proceeding such right to terminate shall only become effective if the Party consents to
the involuntary proceeding or such proceeding is not dismissed within [***] after the filing thereof. 
 (iii) Either
Party may terminate this Agreement by providing written notice to the other Party if (A) the waiting period under the HSR Act has not expired or has not been terminated on or before [***] after the date the HSR Filing is submitted
pursuant to Section 11.6, or (B) such expiration or termination has conditions imposed on a Party by the United States Federal Trade Commission or the Antitrust Division of the United States Department of Justice that such Party in its
sole discretion deems unacceptable. 
 (c) Termination by Indevus. Indevus will have the right to terminate this Agreement in its
entirety or with respect to the affected countries, by written notice to Teva in the event Teva or any of its Affiliates or sublicensees commences any legal proceeding seeking to challenge or otherwise dispute the validity or ownership of any of the
Indevus Patent Rights or any of the claims therein, or knowingly assists any Third Party to do any of the foregoing, which termination shall be effective on the date set forth in such notice. 
 9.3 Rights Not Affected. All rights and licenses granted pursuant to this Agreement are, and shall otherwise be deemed to be, for purposes of
Section 365(n) of Title 11, U.S. Code (the “Bankruptcy Code”) licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code. The Parties agree that Teva and Indevus shall
retain and may fully exercise all of their respective rights, remedies and elections under the Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy or 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 60 

 
reorganization case by or against a Party under the Bankruptcy Code, the other Party shall be entitled to all applicable rights under Section 365
(including Section 365(n)) of the Bankruptcy Code. Upon rejection of this Agreement by a Party or a trustee in bankruptcy for such Party, pursuant to Section 365(n), the other Party may elect (i) to treat this Agreement as terminated
by such rejection or (ii) to retain its rights (including any right to enforce any exclusivity provision of this Agreement) to intellectual property (including any embodiment of such intellectual property) under this Agreement and under any
agreement supplementary to this Agreement for the duration of this Agreement and any period for which this Agreement could have been extended by such other Party, subject, however, to the continued payment of all amounts owing under this Agreement,
all of which amounts shall be deemed to be royalties for purposes of Section 365(n) of the Bankruptcy Code. Upon written request to the trustee in bankruptcy or bankrupt Party, the trustee or Party, as applicable, shall (i) provide to the
other Party any intellectual property, including all Indevus Intellectual Property (including any embodiment of such intellectual property) held by the trustee or the bankrupt Party and shall provide to the other Party a complete duplicate of (or
complete access to, as appropriate) any such intellectual property including all Indevus Intellectual Property and all embodiments of such intellectual property and (ii) not interfere with the rights of the other Party to such intellectual
property as provided in this Agreement or any agreement supplementary to this Agreement, including any right to obtain such intellectual property (or such embodiment or duplicates thereof) from a Third Party. 
 9.4 Effect of Expiration or Termination. 
 (a) Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination, including all accrued payment obligations arising under Article 5. In addition to any other
provisions of this Agreement which by their terms continue after the expiration of this Agreement, the provisions of Article 8 and Article 10 shall survive the expiration or termination of this Agreement and shall continue in effect after the date
of expiration or termination for the longer of (i) [***] or (ii) the respective periods specified therein. In addition, any other provisions required to interpret and enforce the Parties’ rights and obligations under this
Agreement shall also survive, but only to the extent required for the full observation and performance of this Agreement. Any expiration 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 61 

 
or early termination of this Agreement shall be without prejudice to the rights of any Party against the other accrued or accruing under this Agreement prior
to termination. Except as expressly set forth herein, the rights to terminate as set forth herein shall be in addition to all other rights and remedies available under this Agreement, at law, or in equity, or otherwise. 
 (b) Payments of amounts owing to Indevus under this Agreement as of its expiration or termination shall be due and payable either (i) to the extent
such amounts can be calculated and a fixed sum determined at the time of expiration or termination of this Agreement, [***] after the date of such expiration or termination, or (ii) to the extent such amounts cannot be calculated and a
fixed sum determined at the time of expiration or termination of this Agreement, [***] after the date at which such amounts can be calculated and a fixed sum determined. In the event that the milestone event set forth in Section 5.1(g)
is achieved during the Calendar Year in which expiration or termination of this Agreement occurs, but after the effective date of such expiration of termination, Indevus shall be entitled to a pro rata portion of the milestone payment based on the
portion of such Calendar Year completed prior to the effective date of such expiration of termination. 
 (c) Upon termination, but not
expiration, of this Agreement, all rights and licenses granted hereunder with respect to the Indevus Intellectual Property shall immediately cease, subject to the provisions of Section 9.3 and this Section 9.4(c). Within [***] after
the effective date of termination of this Agreement, Teva shall notify Indevus of the amount of Product Teva, its Affiliates and sublicensees then have on hand or in the process of manufacture and shall have the right to sell in the Territory
(except with respect to any country in the Territory in which Product has been withdrawn or there is no Regulatory Approval), its remaining stock of Product for a period ending upon the earlier of: (i) Teva’s, its Affiliates’ and
sublicensees’ sale of all such remaining Product, or (ii) [***] after such termination, and the terms and conditions of this Agreement shall apply to such Product so sold. Indevus hereby grants a non-exclusive license to Teva as
necessary to sell such Product in the Territory, subject to payment of all related amounts due under this Agreement. Any remaining quantities of Product not sold during this period shall, at Indevus’ election, either be destroyed by Teva at
Teva’s cost or sold to Indevus at Teva’s cost to manufacture such Product. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 62 

 (d) In the event of termination of this Agreement pursuant to this Article 9, the following shall also be
applicable: (i) at Indevus’ request, Teva shall promptly transfer and return to Indevus copies of all Data, reports, records and materials in Teva’s possession or control that relate to Compound or Products and return to Indevus all
relevant records and materials in Teva’s possession or control containing Proprietary Information of Indevus, provided that Teva may keep one copy of such Proprietary Information of Indevus for archival purposes only;
(ii) Teva shall transfer to Indevus ownership of any INDs, Regulatory Approvals, Drug Approval Applications and any other regulatory filings or submissions made or filed for Product by Teva or its designees; (iii) Indevus shall promptly
return to Teva all relevant records and materials in Indevus’ possession or control containing Proprietary Information of Teva, provided that Indevus may keep one copy of such Proprietary Information of Teva for archival purposes
only; and (iv) if such termination occurs after the assignment of the Assignable Patents pursuant to Section 7.7, Teva (or any Affiliate of Teva, as applicable) will assign to Indevus all Teva’s (or such Affiliate’s) right, title
and interest to the Assignable Patents at Teva’s sole cost and expense. 
 (e) In the event of termination of this Agreement by Teva
under Section 9.2(a)(ii) or by Indevus under Sections 9.2(b)(i) or 9.2(c), then, upon the written request of Indevus provided to Teva within [***] of such termination, Teva shall (i) assign to Indevus those Teva Patent Rights, if
any, that specifically and only claim the Compound, the use of the Compound and/or methods of making the Compound (and in each case claim no other compound, combination, or product); and (ii) grant to Indevus a non-exclusive, royalty-free,
fully paid-up license in the Territory under (A) any Teva Patent Rights not included in (i) above and (B) any Teva Know-How, in each case which are reasonably necessary for Development and Commercialization by Indevus. 
 (f) During the [***] period immediately following any termination of this Agreement, Teva shall, if so requested by Indevus, reasonably cooperate
with Indevus to provide for an orderly transition to Indevus or its designee(s) of the Development and Commercialization activities being performed by Teva hereunder with respect to Product, and after receipt by Indevus of any notification of
termination by Teva hereunder, will provide Indevus with reasonable assistance that Indevus may request in responding to due diligence requests by Third Parties that Indevus is negotiating with as potential licensees for Compound or 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 63 

 
Product, provided that Teva shall not be required to disclose to such Third Parties Teva Proprietary Information that does not relate to
Compound or Product. In addition, Teva shall cooperate to transition to Indevus upon Indevus’ request any arrangement with any contractor from which Teva had arranged to obtain a supply of Compound or Product, provided that such
arrangement is assignable. In the event that such materials are manufactured by Teva or its Affiliates then, at Indevus’ request, Teva shall (a) provide Indevus, at the then current [***], such materials for the completion of any
Clinical Studies on-going as of the date of transition, and (b) supply to Indevus, at the then current [***], a final, reasonable quantity of material (bulk product or otherwise) as ordered by Indevus within [***] after the end of
the [***] period referenced in this Section 9.4(f). 
 ARTICLE 10 
 INDEMNIFICATION AND INSURANCE 
 10.1 Indemnity. For purposes of this
Article 10, “Indevus Indemnified Parties” refers to Indevus, its Affiliates and the officers, directors, employees, shareholders, agents and successors and assigns of Indevus and its Affiliates, and “Teva Indemnified
Parties” refers to Teva, its Affiliates and officers, directors, employees, shareholders, agents and successors and assigns of Teva and its Affiliates. 
 10.2 Teva Indemnification. Teva shall defend the Indevus Indemnified Parties from and against all suits, claims, actions, demands, complaints, lawsuits or other proceedings, (collectively,
“Claims”), that are brought by a Third Party, and shall indemnify and hold harmless to the fullest extent permitted by law the Indevus Indemnified Parties from and against any and all Losses, that arise out of or are attributable
to, (i) Teva’s negligence, recklessness or willful misconduct in exercising or performing any of its rights or obligations under this Agreement; or (ii) a material breach by Teva of any of its obligations, representations, warranties
or covenants under this Agreement; provided, however, that Teva shall not be obligated under this Section 10.2, to the extent it is shown by evidence acceptable in a court of law having jurisdiction over the subject matter and
meeting the appropriate degree of proof for such Claim that the Claim arose out of the negligence or wrongdoing on the part of Indevus. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 64 

 10.3 Indevus Indemnification. Indevus shall defend the Teva Indemnified Parties from and against
all Claims, in each case that are brought by a Third Party, and shall indemnify and hold harmless to the fullest extent permitted by law the Teva Indemnified Parties from and against any and all Losses that arise out of such Claims that are
attributable to, (i) Indevus’ negligence, recklessness or willful misconduct in exercising or performing any of its rights or obligations under this Agreement; or (ii) a material breach by Indevus of any of its obligations,
representations, warranties or covenants under this Agreement; provided, however, that Indevus shall not be obligated under this Section 10.3, to the extent it is shown by evidence acceptable in a court of law having jurisdiction
over the subject matter and meeting the appropriate degree of proof for such Claim that the Claim arose out of the negligence or wrongdoing on the part of Teva. 
 10.4 Indemnification Procedure. 
 (a) Each Party shall promptly notify the other Party in writing of
any Claim. Concurrent with the provision of notice pursuant to this Section 10.4(a), the Indemnified Party shall provide to the other Party copies of any complaint, summons, subpoena or other court filings or correspondence related to such
Claim and will give such other information with respect thereto as the other Party shall reasonably request. The Indemnifying Party and Indemnified Party shall meet to discuss how to respond to such Claim. Failure to provide prompt notice shall not
relieve any Party of the duty to defend or indemnify unless such failure materially prejudices the defense of any matter. Each Party agrees that it will take reasonable steps to minimize the burdens of the litigation on witnesses and on the ongoing
business of the Indemnified Parties including making reasonable accommodations to witnesses’ schedules when possible and seeking appropriate protective orders limiting the duration and/or location of depositions. 
 (b) Should either Party dispute that any Claim or portion of a Claim (“Disputed Claim”) of which it receives notice pursuant to
Section 10.4(a), is an indemnified Claim, it shall so notify the other Party providing written notice in sufficient time to permit such other Party to retain counsel and timely appear, answer and/or move in any such action. In such event, such
other Party shall defend against such Claim; provided, however, that such other Party shall not settle any Claim which it contends is an indemnified Claim without providing the Indemnifying 

  

 65 

 
Party [***] notice prior to any such settlement and an opportunity to assume the defense and indemnification of such Claim pursuant to this Agreement.
If it is determined that a Disputed Claim is subject to indemnification, the Indemnifying Party will reimburse the costs and expenses, including reasonable attorneys’ fees, of the Indemnified Party. 
 10.5 Settlement of Indemnified Claims. The Indemnifying Party under Section 10.2 or 10.3, as applicable, shall have the sole authority to
settle any Indemnified Claim without the consent of the other Party, provided, however, that an Indemnifying Party shall not, without the written consent of the other Party, as part of any settlement or compromise (i) admit to
liability on the part of the other Party; (ii) agree to an injunction against the other Party; or (iii) settle any matter in a manner that separately apportions fault to the other Party. The Parties further agree that as part of the
settlement of any Indemnified Claim, an Indemnifying Party shall obtain a full, complete and unconditional release from the claimant on behalf of the Indemnified Parties. 
 10.6 Insurance. 
 (a) Each Party shall maintain, commencing as of the Agreement Date, commercial
general liability insurance (including coverage for Product Liability, Contractual Liability, Bodily Injury, Property Damage and Personal Injury), in form and substance reasonably satisfactory to the other Party, with minimum limits of [***]
per occurrence and in the aggregate annually or, in case of Clinical Studies, during the period when such Clinical Studies are being conducted (the “Insurance”). However, if such Insurance is written on a claims-made form, it
shall continue for [***] following termination of this Agreement. The Insurance shall have retroactive date to or coinciding with the Agreement Date. Notwithstanding the foregoing, Teva may satisfy the foregoing obligation with respect to the
Insurance through self-insurance. 
 (b) Such Insurance shall insure against all liability arising out of the manufacture, use, sale,
distribution, or marketing of Product in and for the Territory. During the Agreement Term, each Party shall not permit such Insurance to be reduced, expired, materially amended or canceled during the period of the Insurance without reasonable prior
written notice, unless outside of the control of the Party, that shall be sent by registered mail to the other Party. Upon request each Party shall provide Certificates of Insurance to the other Party evidencing the coverage specified herein.

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 66 

 (c) Except as expressly stated herein, a Party’s liability to the other is in no way limited to the
extent of the Party’s insurance coverage. 
 (d) The Parties agree that neither Party shall be deemed to be an additional insured under
the terms of their respective insurance policies. The Parties further agree that neither Party shall be deemed to be an additional insured vendor under such policies. 
 (e) The Parties will use Commercially Reasonable Efforts that the Insurance shall contain an explicit clause, stating that each Party and its insurer waive their rights of subrogation against the other Party and its
directors, employees and/or any one on its behalf with respect to the Insurance. Such waiver shall not apply in the event of a malicious act. 
 (f) The Insurance shall be primary to any other insurance maintained by each Party and each Party hereby waives any claim or demand as to participation in any such other insurance. 
 (g) The Insurance shall be valid in any location worldwide regarding the activities performed by each Party hereunder (including worldwide jurisdictions)
for any destination or lawsuit which will be served against the other Party. 
 10.7 Limitation of Liability. IN NO EVENT SHALL EITHER
PARTY BE LIABLE TO THE OTHER OR ANY OF ITS AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES,
WHETHER BASED UPON A CLAIM OR ACTION OF CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER TORT, OR OTHERWISE, ARISING OUT OF THIS AGREEMENT. THE FOREGOING SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY
FROM AND AGAINST THIRD PARTY CLAIMS UNDER THIS ARTICLE 10. 
  

 67 

 ARTICLE 11 
 MISCELLANEOUS 
 11.1 Force Majeure. Neither Party shall be held liable or responsible to the
other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement during the period of time when such failure or delay is caused by or results from fire, flood,
earthquake, explosion, storm, blockage, embargo, war, acts of war (whether war be declared or not), terrorism, insurrection, riot, civil commotion, strike, lockout or other labor disturbance, failure of public utilities or common carriers, act of
God or act, omission or delay in acting by any governmental authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable. 
 11.2 Assignment. This Agreement may not be assigned or otherwise transferred without the prior written consent of the other Party;
provided, however, that either Party may assign this Agreement (a) to an Affiliate, (b) in connection with a Change of Control, or (c) if divestiture of Product (either alone or as a choice among one or more other
products) is required by Law, in each case without such consent; provided further, however, that such assignment shall not relieve the Party of its responsibilities for performance of its obligations under this Agreement. This
Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties. Any assignment not in accordance with this Agreement shall be void. 
 11.3 Severability. In the event that any of the provisions contained in this Agreement are held invalid, illegal or unenforceable in any respect,
the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties.
In such event, the Parties covenant and agree to renegotiate any such term, covenant or application thereof in good faith in order to provide a reasonably acceptable alternative to the term, covenant or condition of this Agreement or the application
thereof that is invalid or unenforceable, it being the intent of the Parties that the basic purposes of this Agreement are to be effectuated. 
  

 68 

 11.4 Notices. 
 (a) Correspondence, reports, documentation, and any other communication in writing between the Parties in the course of ordinary implementation of this Agreement (but not including any notice required by this
Agreement) shall be in writing and delivered by hand, sent by facsimile, or by overnight express mail (e.g., FedEx) to (i) during the U.S. Collaboration Period, any one (1) member of the CSC appointed by the Party which is to
receive such written communication, or any other way as the CSC deems appropriate, and (ii) during the remainder of the Agreement Term, in accordance with the provisions of Section 11.4(b). 
 (b) Extraordinary notices and communications (including but not limited to notices of termination, force majeure, material breach, change of address, or
any other notices required by this Agreement) shall be in writing and shall be deemed to have been given when delivered in person, or sent by overnight courier service (e.g., FedEx), postage prepaid, or by facsimile confirmed by prepaid
registered or certified air mail letter or by overnight express mail (e.g., FedEx), or sent by prepaid certified or registered air mail, return receipt requested, to the following addresses of the Parties (or to such other address or
addresses as may be specified from time to time in a written notice), and shall be deemed to have been properly served to the addressee upon receipt of such written communication, to the following addresses of the Parties: 
 if to Indevus to: 
 INDEVUS PHARMACEUTICALS,
INC. 
 33 Hayden Avenue 
 Lexington, MA 02421 
 Attention: Chief Executive Officer 
 Fax No.: [***] 
 if to Teva to:

 TEVA PHARMACEUTICAL INDUSTRIES LTD. 
 5 Basel Street 
 P.O. Box 3190 
 Petah Tiqva 49131 
 Israel 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 69 

 Attention: Vice President, Global Innovative Pipeline Management 
 Fax No.: [***] 
 With a copy to:

 TEVA PHARMACEUTICALS USA, INC. 
 425 Privet Road 
 Horsham, PA 19044 
 Attention: General Counsel 
 Fax No.: [***] 
 With a second copy to: 
 TEVA NEUROSCIENCE,
INC. 
 901 E. 104th Street 
 Kansas City, MO 64131 
 Attention: Vice President of Business Development 
 Fax No.: [***] 
 or to such other address as the Party to whom notice is to be given may have furnished to the other Parties in writing in
accordance herewith. Any such communication shall be deemed to have been given when delivered if personally delivered or sent by facsimile on a Business Day, upon confirmed delivery by nationally-recognized overnight courier if so delivered, and on
the third Business Day following the date of mailing if sent by registered or certified mail. 
 11.5 Specific Performance. Each of
the Parties acknowledges and agrees that the other Party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in all material respects or otherwise are breached. Accordingly, and notwithstanding 

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 70 

 
anything herein to the contrary, each of the Parties agrees that the other Party shall be entitled to seek injunctive relief to prevent breaches of the
provisions of this Agreement, and/or to enforce specifically this Agreement and the terms and provisions hereof, in any action instituted in any court or tribunal having jurisdiction over the Parties and the matter, without posting any bond or other
security, and that such injunctive relief shall be in addition to any other remedies to which such Party may be entitled, at law or in equity. 
 11.6 HSR Filing. 
 (a) On or about [***] from the Agreement Date, or such other date as the Parties may mutually
agree, each of Teva and Indevus will file with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice, any filing required of it in the reasonable opinion of both Parties under the HSR Act
with respect to the transactions contemplated hereby (an “HSR Filing”). A failure by a Party to so file shall entitle the other Party to immediately terminate this Agreement under Section 9.2(b)(i) without any cure period or
waiting period. The Parties will cooperate with one another to the extent necessary in the preparation of any such HSR Filing and shall seek early termination of the waiting period. Each Party will be responsible for its own costs and expenses and
one-half of the filing fees associated with any HSR Filing. Notwithstanding any other provision of this Agreement to the contrary, including those under Sections 4.1 and 5.1, neither Party shall be required to perform any obligation under this
Agreement (other than this Section 11.6(a)) until the Effective Date. 
 (b) In respect of any HSR Filing, each of Teva and Indevus will
use its good faith efforts to eliminate any concern on the part of any court or government authority regarding the legality of the proposed transaction, including cooperating in good faith with any government investigation and the prompt production
of documents and information demanded by a second request for documents and of witnesses if requested. 
 11.7 Further Assurances.
Each of the Parties shall take such further actions as shall be necessary or desirable in order to effectuate the respective rights and obligations hereunder in accordance with the terms and conditions of this Agreement. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 71 

 11.8 Applicable Law, Venue and Dispute Resolution. This Agreement shall be governed by the laws of
the State of New York. The United Nations Convention on Contracts for the International Sale of Goods shall not apply in any action, suit or proceeding arising out of or relating to this Agreement. All actions, suits or proceedings arising out of or
relating to this Agreement shall be heard and determined in any New York State or federal court sitting in the City of New York, County of Manhattan, and the Parties hereto hereby irrevocably submit to the exclusive jurisdiction of such courts in
any such action or proceeding and irrevocably waive any defense of an inconvenient forum to the maintenance of any such action or proceeding. The Parties further agree that, prior to the commencement of any action, suit or proceeding arising out of
or relating to this Agreement, the Parties will (a) first present the dispute to the Chief Executive Officer of Indevus and an Executive Vice President of Teva for resolution, and (b) if the Parties’ respective officers are unable to
resolve the dispute within [***] after it has been presented to them, the Parties will then attempt in good faith to resolve the dispute through non-binding mediation under the then-current Mediation Procedure of the International Institute
for Conflict Prevention and Resolution. If efforts at mediation are unsuccessful within [***] after the dispute has been presented for resolution, any such unresolved dispute shall be resolved at law or in equity in the forum set forth above.

 11.9 Entire Agreement. This Agreement, including the exhibits and schedules hereto, contains the entire understanding of the
Parties with respect to the subject matter. All express or implied agreements and understandings, either oral or written, heretofore made, including any offering letters, letters of intent, or term sheets, are expressly superseded by this Agreement.
This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by all Parties hereto. 
 11.10
Independent Contractors. It is expressly agreed that the Parties shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency. Neither Party shall have the
authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior consent of such other Party. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 
  

 72 

 11.11 Waiver. The waiver by a Party hereto of any right hereunder or the failure to perform or of
a breach by another Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 
 11.12 Headings; References. The captions to the several Articles and Sections hereof are not a part of this Agreement, but are merely guides or
labels to assist in locating and reading the several Articles and Sections hereof. Any reference in this Agreement to an Article, Exhibit, Schedule or Section shall, unless otherwise specifically provided, be to an Article, Exhibit, Schedule or
Section of this Agreement. The words “including”, “includes” and “such as” are used in their non-limiting sense and have the same meaning as “including without limitation” and “including but not limited
to.” “Hereunder” and “hereto” means under or pursuant to any provision of this Agreement. 
 11.13
Interpretation. Both Parties have had the opportunity to have this Agreement reviewed by an attorney; therefore, neither this Agreement nor any provision hereof shall be construed against the drafter of this Agreement. 
 11.14 Counterparts. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Signatures to this Agreement transmitted by fax, by email in “portable document format” (“.pdf”) or by any other electronic means intended to preserve the original graphic
and pictorial appearance of this Agreement shall have the same effect as physical delivery of the paper document bearing an original signature. 
 11.15 No Third Party Beneficiaries. Except as specifically set forth herein, none of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of either Party hereto. No
such Third Party shall obtain any right under any provision of this Agreement or shall by reasons of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party hereto. 
 11.16 Delegation by Teva. Teva may delegate the full or partial discharge of Teva’s covenants, agreements, obligations and liabilities under
this Agreement including, the due and 

  

 73 

 
punctual payment of all amounts which are or may become due and payable by Teva hereunder to any Affiliate of Teva at the time of such delegation,
provided, however, that any such delegation shall not relieve Teva of its obligations hereunder. 
  

 74 

 IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

  

			
	INDEVUS PHARMACEUTICALS, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	TEVA PHARMACEUTICAL INDUSTRIES LTD.
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

  

 75 

 SCHEDULE 1.20 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 1.40 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 Schedule 1.40 
 FIELD ALLOCATIONS 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 1.53(A) 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 1.53(B) 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 1.53(C) 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 1.62 
  

			
	TITLE	  	[***]
		
	METHOD	  	[***]
		
	CLINICAL PHASE	  	[***]
		
	TREATMENT GROUPS	  	[***]
		
	STUDY POPULATION	  	[***]
		
	NUMBER OF SUBJECTS	  	[***]
		
	STUDY DURATION	  	[***]
		
	INCLUSION CRITERIA	  	[***]
		
	EXCLUSION CRITERIA	  	[***]
		
	STUDY DESIGN	  	[***]
		
	ENDPOINTS	  	[***]
		
	STATISTICAL CONSIDERATIONS	  	[***]

  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 Table 1- Schedule of Events 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 1.64(a)        DATA MANAGEMENT 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 2.6(a) 
  

									
	 Vendor
	  	 Contract Scope
	  	 PO #
	  	 	  	 
	 [***]
	  	      [***]	  	[***]	  		  	

 SCHEDULE 2.6(b) 
 None. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 3.1        INITIAL MEMBERS OF CSC 
 Teva Designees: 
 [***] 
 Indevus Designees: 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 4.4(b)        NEXT TRIAL BUDGET 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 SCHEDULE 5.3(a)        U.S. LICENSE PERIOD ROYALTY RATES AND MILESTONE
PAYMENTS 
 A. Royalty rates applicable after occurrence of the Decision Point set forth in Section 1.26(a) and the applicable Royalty Conversion
Event pursuant to Section 5.3(b): 
  

					
	 Period
	 	 Annual (Calendar Year)
 Net Sales of Product in
 the United
States
	 	 Royalty Rate

	 [***]
	 	[***]	 	[***]

 The above royalty rates shall also apply after the occurrence, if any, of a Decision Point set forth in
Section 1.26(c) (occurrence of a Significant Plan Amendment) or Section 1.26(d) (Change of Control), and the applicable Royalty Conversion Event pursuant to Section 5.3(b), if either such Decision Point occurs before the occurrence of
the Decision Point set forth in 1.26(b). 
 B. Royalty rates applicable after occurrence of Decision Point set forth in Section 1.26(b) and the
applicable Royalty Conversion Event pursuant to Section 5.3(b): 
  

					
	 Period
	 	 Annual (Calendar Year)
 Net Sales of Product in
 the United
States
	 	 Royalty Rate

	[***]	 	[***]	 	[***]

 The above royalty rates shall also apply after the occurrence, if any, of a Decision Point set forth in
Section 1.26(c) (occurrence of a Significant Plan Amendment) or Section 1.26(d) (Change of Control), and the applicable Royalty Conversion Event pursuant to Section 5.3(b), if either such Decision Point occurs after the occurrence of
the Decision Point set forth in 1.23(b). 
 C. Milestone payments payable after occurrence of any of the Decision Points set forth in
Section 1.26(a)-(d) and Royalty Conversion Event pursuant to Section 5.3(b): 
 [***] 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTED 

 [***] 
 The above
milestone payments are contingent upon the occurrence of the annual U.S. Net Sales thresholds specified above, and each milestone payment shall be made no more than once with respect to the achievement of such threshold, but shall be payable the
first time such threshold is reached. Teva shall notify Indevus in writing of the achievement of the milestones set forth above within [***] after such milestone is achieved. On the date of such notice, the applicable milestone payment shall
be paid by Teva. 
  

  
 *** CONFIDENTIAL TREATMENT REQUESTEDForm of Indenture

 HARLEY-DAVIDSON, INC. 
 to 
 [                                       
 ] 
 Trustee 
  
  
 INDENTURE 
 Dated as of
[                    ] 
  
  
 Debt Securities 

 TABLE OF CONTENTS* 
  

					
	 	  	 	  	Page
	Parties	  		  	1
	Recitals	  		  	1
			
	ARTICLE ONE.	  	DEFINITIONS	  	1
			
	    SECTION 1.01	  	DEFINITIONS	  	1
			
	ARTICLE TWO.	  	DEBT SECURITY FORMS	  	12
			
	    SECTION 2.01	  	FORMS GENERALLY	  	12
	    SECTION 2.02	  	FORMS OF DEBT SECURITIES	  	12
	    SECTION 2.03	  	FORM OF TRUSTEE’S CERTIFICATE OF AUTHENTICATION	  	13
	    SECTION 2.04	  	DEBT SECURITIES IN GLOBAL FORM	  	13
			
	ARTICLE THREE.	  	THE DEBT SECURITIES	  	15
			
	    SECTION 3.01	  	TITLE AND TERMS	  	15
	    SECTION 3.02	  	DENOMINATIONS	  	17
	    SECTION 3.03	  	PAYMENT OF PRINCIPAL AND INTEREST	  	17
	    SECTION 3.04	  	EXECUTION OF DEBT SECURITIES	  	17
	    SECTION 3.05	  	TEMPORARY DEBT SECURITIES	  	19
	    SECTION 3.06	  	EXCHANGE AND REGISTRATION OF TRANSFER OF DEBT
SECURITIES	  	20
	    SECTION 3.07	  	MUTILATED, DESTROYED, LOST OR STOLEN DEBT SECURITIES	  	21
	    SECTION 3.08	  	PAYMENT OF INTEREST; INTEREST RIGHTS PRESERVED	  	22
	    SECTION 3.09	  	PERSONS DEEMED OWNERS	  	23
	    SECTION 3.10	  	CANCELLATION OF DEBT SECURITIES PAID, ETC.	  	23
	    SECTION 3.11	  	CURRENCY AND MANNER OF PAYMENTS	  	24
	    SECTION 3.12	  	CUSIP NUMBERS	  	26
			
	ARTICLE FOUR.	  	REDEMPTION OF DEBT SECURITIES; SINKING FUNDS	  	26
			
	    SECTION 4.01	  	APPLICABILITY OF ARTICLE	  	26
	    SECTION 4.02	  	NOTICE OF REDEMPTION; SELECTION OF DEBT SECURITIES	  	26
	    SECTION 4.03	  	PAYMENT OF DEBT SECURITIES CALLED FOR REDEMPTION	  	27
	    SECTION 4.04	  	EXCLUSION OF CERTAIN SECURITIES FROM ELIGIBILITY FOR SELECTION
FOR REDEMPTION	  	28
	    SECTION 4.05	  	PROVISIONS WITH RESPECT TO ANY SINKING FUNDS	  	28
			
	ARTICLE FIVE.	  	PARTICULAR COVENANTS OF THE COMPANY	  	30
			
	    SECTION 5.01	  	PAYMENT OF PRINCIPAL, PREMIUM AND INTEREST	  	30
	    SECTION 5.02	  	OFFICES FOR NOTICES AND PAYMENTS, ETC.	  	30
	    SECTION 5.03	  	APPOINTMENTS TO FILL VACANCIES IN TRUSTEE’S
OFFICE.	  	31
	    SECTION 5.04	  	PROVISIONS AS TO PAYING AGENT	  	31
	    SECTION 5.05	  	LIMITATION ON SECURED DEBT	  	31
	    SECTION 5.06	  	SALE AND LEASEBACK TRANSACTIONS	  	34
	    SECTION 5.07	  	RESTRICTIONS ON TRANSFER OF PRINCIPAL PROPERTY TO UNRESTRICTED
SUBSIDIARIES	  	34
	    SECTION 5.08	  	CERTIFICATE TO TRUSTEE	  	35
	    SECTION 5.09	  	WAIVERS OF COVENANTS	  	35
			
	ARTICLE SIX.	  	HOLDERS’ LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE	  	35
			
	    SECTION 6.01	  	HOLDERS’ LISTS	  	35

  

	*	This table of contents shall not, for any purpose, be deemed to be a part of the Indenture. 

  

 i 

					
	    SECTION 6.02	  	PRESERVATION AND DISCLOSURE OF LISTS	  	36
	    SECTION 6.03	  	REPORTS BY THE COMPANY	  	36
	    SECTION 6.04	  	REPORTS BY THE TRUSTEE	  	36
	    SECTION 6.05	  	STATEMENT BY OFFICERS AS TO DEFAULT	  	37
			
	ARTICLE SEVEN.	  	REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT	  	37
			
	    SECTION 7.01	  	EVENTS OF DEFAULT	  	37
	    SECTION 7.02	  	PAYMENT OF DEBT SECURITIES UPON DEFAULT; SUIT
THEREFOR	  	40
	    SECTION 7.03	  	APPLICATION OF MONEYS COLLECTED BY TRUSTEE	  	42
	    SECTION 7.04	  	PROCEEDINGS BY HOLDERS	  	43
	    SECTION 7.05	  	PROCEEDINGS BY TRUSTEE	  	43
	    SECTION 7.06	  	REMEDIES CUMULATIVE AND CONTINUING	  	43
	    SECTION 7.07	  	DIRECTION OF PROCEEDINGS AND WAIVER OF DEFAULTS BY
MAJORITY OF HOLDERS	  	44
	    SECTION 7.08	  	NOTICE OF DEFAULTS	  	44
	    SECTION 7.09	  	UNDERTAKING TO PAY COSTS	  	45
	    SECTION 7.10	  	UNCONDITIONAL RIGHT OF HOLDERS TO RECEIVE PRINCIPAL, PREMIUM
AND INTEREST	  	45
			
	ARTICLE EIGHT.	  	CONCERNING THE TRUSTEE	  	45
			
	    SECTION 8.01	  	DUTIES AND RESPONSIBILITIES OF TRUSTEE	  	45
	    SECTION 8.02	  	RELIANCE ON DOCUMENTS, OPINIONS, ETC.	  	46
	    SECTION 8.03	  	NO RESPONSIBILITY FOR RECITALS, ETC.	  	48
	    SECTION 8.04	  	TRUSTEE AND AGENTS MAY OWN DEBT SECURITIES	  	48
	    SECTION 8.05	  	MONEYS TO BE HELD IN TRUST	  	48
	    SECTION 8.06	  	COMPENSATION AND EXPENSES OF TRUSTEE	  	48
	    SECTION 8.07	  	OFFICERS’ CERTIFICATE AS EVIDENCE	  	49
	    SECTION 8.08	  	CONFLICTING INTEREST OF TRUSTEE	  	49
	    SECTION 8.09	  	ELIGIBILITY OF TRUSTEE	  	49
	    SECTION 8.10	  	RESIGNATION OR REMOVAL OF TRUSTEE	  	50
	    SECTION 8.11	  	ACCEPTANCE BY SUCCESSOR TRUSTEE	  	51
	    SECTION 8.12	  	SUCCESSION BY MERGER, ETC.	  	52
	    SECTION 8.13	  	LIMITATION ON RIGHTS OF TRUSTEE AS A CREDITOR	  	52
	    SECTION 8.14	  	AUTHENTICATING AGENTS	  	52
			
	ARTICLE NINE.	  	CONCERNING THE HOLDERS	  	55
			
	    SECTION 9.01	  	ACTION BY HOLDERS	  	55
	    SECTION 9.02	  	PROOF OF EXECUTION BY HOLDERS	  	56
	    SECTION 9.03	  	WHO ARE DEEMED ABSOLUTE OWNERS	  	56
	    SECTION 9.04	  	COMPANY-OWNED DEBT SECURITIES DISREGARDED	  	56
	    SECTION 9.05	  	REVOCATION OF CONSENTS; FUTURE HOLDERS BOUND	  	57
			
	ARTICLE TEN.	  	HOLDERS’ MEETINGS	  	57
			
	    SECTION 10.01	  	PURPOSES OF MEETINGS	  	57
	    SECTION 10.02	  	CALL OF MEETINGS BY TRUSTEE	  	57
	    SECTION 10.03	  	CALL OF MEETINGS BY COMPANY OR HOLDERS	  	58
	    SECTION 10.04	  	QUALIFICATIONS FOR VOTING	  	58
	    SECTION 10.05	  	REGULATIONS	  	58
	    SECTION 10.06	  	VOTING	  	59
	    SECTION 10.07	  	NO DELAY OF RIGHTS BY MEETING	  	59
			
	ARTICLE ELEVEN.	  	SUPPLEMENTAL INDENTURES	  	59
			
	    SECTION 11.01	  	SUPPLEMENTAL INDENTURES WITHOUT CONSENT OF HOLDERS	  	59
	    SECTION 11.02	  	SUPPLEMENTAL INDENTURES WITH CONSENT OF HOLDERS	  	61
	    SECTION 11.03	  	EFFECT OF SUPPLEMENTAL INDENTURES	  	62
	    SECTION 11.04	  	NOTATION ON DEBT SECURITIES	  	62
	    SECTION 11.05	  	EVIDENCE OF COMPLIANCE OF SUPPLEMENTAL INDENTURE TO BE
FURNISHED TRUSTEE	  	62

  

 ii 

					
	ARTICLE TWELVE.	  	CONSOLIDATION, MERGER, SALE AND CONVEYANCE	  	63
			
	    SECTION 12.01	  	COMPANY MAY CONSOLIDATE, ETC., ON CERTAIN TERMS	  	63
	    SECTION 12.02	  	SUCCESSOR ENTITY TO BE SUBSTITUTED	  	63
	    SECTION 12.03	  	OPINION OF COUNSEL TO BE GIVEN TRUSTEE	  	64
			
	ARTICLE THIRTEEN.	  	SATISFACTION AND DISCHARGE OF INDENTURE	  	64
			
	    SECTION 13.01	  	SATISFACTION, DISCHARGE AND DEFEASANCE OF DEBT SECURITIES OF
ANY SERIES	  	64
	    SECTION 13.02	  	DEFEASANCE OF DEBT SECURITIES OF ANY SERIES	  	65
	    SECTION 13.03	  	APPLICATION OF TRUST FUNDS; INDEMNIFICATION	  	66
	    SECTION 13.04	  	RETURN OF UNCLAIMED MONEYS	  	67
			
	ARTICLE FOURTEEN.	  	IMMUNITY OF INCORPORATORS, STOCKHOLDERS, ETC.	  	68
			
	    SECTION 14.01	  	INDENTURE AND DEBT SECURITIES SOLELY OBLIGATIONS OF THE
COMPANY	  	68
			
	ARTICLE FIFTEEN.	  	MISCELLANEOUS PROVISIONS	  	68
			
	    SECTION 15.01	  	PROVISIONS BINDING ON SUCCESSORS OF THE COMPANY	  	68
	    SECTION 15.02	  	INDENTURE FOR SOLE BENEFIT OF PARTIES AND HOLDERS OF
DEBT SECURITIES	  	68
	    SECTION 15.03	  	ADDRESSES FOR NOTICES, ETC.	  	68
	    SECTION 15.04	  	NEW YORK CONTRACT	  	69
	    SECTION 15.05	  	EVIDENCE OF COMPLIANCE WITH CONDITIONS PRECEDENT	  	69
	    SECTION 15.06	  	LEGAL HOLIDAYS	  	69
	    SECTION 15.07	  	TRUST INDENTURE ACT OF 1939 TO CONTROL	  	70
	    SECTION 15.08	  	TABLE OF CONTENTS, HEADINGS, ETC.	  	70
	    SECTION 15.09	  	DETERMINATION OF PRINCIPAL AMOUNT	  	70
	    SECTION 15.10	  	EXECUTION IN COUNTERPARTS	  	70
	    SECTION 15.11	  	WAIVER OF JURY TRIAL	  	70
	    SECTION 15.12	  	FORCE MAJEURE	  	71
			
	Signatures	  		  	

  

 iii 

 CROSS REFERENCE SHEET 
 Between 
 Provisions of Sections 310 through 318(a) inclusive of Trust Indenture Act of 1939 and the
Indenture dated as of [                    ] between Harley-Davidson, Inc. and
[                            ], as Trustee. 
  

			
	 Section of Act
	  	 Section of Indenture

	310(a)(1) and (2)	  	8.09
	310(a)(3) and (4)	  	*
	310(b)	  	8.08 and 8.10
	310(c)	  	*
	311(a)	  	8.13
	311(b)	  	8.13
	311(c)	  	*
	312(a)	  	6.01 and 6.02(a)
	312(b)	  	6.02(b)
	312(c)	  	6.02(c)
	313(a)(1), (2), (3), (4), (6) and (7)	  	6.04(a)
	313(a)(5)	  	*
	313(b)(1)	  	*
	313(b)(2)	  	6.04(a)
	313(c)	  	6.04(a)
	313(d)	  	6.04(b)
	314(a)(1)	  	6.03
	314(a)(2)	  	6.03
	314(a)(3)	  	6.03
	314(a)(4)	  	6.03
	314(b)	  	*
	314(c)(1)	  	15.05
	314(c)(2)	  	15.05
	314(c)(3)	  	*
	314(d)	  	*
	314(e)	  	15.05
	314(f)	  	*
	315(a), (c) and (d)	  	8.01
	315(b)	  	7.08
	315(e)	  	7.09
	316(a)(1)	  	7.07
	316(a)(2)	  	*
	316(a) last para.	  	9.04
	316(b)	  	7.10
	317(a)	  	7.02
	317(b)	  	5.04
	318(a)	  	15.07

  

	*	Not applicable. 

	**	This cross reference sheet shall not, for any purpose, be deemed to be part of the Indenture. 

  

 iv 

 THIS INDENTURE, dated as of
[                    ], is between Harley-Davidson, Inc., a Wisconsin corporation (the “Company”), and
[                                ], as trustee (the “Trustee”).

 RECITALS OF THE COMPANY 
 The Company has duly authorized the execution and delivery of this Indenture to provide for the issue from time to time of its unsecured debentures, notes, bonds or other evidences of indebtedness to be issued in one or more series as in
this Indenture provided, up to such principal amount or amounts as may from time to time be authorized in or pursuant to one or more resolutions of the Board of Directors. 
 All things necessary to make this Indenture a valid agreement of the Company, in accordance with its terms, have been done. 
 NOW, THEREFORE, THIS INDENTURE WITNESSETH: 
 For and in consideration of the premises and the purchase or acceptance of the Debt Securities by the Holders thereof, it is mutually covenanted and agreed, for the equal and proportionate benefit of the respective Holders from time to time
of the Debt Securities or of any series thereof as follows: 
 ARTICLE ONE. DEFINITIONS 
 SECTION 1.01 Definitions. The terms defined in this Section 1.01 (except as herein otherwise expressly provided or unless the
context otherwise requires) for all purposes of this Indenture and of any indenture supplemental hereto shall have the respective meanings specified in this Section 1.01. All other terms used in this Indenture which are defined in the
Trust Indenture Act of 1939 or which are by reference therein defined in the Securities Act of 1933, as amended, shall have (except as herein otherwise expressly provided or unless the context otherwise requires) the meanings assigned to such terms
in said Trust Indenture Act of 1939 and in said Securities Act as in force at the date of the execution of this Indenture. All accounting terms not otherwise defined herein have the meanings assigned to them in accordance with generally accepted
accounting principles and, except as otherwise herein expressly provided, the term “generally accepted accounting principles” with respect to any computation required or permitted hereunder or under any Board Resolution or Officers’
Certificate establishing a series of Debt Securities, any indenture supplemental hereto or any Debt Security shall mean such accounting principles as are generally accepted in the United States for domestic companies at the date of such computation
as reasonably determined by the Company. All references to such terms herein shall be both to the singular or the plural, as the context so requires. 
 Affiliate: 
 The term “Affiliate”, when used with respect to any specified Person, means any other Person directly
or indirectly controlling or controlled by or under direct or indirect 

 
common control with such specified Person. For the purposes of this definition, “control” when used with respect to any specified Person means the
power to direct the management and policies of such Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings
correlative to the foregoing. 
 Authenticating Agent: 
 The term “Authenticating Agent” shall mean the agent of the Trustee, if any, which at the time shall be appointed and acting pursuant to Section 8.14. 
 Board of Directors: 
 The term “Board of
Directors” shall mean the Board of Directors of the Company or any authorized committee of such Board of Directors designated by such Board of Directors or the by-laws or the articles of incorporation of the Company to act for such Board of
Directors for purposes of this Indenture. 
 Board Resolution: 
 The term “Board Resolution” means a copy of a resolution certified by a Vice President, the Secretary or an Assistant Secretary of the Company to have been duly adopted by the Board of Directors and to be in
full force and effect on the date of such certification, and delivered to the Trustee. 
 Business Day: 
 The term “Business Day”, when used with respect to any Place of Payment, means each Monday, Tuesday, Wednesday, Thursday and Friday which is
not a day on which banking institutions in that Place of Payment are authorized or obligated by law to close. 
 Capitalized Rent: 
 The term “Capitalized Rent” means the total net amount of rent payable for the remaining term as of the date of determination thereof under a
lease of Principal Property by the Company or any of its Restricted Subsidiaries, discounted from the respective due dates thereof to such date at the rate per annum equal to the weighted average interest rate borne by the Debt Securities. The
weighted average interest rate borne by the Debt Securities shall be calculated by dividing the aggregate of the annual interest payments required on the Debt Securities, based on the amount Outstanding at the latest date any Debt Securities were
issued hereunder, by the aggregate principal amount of the Debt Securities Outstanding at such date. The total net amount of rent payable under any such lease for any period shall be the total amount of the rent payable by the lessee with respect to
such period but shall not include amounts required to be paid on account of maintenance and repairs, insurance, taxes, assessments, water rates, sewer rents and similar charges and contingent rents such as those based on sales. The remaining term

  

 2 

 
under any lease shall be calculated without giving effect to any unexercised option of the lessee for the renewal or extension of any term. In the case of
any lease which is terminable by the lessee upon the payment of a penalty, such net amount shall also include the amount of such penalty, but no rent shall be considered as required to be paid under such lease subsequent to the first date upon which
it may be so terminated. 
 Company: 
 The term “Company” shall mean Harley-Davidson, Inc., a Wisconsin corporation, and, subject to Article Twelve, shall include its successors and assigns. 
 Company Request and Company Order: 
 The terms “Company Request” and “Company
Order” mean, respectively, a written request or order signed in the name of the Company by its Chairman of the Board, Vice Chairman of the Board, President or a Vice President, and by its Treasurer, Secretary, Assistant Secretary or Assistant
Treasurer, and delivered to the Trustee. 
 Consolidated Current Liabilities: 
 The term “Consolidated Current Liabilities” means the aggregate of the current liabilities of the Company and its Consolidated Subsidiaries
(excluding billings on uncompleted contracts in excess of related costs and profits) appearing on the most recent available consolidated balance sheet of the Company and its Consolidated Subsidiaries, all in accordance with generally accepted
accounting principles; provided, however, that in no event shall Consolidated Current Liabilities include any obligation of the Company or its Consolidated Subsidiaries issued under a revolving credit or similar agreement if the
obligation issued under such agreement matures by its terms within 12 months from the date thereof but by the terms of such agreement such obligation may be renewed or extended or the amount thereof reborrowed or refunded at the option of the
Company or any Consolidated Subsidiary for a term in excess of 12 months from the date of determination. 
 Consolidated Net Tangible Assets:

 The term “Consolidated Net Tangible Assets” means Consolidated Tangible Assets after deduction of Consolidated Current
Liabilities. 
 Consolidated Subsidiary 
 The term “Consolidated Subsidiary” shall mean, as to any Person, each Subsidiary of such Person (whether now existing or hereafter created or acquired) the financial statements of which shall be (or should have been) consolidated
with the financial statements of such Person in accordance with generally accepted accounting principles. 
  

 3 

 Consolidated Tangible Assets: 
 The term “Consolidated Tangible Assets” means the aggregate of all assets of the Company and its Consolidated Subsidiaries (including the value of all existing Sale and Leaseback Transactions (as defined in
Section 5.06) and any assets resulting from the capitalization of other long-term lease obligations in accordance with generally accepted accounting principles) appearing on the most recent available consolidated balance sheet of the
Company and its Consolidated Subsidiaries at their net book values, after deducting related depreciation, amortization and other valuation reserves, and excluding patent, trademark and copyright rights, goodwill and other like intangible items, all
in accordance with generally accepted accounting principles. 
 Conversion Date: 
 The term “Conversion Date” shall have the meaning set forth in Section 3.11. 
 Corporate Trust Office: 
 The term “Corporate
Trust Office” means the principal office of the Trustee at which at any time its corporate trust business shall be administered, which office at the date hereof is located at
[                                ], or such other address as the Trustee
may designate from time to time by notice to the Holders and the Company, or the principal corporate trust office of any successor Trustee (or such other address as such successor Trustee may designate from time to time by notice to the Holders and
the Company). 
 Currency Determination Agent: 
 The term “Currency Determination Agent” shall mean the financial institution, if any, from time to time selected by the Company for purposes of Section 3.11. 
 Debt Security or Debt Securities: 
 The terms
“Debt Security” or “Debt Securities” shall mean any unsecured notes, debentures or other indebtedness of any series, as the case may be, issued by the Company from time to time, and authenticated and delivered under this
Indenture. 
 Debt Security Register: 
 The term “Debt Security Register” shall have the meaning set forth in Section 3.06. 
 Depository: 
 The term “Depository” shall mean, unless otherwise specified by the Company pursuant to Section 3.01, with respect to Debt
Securities of any series issuable or issued as a 

  

 4 

 
Global Debt Security, The Depository Trust Company, New York, New York, or any successor thereto registered as a clearing agency pursuant to the provisions
of Section 17A of the Securities Exchange Act of 1934, as amended, or other applicable statute or regulation. 
 Dollar: 
 The term “Dollar” shall mean the coin or currency of the United States of America which as of the time of payment is legal tender for the
payment of public and private debts. 
 Dollar Equivalent of the Foreign Currency: 
 The term “Dollar Equivalent of the Foreign Currency” shall have the meaning set forth in Section 3.11. 
 Event of Default: 
 The term “Event of
Default” shall mean any event specified in Section 7.01, continued for the period of time, if any, and after the giving of the notice, if any, therein designated. 
 Foreign Currency: 
 The term “Foreign Currency” shall mean a currency issued by the
government of any country other than the United States of America. 
 Funded Debt: 
 The term “Funded Debt” means all indebtedness for money borrowed having a maturity of more than twelve months from the date of the most recent
consolidated balance sheet of the Company and its Consolidated Subsidiaries or renewable and extendible beyond twelve months at the option of the borrower and all obligations in respect of lease rentals which under generally accepted accounting
principles would be shown on a consolidated balance sheet of the Company as a liability item other than a current liability; provided, however, that Funded Debt shall not include any of the foregoing to the extent that such
indebtedness or obligations are not required by generally accepted accounting principles to be shown on the consolidated balance sheet of the Company. 
 Global Debt Security: 
 The term “Global Debt Security” means a Debt Security issued to evidence all or part of a
series of Debt Securities. 
  

 5 

 Government Obligations: 
 The term “Government Obligations” means securities which are (i) direct obligations of the government which issued the currency in which the Debt Securities of a series are denominated or
(ii) obligations of a person controlled or supervised by and acting as an agency or instrumentality of the government which issued the currency in which the Debt Securities of such series are denominated, the payment of which obligations is
unconditionally guaranteed by such government, and which, in either case, are full faith and credit obligations of such government, are denominated in the currency in which the Debt Securities of such series are denominated and which are not
callable or redeemable at the option of the issuer thereof and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such Government Obligation or a specific payment of interest on or principal of
or other amount with respect to any such Government Obligation held by such custodian for the account of the holder of a depository receipt, provided that (except as required by law) such custodian is not authorized to make any deduction from
the amount payable to the holder of such depository receipt from any amount received by the custodian in respect of the Government Obligation or the specific payment of interest on or principal of or other amount with respect to the Government
Obligation evidenced by such depository receipt. 
 Holder: 
 The term “Holder” means any Person in whose name a Debt Security of any series is registered in the Debt Security Register applicable to Debt Securities of such series. 
 Indenture: 
 The term “Indenture” shall
mean this instrument as originally executed or, if amended or supplemented as herein provided, as so amended or supplemented, pursuant to the applicable provisions hereof. 
 Indexed Debt Security 
 The term “Indexed Debt Security” means a Debt Security the terms of
which provide that the principal amount thereof payable at Stated Maturity may be more or less than the principal face amount thereof at original issuance. 
 Interest: 
 The term “interest”, when used with respect to an Original Issue Discount Debt Security which by its
terms bears interest only after maturity, means interest payable after maturity. 
  

 6 

 Interest Payment Date: 
 The term “Interest Payment Date”, when used with respect to any series of Debt Securities, means the Stated Maturity of an installment of interest on such Debt Securities. 
 Market Exchange Rate: 
 The term “Market
Exchange Rate” shall have the meaning set forth in Section 3.11. 
 Officers’ Certificate: 
 The term “Officers’ Certificate”, when used with respect to the Company, shall mean a certificate signed by its Chairman of the Board,
Vice Chairman of the Board, President, or a Vice President and by its Treasurer, Secretary, Assistant Secretary or Assistant Treasurer and delivered to the Trustee. Each such certificate shall include the statements provided for in
Section 15.05 to the extent required by the provisions of such Section. 
 Opinion of Counsel: 
 The term “Opinion of Counsel” shall mean an opinion in writing signed by legal counsel who may be an employee of or counsel to the Company.
Each such opinion shall be reasonably acceptable to the Trustee and shall include the statements provided for in Section 3.04 and Section 15.05 to the extent required by the provisions of such Sections. 
 Original Issue Discount Debt Security: 
 The term
“Original Issue Discount Debt Security” means any Debt Security which provides for an amount less than the principal amount thereof to be due and payable upon a declaration of acceleration of the maturity thereof pursuant to
Section 7.01. 
 Outstanding: 
 The term “Outstanding”, when used with respect to Debt Securities or Debt Securities of any series, means, as of the date of determination, all such Debt Securities theretofore authenticated and delivered under this Indenture,
except: 
  

	 	(i)	such Debt Securities theretofore cancelled by the Trustee or delivered to the Trustee for cancellation; 

  

	 	(ii)	 such Debt Securities for whose payment or redemption money in the necessary amount and in the specified currency has been theretofore deposited with the Trustee or
any paying agent (other than the Company) in trust or set aside and segregated in trust by the Company (if the Company shall act as its own paying agent) for the Holders of such Debt 

  

 7 

	 	 
Securities, provided, however, that if such Debt Securities are to be redeemed, notice of such redemption has been duly given pursuant to this
Indenture or provision therefor satisfactory to the Trustee has been made; 

  

	 	(iii)	such Debt Securities in exchange for or in lieu of which other such Debt Securities have been authenticated and delivered pursuant to this Indenture, or such Debt Securities which
have been paid, pursuant to this Indenture, unless proof satisfactory to the Trustee is presented that any such Debt Securities are held by Persons in whose hands any of such Debt Securities are a legal, valid and binding obligation of the Company;
and 

  

	 	(iv)	such Debt Securities the indebtedness in respect to which has been discharged in accordance with Section 13.01; 

 provided, however, that in determining whether the Holders of the requisite principal amount of such Outstanding Debt Securities have given any request,
demand, authorization, direction, notice, consent or waiver hereunder, such Debt Securities owned by the Company or any other obligor upon such Debt Securities or any Affiliate of the Company or such other obligor shall be disregarded and deemed not
to be Outstanding, except that, in determining whether the Trustee shall be protected in relying upon any such request, demand, authorization, direction, notice, consent or waiver, only such Debt Securities which a Responsible Officer of the Trustee
actually knows to be so owned shall be so disregarded. Such Debt Securities so owned which have been pledged in good faith may be regarded as Outstanding if the pledgee establishes to the satisfaction of the Trustee the pledgee’s right so to
act with respect to such Debt Securities and that the pledgee is not the Company or any other such obligor upon such Debt Securities or any Affiliate of the Company or such other obligor. In case of a dispute as to such right, the decision of the
Trustee upon the advice of counsel shall be full protection to the Trustee. Upon request of the Trustee, the Company shall furnish to the Trustee promptly an Officers’ Certificate listing and identifying all such Debt Securities, if any, known
by the Company to be owned or held by or for the account of any of the above described Persons; and, subject to the provisions of Section 8.01, the Trustee shall be entitled to accept such Officers’ Certificate as conclusive
evidence of the facts therein set forth and of the fact that all such Debt Securities not listed therein are Outstanding for the purpose of any such determination. 
 Permitted Receivables Financing: 
 The term “Permitted Receivables Financing” means any financing pursuant to
which the Company or any Subsidiary or Subsidiaries of the Company may sell, convey or otherwise transfer, directly or indirectly, to a Receivables Subsidiary or any other Person, or grant a Security Interest in, any accounts receivable, general
intangibles, chattel paper or other financial assets (and related rights and assets) of the Company or such Subsidiary or Subsidiaries, provided that such financing shall be with limited or no recourse to the Company and its Subsidiaries
(other than the Receivables Subsidiary) except to the extent customary (in the reasonable judgment of the Company) for such transactions. 
  

 8 

 Person: 
 The term “Person” means any individual, corporation, partnership, limited liability company, joint venture, association, joint-stock company, trust, unincorporated organization or government or any agency or political subdivision
thereof. 
 Place of Payment: 
 The term
“Place of Payment”, when used with respect to the Debt Securities of any series, means the place or places where the principal of (and premium, if any) and interest on the Debt Securities of that series are payable as specified in
accordance with Section 3.01. 
 Predecessor Debt Security: 
 The term “Predecessor Debt Security” of any particular Debt Security means every previous Debt Security evidencing all or a portion of the same debt as that evidenced by such particular Debt Security, and
for the purposes of this definition, any Debt Security authenticated and delivered under Section 3.07 in lieu of a mutilated, lost, destroyed or stolen Debt Security shall be deemed to evidence the same debt as the mutilated, lost,
destroyed or stolen Debt Security. 
 Principal Property: 
 The term “Principal Property” means any manufacturing plant or similar facility (including associated fixtures but excluding leases and other contract rights which might otherwise be deemed real property)
owned by the Company or any Restricted Subsidiary, whether owned on the date hereof or thereafter, provided each such plant or similar facility has a gross book value (without deduction for any depreciation reserves) at the date as of which the
determination is being made of in excess of one percent of the Consolidated Net Tangible Assets of the Company and its Consolidated Subsidiaries and is located in the United States of America, Canada or the Commonwealth of Puerto Rico, other than
any such plant or similar facility or portion thereof which, in the opinion of the Board of Directors (evidenced by a certified Board Resolution thereof delivered to the Trustee), is not of material importance to the business conducted by the
Company and its Consolidated Subsidiaries taken as a whole. 
 Receivables Subsidiary: 
 The term “Receivables Subsidiary” means a bankruptcy remote, special purpose wholly owned Subsidiary of the Company (or another wholly-owned
Subsidiary of the Company) formed in connection with a Permitted Receivables Financing. 
 Redemption Date: 
 The term “Redemption Date”, when used with respect to any Debt Security to be redeemed, means the date fixed for such redemption by or pursuant
to this Indenture. 
  

 9 

 Redemption Price: 
 The term “Redemption Price”, when used with respect to any Debt Security to be redeemed, means the price specified in such Debt Security at which it is to be redeemed pursuant to this Indenture. 

Regular Record Date: 
 The term “Regular
Record Date” for the interest payable on any Debt Security on any Interest Payment Date means the date specified in such Debt Security as the “Regular Record Date” as contemplated by Section 3.01. 
 Responsible Officer: 
 The term “Responsible
Officer”, when used with respect to the Trustee, means any vice president, assistant vice president, any assistant treasurer, any trust officer or assistant trust officer or any other officer of the Trustee customarily performing functions
similar to those performed by any of the above designated officers or, with respect to a particular trust matter, to whom such matter is referred because of such officer’s knowledge of and familiarity with the particular subject and who shall
have direct responsibility for the administration of this Indenture. 
 Restricted Subsidiary: 
 The term “Restricted Subsidiary” means any Subsidiary of the Company that is not an Unrestricted Subsidiary. 
 Secured Debt: 
 The term “Secured Debt”
means indebtedness for money borrowed which is secured by a Security Interest in (a) any Principal Property or (b) any shares of capital stock or indebtedness of any Restricted Subsidiary. 
 Security Interest: 
 The term “Security
Interest” shall mean any mortgage, pledge, lien, encumbrance, conditional sale agreement, title retention agreement (excluding an operating lease) or other security interest which secures payment or performance of an obligation. 
 Special Record Date: 
 The term “Special Record
Date” for the payment of any Defaulted Interest (as defined in Section 3.08) means a date fixed by the Trustee pursuant to Section 3.08. 
  

 10 

 Stated Maturity: 
 The term “Stated Maturity” when used with respect to any Debt Security or any installment of principal thereof or of interest thereon, means the date specified in such Debt Security as the fixed date on
which the principal of such Debt Security, or such installment of interest, is due and payable. 
 Subsidiary: 
 The term “Subsidiary” means any Person of which the Company, or the Company and one or more Subsidiaries, or any one or more Subsidiaries,
directly or indirectly own more than 50% of the Voting Stock. 
 Trustee: 
 The term “Trustee” shall mean
[                                ] and, subject to the provisions of Article
Eight hereof, shall also include its successors and assigns as Trustee hereunder. 
 Trust Indenture Act of 1939: 
 The term “Trust Indenture Act of 1939” means the Trust Indenture Act of 1939, as amended, as in force at the date as of which this Indenture
was executed; provided, however, that in the event the Trust Indenture Act of 1939 is amended after such date, “Trust Indenture Act of 1939” means to the extent required by any such amendment, the Trust Indenture Act of 1939
as so amended. 
 Unrestricted Subsidiary: 
 The term “Unrestricted Subsidiary” means (a) any Subsidiary of the Company that at the time of determination shall be designated an Unrestricted Subsidiary by the Board of Directors (provided, however, that any
Subsidiary of the Company having, as of the end of the Company’s most recently completed fiscal year, (i) assets with a gross book value in excess of 10% of the total gross book value of the assets of the Company and its Subsidiaries taken
as a whole, or (ii) gross revenue in excess of 10% of the total gross revenue of the Company and its Subsidiaries taken as a whole, may not be designated as an Unrestricted Subsidiary hereunder); and (b) any Subsidiary of an Unrestricted
Subsidiary. 
 Valuation Date: 
 The term
“Valuation Date” shall have the meaning set forth in Section 3.11. 
  

 11 

 Voting Stock: 
 The term “Voting Stock” means outstanding shares of capital stock or similar equity interests having under ordinary circumstances voting power for the election of directors, managers or the substantial
equivalent thereof whether at all times or only so long as no senior class of stock or similar equity interest has such voting power by reason of the happening of any contingency. 
 ARTICLE TWO. DEBT SECURITY FORMS 
 SECTION 2.01 Forms Generally. The
Debt Securities of each series and the certificates of authentication thereon shall have such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this Indenture (the provisions of which shall be
appropriate to reflect the terms of each series of Debt Securities, including the currency or denomination, which may be Dollars or Foreign Currency), and may have such letters, numbers or other marks of identification and such legends or
endorsements placed thereon, as may be required to comply with the rules of any securities exchange, or as may, consistently herewith, be determined by the officers executing such Debt Securities, as evidenced by their signing of such Debt
Securities. Any portion of the text of any Debt Security may be set forth on the reverse thereof, with an appropriate reference thereto on the face of the Debt Security. The definitive Debt Securities shall be printed, lithographed or engraved or
produced by any combination of these methods or may be produced in any other manner permitted by the rules of any securities exchange, all as determined by the officers executing such Debt Securities, as evidenced by their signing of such Debt
Securities. 
 SECTION 2.02 Forms of Debt Securities. The Debt Securities of each series shall be in such form or forms
(including global form) as shall be established by or pursuant to a Board Resolution. Prior to the delivery of a Debt Security of any series in any such form to the Trustee for the Debt Securities of such series for authentication, the Company shall
deliver to the Trustee the following: 
 (a) The Board Resolution by or pursuant to which such form of Debt Security has been
approved; 
 (b) An Officers’ Certificate dated the date such Certificate is delivered to the Trustee stating that all
conditions precedent provided for in this Indenture relating to the authentication and delivery of Debt Securities in such form have been complied with; and 
 (c) An Opinion of Counsel stating that Debt Securities in such form, together with any coupons appertaining thereto, when
(a) completed by appropriate insertions and executed and delivered by the Company to the Trustee for authentication in accordance with this Indenture, (b) authenticated and delivered by such Trustee in accordance with this Indenture within
the authorization as to aggregate principal amount established from time to time by the Board of Directors, and (c) sold in the manner specified in such Opinion of Counsel, will be the legal, valid and binding obligations of the Company,

  

 12 

 
subject to applicable bankruptcy, reorganization, insolvency and other similar laws generally affecting creditors’ rights, to general equitable
principles and to such other qualifications as such counsel shall conclude do not materially affect the rights of Holders of such Debt Securities. 
 The
definitive Debt Securities and coupons, if any, shall be printed, lithographed or engraved or produced by any combination of these methods or may be produced in any other manner, all as determined by the officers executing such Debt Securities or
coupons, as evidenced by their execution thereof. 
 SECTION 2.03 Form of Trustee’s Certificate of Authentication. The
following is the form of the Certificate of Authentication of the Trustee to be endorsed on the face of all Debt Securities substantially as follows: 
 This is one of the Debt Securities of the series designated herein issued under the within-mentioned Indenture. 
  

									
		 	[                                       
     ],	  		  	
		 	as Trustee	  		  	
				
		 	Dated:	  		  	
					
		 	By	 	  
	  		  	
		 		 	Authorized Signatory	  		  	

 SECTION 2.04 Debt Securities in Global Form. 
 (a) If the Company shall establish pursuant to Section 3.01 that the Debt Securities of a particular series are to be issued
in whole or in part in the form of one or more Global Debt Securities, then the Company shall execute and the Trustee or its agent shall, in accordance with Section 3.04 and the Company Order delivered to the Trustee or its agent
thereunder, authenticate and deliver such Global Debt Security or Global Debt Securities, which (i) shall represent, and shall be denominated in an amount equal to the aggregate principal amount of, the Outstanding Debt Securities of such
series to be represented by such Global Debt Security or Global Debt Securities, or such portion thereof as the Company shall specify in a Company Order, (ii) shall be registered in the name of the Depository for such Global Debt Security or
Global Debt Securities or its nominee, (iii) shall be delivered by the Trustee or its agent to the Depository or pursuant to the Depository’s instruction and (iv) shall bear a legend substantially to the following effect: “Unless
this certificate is presented by an authorized representative of the Depository to the Company or its agent for registration of transfer, exchange, or payment, and any certificate issued is registered in the name of the nominee of the Depository or
in such other name as is requested by an authorized representative of the Depository (and any payment is made to the nominee of the Depository or to such other entity as is requested by an authorized representative of the Depository), ANY TRANSFER,
PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the registered owner hereof, the nominee of the Depository, has an interest herein.” 
  

 13 

 (b) Notwithstanding any other provision of this Section 2.04 or of
Section 3.06, and subject to the provisions of paragraph (c) below, unless the terms of a Global Debt Security expressly permit such Global Debt Security to be exchanged in whole or in part for individual certificates
representing Debt Securities, a Global Debt Security may be transferred, in whole but not in part and in the manner provided in Section 3.06, only to a nominee of the Depository for such Global Debt Security, or to the Depository, or a
successor Depository for such Global Debt Security selected or approved by the Company, or to a nominee of such successor Depository. 
 (c) (1) If at any time the Depository for a Global Debt Security notifies the Company that it is unwilling or unable to continue as Depository for such Global Debt Security or if at any time the Depository for the
Global Debt Securities for such series shall no longer be eligible or in good standing under the Securities Exchange Act of 1934, as amended, or other applicable statute or regulation, the Company shall appoint a successor Depository with respect to
such Global Debt Security. If a successor Depository for such Global Debt Security is not appointed by the Company within 90 days after the Company receives notice or becomes aware of such ineligibility, the Company will execute, and the Trustee or
its agent, upon receipt of a Company Request for the authentication and delivery of certificates representing Debt Securities of such series in exchange for such Global Debt Security, will authenticate and deliver, certificates representing Debt
Securities of such series of like tenor and terms in an aggregate principal amount equal to the principal amount of the Global Debt Security in exchange for such Global Debt Security. 
 (2) The Company may at any time and in its sole discretion determine that the Debt Securities of any series or portion thereof issued or
issuable in the form of one or more Global Debt Securities shall no longer be represented by such Global Debt Security or Global Debt Securities. In such event the Company will execute, and the Trustee, upon receipt of a Company Request for the
authentication and delivery of certificates representing Debt Securities of such series in exchange in whole or in part for such Global Debt Security, will authenticate and deliver certificates representing Debt Securities of such series of like
tenor and terms in definitive form in an aggregate principal amount equal to the principal amount of such Global Debt Security or Global Debt Securities representing such series or portion thereof in exchange for such Global Debt Security or Global
Debt Securities. 
 (3) If specified by the Company pursuant to Section 3.01 with respect to Debt Securities
issued or issuable in the form of a Global Debt Security, the Depository for such Global Debt Security may surrender such Global Debt Security in exchange in whole or in part for certificates representing Debt Securities of such series of like tenor
and terms in definitive form on such terms as are acceptable to the Company and such Depository. 

  

 14 

 
Thereupon the Company shall execute, and the Trustee or its agent shall authenticate and deliver, without a service charge, (1) to each Holder specified
by the Debt Security registrar (as defined in Section 3.06) or the Depository a certificate or certificates representing Debt Securities of the same series of like tenor and terms and of any authorized denomination as requested by such
person in an aggregate principal amount equal to and in exchange for such Holder’s beneficial interest as specified by the Debt Security registrar or the Depository in the Global Debt Security; and (2) to such Depository a new Global Debt
Security of like tenor and terms and in an authorized denomination equal to the difference, if any, between the principal amount of the surrendered Global Debt Security and the aggregate principal amount of certificates representing Debt Securities
delivered to Holders thereof. 
 (4) In any exchange provided for in any of the preceding three paragraphs, the Company will
execute and the Trustee or its agent will authenticate and deliver certificates representing Debt Securities in definitive registered form in authorized denominations for Debt Securities of the same series or any integral multiple thereof. Upon the
exchange of the entire principal amount of a Global Debt Security for certificates representing Debt Securities, such Global Debt Security shall be cancelled by the Trustee or its agent. Except as provided in the preceding paragraph, certificates
representing Debt Securities issued in exchange for a Global Debt Security pursuant to this Section shall be registered in such names and in such authorized denominations for Debt Securities of that series or any integral multiple thereof, as the
Debt Security registrar (as defined in Section 3.06) or Depository shall instruct the Trustee or its agent. The Trustee or the Debt Security registrar shall deliver at its trust office such certificates representing Debt Securities to
the Holders in whose names such Debt Securities are so registered. 
 ARTICLE THREE. THE DEBT SECURITIES 
 SECTION 3.01 Title and Terms. The aggregate principal amount of Debt Securities which may be authenticated and delivered under this Indenture
is unlimited. The Debt Securities may be issued up to the aggregate principal amount of Debt Securities from time to time authorized by or pursuant to a Board Resolution. The Debt Securities may be issued in one or more series. All Debt Securities
of each series issued under this Indenture shall in all respects be equally and ratably entitled to the benefits hereof with respect to such series without preference, priority or distinction on account of the actual time or times of the
authentication and delivery or maturity of the Debt Securities of such series. There shall be established in or pursuant to a Board Resolution, and set forth in an Officers’ Certificate to the extent not established in a Board Resolution, or
established in one or more indentures supplemental hereto, prior to the issuance of Debt Securities of any series: 
 (a) the
title of the Debt Securities of the series (which shall distinguish the Debt Securities of the series from all other series of Debt Securities); 
  

 15 

 (b) any limit upon the aggregate principal amount of the Debt Securities of the series
which may be authenticated and delivered under this Indenture (except for Debt Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Debt Securities of that series pursuant to this
Article Three, the second paragraph of Section 4.03, or Section 11.04); 
 (c) the date or
dates (or the manner of calculation thereof) on which the principal of the Debt Securities of the series is payable; 
 (d)
the rate or rates (or the manner of calculation thereof) at which the Debt Securities of the series shall bear interest, if any, the date or dates from which such interest shall accrue, the Interest Payment Dates on which such interest shall be
payable and the Regular Record Date for the interest payable on any Interest Payment Date; 
 (e) the Place of Payment;

 (f) the period or periods within which, the price or prices at which, the currency or currency units in which, and the
terms and conditions upon which Debt Securities of the series may be redeemed, in whole or in part, at the option of the Company; 
 (g) the obligation, if any, of the Company to redeem or purchase Debt Securities of the series pursuant to any sinking fund or analogous provisions or at the option of a Holder thereof and the period or periods within which, the price or
prices in the currency at which, the currency or currency units in which, and the terms and conditions upon which Debt Securities of the series shall be redeemed or purchased, in whole or in part, pursuant to such obligation; 
 (h) the denominations in which the Debt Securities of such series shall be issuable if other than denominations of $1,000 and any integral
multiple thereof; 
 (i) if other than Dollars, the currencies in which payments of interest or principal of (and premium, if
any, with respect to) the Debt Securities of the series are to be made; 
 (j) if the interest on or principal of (or premium,
if any, with respect to) the Debt Securities of the series are to be payable, at the election of the Company or a Holder thereof or otherwise, in a currency other than that in which such Debt Securities are payable, the period or periods within
which, and the other terms and conditions upon which, such election may be made, and the time and manner of determining the exchange rate between the currency in such Debt Securities are denominated or stated to be payable and the currency in which
such Debt Securities or any of them are to be so payable; 
 (k) whether the amount of payments of interest on or principal of
(or premium, if any, with respect to) the Debt Securities of such series may be determined with reference to an index, formula or other method (which index, formula or method or method 

  

 16 

 
may be based, without limitation, on one or more currencies, commodities, equity indices or other indices), and, if so, the terms and conditions upon which
and the manner in which such amounts shall be determined and paid or payable; 
 (l) the extent to which any Debt Securities
will be issuable in permanent global form, the manner in which any payments on a permanent global Debt Security will be made, and the appointment of any Depository relating thereto; 
 (m) any deletions from, modifications of or additions to the Events of Default or covenants with respect to the Debt Securities of such
series, whether or not such Events of Default or covenants are consistent with the Events of Default or covenants set forth herein; 
 (n) if any of the Debt Securities of such series are to be issuable upon the exercise of warrants, this shall be so established as well as the time, manner and place for such Debt Securities to be authenticated and delivered; 
 (o) if applicable, the terms of any right to convert the Debt Securities of such series into, or exchange such Debt Securities for, shares
of common stock of the Company or other securities or property or cash in lieu of such common stock or other securities or property, or any combination thereof, and any corresponding changes to the provisions of this Indenture as then in effect with
respect to such series; and 
 (p) any other terms of the series (which terms shall not be inconsistent with the provisions of
this Indenture). 
 All Debt Securities of any one series shall be substantially identical except as to denomination and except as may otherwise be provided
in or pursuant to such Board Resolution and set forth in such Officers’ Certificate or in any such indenture supplemental hereto. 
 SECTION 3.02 Denominations. The Debt Securities of each series shall be issuable in registered form without coupons in such denominations as shall be specified as contemplated in Section 3.01. In the absence of any
specification with respect to the Debt Securities of any series, the Debt Securities of such series shall be issuable in denominations of $1,000 and any integral multiple thereof, which may be in Dollars or any Foreign Currency. 
 SECTION 3.03 Payment of Principal and Interest. The principal of, premium, if any, and interest on the Debt Securities shall be payable at
the office or agency of the Company designated for that purpose in the Place of Payment, as provided in Section 5.02; provided, however, that interest may be payable at the option of the Company by check mailed to the
address of the Person entitled thereto as such address shall appear on the Debt Security Register on the Regular Record Date for such interest payment. 
 SECTION 3.04 Execution of Debt Securities. The Debt Securities shall be executed manually or by facsimile in the name and on behalf of the Company by its Chairman of 

  

 17 

 
the Board of Directors, its President, one of its Vice Presidents or its Treasurer and by its Secretary or one of its Assistant Secretaries. Only such Debt
Securities as shall bear thereon a certificate of authentication substantially in the form hereinbefore recited, manually executed by the Trustee, shall be entitled to the benefits of this Indenture or be valid or become obligatory for any purpose.
Such certificate by the Trustee upon any Debt Security executed by the Company shall be conclusive evidence that the Debt Security so authenticated has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits
of this Indenture. Unless otherwise provided in the form of Debt Security for any series, all Debt Securities shall be dated the date of their authentication. 
 In case any officer of the Company who shall have executed any of the Debt Securities shall cease to be such officer before the Debt Securities so executed shall have been authenticated and delivered by the Trustee,
or disposed of by the Company, such Debt Securities nevertheless shall be valid and binding and may be authenticated and delivered or disposed of as though the Person who executed such Debt Securities had not ceased to be such officer of the
Company; and any Debt Securities may be executed on behalf of the Company by such Persons as, at the actual date of the execution of such Debt Security, shall be the proper officers of the Company, although at the date of such Debt Security or of
the execution of this Indenture any such Person was not such an officer. 
 At any time and from time to time after the execution and
delivery of this Indenture, the Company may deliver Debt Securities of any series, properly created in accordance with Section 3.01 and executed by the Company, to the Trustee for authentication; and the Trustee shall authenticate and
deliver such Debt Securities upon Company Order. In the event that any other Person performs the Trustee’s duties as Authenticating Agent pursuant to a duly executed agreement, the Company shall notify the Trustee in writing of the issuance of
any Debt Securities hereunder, such notice to be delivered in accordance with the provisions of Section 15.03 on the date such Debt Securities are delivered by the Company for authentication to such other Person. 
 Prior to any such authentication and delivery, the Trustee shall be provided with, and shall be fully protected in relying upon, in addition to the
Opinion of Counsel to be furnished to the Trustee pursuant to Section 15.05 and the Officers’ Certificate relating to the issuance of any series of Debt Securities pursuant to Sections 15.05 and 3.01, Opinions of
Counsel stating that: 
 (1) all instruments furnished to the Trustee conform to the requirements of this Indenture and
constitute sufficient authority hereunder for the Trustee to authenticate and deliver such Debt Securities; 
 (2) all laws
and requirements with respect to the form and execution by the Company of the supplemental indenture, if any, have been complied with, the execution and delivery of the supplemental indenture, if any, will not violate the terms of this Indenture,
the supplemental indenture has been duly qualified under the Trust Indenture Act of 1939, the Company has legal power to execute and deliver any such supplemental 

  

 18 

 
indenture and has taken all necessary entity action for those purposes and any such supplemental indenture has been executed and delivered and constitutes
the legal, valid and binding obligation of the Company enforceable in accordance with its terms (subject, as to enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium or other laws affecting creditors’ rights
generally from time to time in effect); 
 (3) the form and terms of such Debt Securities have been established in conformity
with the provisions of this Indenture; 
 (4) all laws and requirements with respect to the execution and delivery by the
Company of such Debt Securities have been complied with, the authentication and delivery of the Debt Securities by the Trustee will not violate the terms of this Indenture, the Company has the legal power to issue such Debt Securities and such Debt
Securities, assuming due authentication and delivery by the Trustee, constitute legal, valid and binding obligations of the Company in accordance with their terms (subject, as to enforcement of remedies, to applicable bankruptcy, reorganization,
insolvency, moratorium or other laws affecting creditors’ rights generally from time to time in effect) and are entitled to the benefits of this Indenture, equally and ratably with all other Outstanding Debt Securities, if any, of such series;
and 
 (5) such other matters as the Trustee may reasonably request. 
 The Trustee shall not be required to authenticate such Debt Securities if the issue thereof will adversely affect the Trustee’s own rights, duties
or immunities under the Debt Securities and this Indenture or otherwise in a manner which is not reasonably acceptable to the Trustee or such action would expose the Trustee to personal liability to existing Holders. 
 No Debt Security shall be entitled to any benefit under this Indenture or be valid or obligatory for any purpose, unless there appears on such Debt
Security a certificate of authentication substantially in the form provided for herein executed by the Trustee by manual signature, and such certificate upon any Debt Security shall be conclusive evidence, and the only evidence, that such Debt
Security has been duly authenticated and delivered hereunder. 
 SECTION 3.05 Temporary Debt Securities. Pending the preparation
of definitive Debt Securities of any series, the Company may execute, and upon receipt of the documents required by Sections 2.02, 3.01 and 3.04, together with a Company Order, the Trustee shall authenticate and deliver, such
temporary Debt Securities which may be printed, lithographed, typewritten, mimeographed or otherwise produced, in any authorized denominations, substantially of the tenor of such definitive Debt Securities in lieu of which they are issued and with
such appropriate insertions, omissions, substitutions and other variations as the officers executing such temporary Debt Securities may determine, as evidenced by their execution of such temporary Debt Securities. 
  

 19 

 If temporary Debt Securities of any series are issued, the Company will cause definitive Debt Securities
of such series to be prepared without unreasonable delay. After the preparation of definitive Debt Securities of any series, the temporary Debt Securities of such series shall be exchangeable for definitive Debt Securities of such series, upon
surrender of the temporary Debt Securities of such series at any office or agency maintained by the Company for such purposes as provided in Section 5.02, without charge to the Holder. Upon surrender for cancellation of any one or more
temporary Debt Securities of any series, the Company shall execute and the Trustee shall authenticate and deliver in exchange therefore a like principal amount of definitive Debt Securities of such series having the same interest rate and Stated
Maturity and bearing interest from the same date of any authorized denominations. Until so exchanged the temporary Debt Securities of such series shall in all respects be entitled to the same benefits under this Indenture as definitive Debt
Securities of such series. 
 SECTION 3.06 Exchange and Registration of Transfer of Debt Securities. Debt Securities may be
exchanged for a like aggregate principal amount of Debt Securities of such series that are of other authorized denominations. Debt Securities to be exchanged shall be surrendered at any office or agency to be maintained for such purpose by the
Company, as provided in Section 5.02, and the Company shall execute and the Trustee shall authenticate and deliver in exchange therefore the Debt Security or Debt Securities of authorized denominations which the Debt Security Holder
making the exchange shall be entitled to receive. Each agent of the Company appointed pursuant to Section 5.02 as a person authorized to register, and register transfer of, Debt Securities is sometimes herein referred to as a
“Debt Security registrar.” 
 The Company shall keep, at each such office or agency of the Company maintained for such
purpose, as provided in Section 5.02, a register for each series of Debt Securities hereunder (the registers of all Debt Security registrars being herein sometimes collectively referred to as the “Debt Security
Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of Debt Securities and shall register the transfer of Debt Securities as in this Article Three provided.
At all reasonable times, such Debt Security Register shall be open for inspection by the Trustee and any Debt Security registrar other than the Trustee. Upon due presentment for registration of transfer of any Debt Security at any such office or
agency, the Company shall execute and register and the Trustee shall authenticate and deliver in the name of the transferee or transferees a new Debt Security or Debt Securities of authorized denominations for an equal aggregate principal amount.
Registration or registration of transfer of any Debt Security by any Debt Security registrar in the registry books maintained by such Debt Security registrar, and delivery of such Debt Security, duly authenticated, shall be deemed to complete the
registration or registration of transfer of such Debt Security. 
 The Trustee shall act as the repository of a master list of names and
addresses of Holders of the Debt Securities unless and until some other Person is, by written notice from the 

  

 20 

 
Company to the Trustee and each Debt Security registrar, designated by the Company to act as such. The Company shall cause each Debt Security registrar to
furnish to such repository, on a current basis, such information as such repository may reasonably request as to registrations, transfers, exchanges and other transactions effected by such registrar, as may be necessary or advisable to enable such
repository to maintain such master list on as current a basis as is reasonably practicable. 
 No Person shall at any time be appointed as
or act as a Debt Security registrar unless such Person is at such time empowered under applicable law to act as such and duly registered to act as such under and to the extent required by applicable law and regulations. 
 All Debt Securities presented to a Debt Security registrar for registration of transfer shall be duly endorsed by, or be accompanied by a written
instrument or instruments of transfer in form satisfactory to the Company and such Debt Security registrar duly executed by, the registered Holder or such Holder’s attorney duly authorized in writing. 
 No service charge shall be made for any exchange or registration of transfer of Debt Securities, but the Company may require payment of a sum sufficient
to cover any tax or other governmental charge that may be imposed in connection therewith. 
 The Company shall not be required to issue,
exchange or register a transfer of (a) any Debt Securities of any series for a period of 15 days next preceding the mailing of a notice of redemption of Debt Securities of such series and ending at the close of business on the day of the
mailing of a notice of redemption of Debt Securities of such series so selected for redemption, or (b) any Debt Securities selected, called or being called for redemption except, in the case of any Debt Security to be redeemed in part, the
portion thereof not so to be redeemed. 
 All Debt Securities issued in exchange for or upon registration of transfer of Debt Securities
shall be valid obligations of the Company, evidencing the same debt, and entitled to the same benefits under this Indenture, as the Debt Securities surrendered for such exchange or registration of transfer. 
 None of the Trustee, any agent of the Trustee, any paying agent or the Company will have any responsibility or liability for any aspect of the records
relating to or payments made on account of beneficial ownership interests of a Global Debt Security or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests. 
 SECTION 3.07 Mutilated, Destroyed, Lost or Stolen Debt Securities. In case any temporary or definitive Debt Security shall become mutilated
or be destroyed, lost or stolen, the Company in its discretion may execute, and upon its request the Trustee shall authenticate and deliver, a new Debt Security, bearing a number, letter or other distinguishing mark not contemporaneously
Outstanding, in exchange and substitution for the mutilated Debt Security, or in lieu of and in substitution for the Debt Security so destroyed, lost or stolen. In every case the applicant for a substituted Debt Security shall furnish to the Company
and to the Trustee such security or indemnity as may be required by them to save each of them harmless, and, in every 

  

 21 

 
case of destruction, loss or theft, the applicant shall also furnish to the Company and to the Trustee evidence to their satisfaction of the destruction,
loss or theft, of such Debt Security and of the ownership thereof. 
 In the absence of notice to the Trustee or the Company that such Debt
Security has been acquired by a bona fide purchaser, the Trustee shall authenticate any such substituted Debt Security and deliver the same upon any Company Request. Upon the issuance of any substituted Debt Security, the Company may require the
payment of a sum sufficient to cover any tax or other governmental charge that may be imposed in relation thereto and any other expenses connected therewith. In case any Debt Security which has matured or is about to mature shall become mutilated or
be destroyed, lost or stolen, the Company may, instead of issuing a substituted Debt Security, pay or authorize the payment of the same (without surrender thereof except in the case of a mutilated Debt Security) if the applicant for such payment
shall furnish to the Company and to the Trustee such security or indemnity as may be required by them to save each of them harmless and, in case of destruction, loss or theft, evidence satisfactory to the Company and to the Trustee of the
destruction, loss or theft of such Debt Security and of the ownership thereof. 
 Every substituted Debt Security issued pursuant to the
provisions of this Section 3.07 by virtue of the fact that any Debt Security is destroyed, lost or stolen shall constitute an additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Debt Security
shall be found at any time, and shall be entitled to all the benefits of this Indenture equally and proportionately with any and all other Debt Securities duly issued hereunder. All Debt Securities shall be held and owned upon the express condition
that the foregoing provisions are exclusive with respect to the replacement or payment of mutilated, destroyed, lost or stolen Debt Securities and shall preclude (to the extent permitted by law) any and all other rights or remedies with respect to
the replacement or payment of negotiable instruments or other securities without their surrender. 
 SECTION 3.08 Payment of
Interest; Interest Rights Preserved. Interest which is payable, and is punctually paid or duly provided for, on any Interest Payment Date, on any Debt Security, shall unless otherwise provided in such Debt Security be paid to the Person in whose
name the Debt Security (or one or more Predecessor Debt Securities) is registered at the close of business on the Regular Record Date for such interest. Unless otherwise stated in the form of Debt Security of a series, interest on the Debt
Securities of any series shall be computed on the basis of a 360 day year comprised of twelve 30 day months. 
 Any interest on any Debt
Security which is payable, but is not punctually paid or duly provided for, on any Interest Payment Date (herein called “Defaulted Interest”) shall forthwith cease to be payable to the registered Holder on the relevant Regular
Record Date by virtue of having been such Holder, and such Defaulted Interest may be paid by the Company, at its election in each case, as provided in Clause (1) or (2) below: 
  

 22 

 (1) The Company may elect to make payment of any Defaulted Interest to the Persons in
whose names any such Debt Securities (or their respective Predecessor Debt Securities) are registered at the close of business on a Special Record Date for the payment of such Defaulted Interest, which shall be fixed in the following manner. The
Company shall notify the Trustee in writing of the amount of Defaulted Interest proposed to be paid on each Debt Security and the date of the proposed payment, and at the same time the Company shall deposit with the Trustee an amount of money equal
to the aggregate amount proposed to be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the Trustee for such deposit prior to the date of the proposed payment, such money when deposited to be held in trust for
the benefit of the Persons entitled to such Defaulted Interest as in this clause provided. Thereupon the Trustee shall fix a Special Record Date for the payment of such Defaulted Interest which shall be not more than 15 days and not less than 10
days prior to the date of the proposed payment and not less than 10 days after the receipt by the Trustee of the notice of the proposed payment. The Trustee shall promptly notify the Company of such Special Record Date and, in the name and at the
expense of the Company, shall cause notice of the proposed payment of such Defaulted Interest and the Special Record Date therefore to be mailed, first-class postage prepaid, to each Holder of such Debt Securities, at such Holder’s address as
it appears in the Debt Security Register, not less than 10 days prior to such Special Record Date. Notice of the proposed payment of such Defaulted Interest and the Special Record Date therefore having been mailed as aforesaid, such Defaulted
Interest shall be paid to the Persons in whose names such Debt Securities (or their respective Predecessor Debt Securities) are registered on such Special Record Date and shall no longer be payable pursuant to the following Clause (2).

 (2) The Company may make payment of any Defaulted Interest in any other lawful manner not inconsistent with the
requirements of any securities exchange on which the Debt Securities of that series may be listed, and upon such notice as may be required by such exchange, if, after notice given by the Company to the Trustee of the proposed payment pursuant to
this Clause, such payment shall be deemed practicable by the Trustee. 
 Subject to the foregoing provisions of this Section, each Debt Security delivered
under this Indenture upon transfer of or in exchange for or in lieu of any other Debt Security shall carry the rights to interest accrued and unpaid, and to accrue, which were carried by such other Debt Security. 
 SECTION 3.09 Persons Deemed Owners. The Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name
any Debt Security is registered as the owner of such Debt Security for the purpose of receiving payment of principal of, premium, if any, and (subject to Section 3.08) interest on, such Debt Security and for all other purposes whatsoever
whether or not such Debt Security be overdue, and neither the Company, the Trustee, nor any agent of the Company or the Trustee shall be affected by notice to the contrary. 
  

 23 

 SECTION 3.10 Cancellation of Debt Securities Paid, etc. All Debt Securities surrendered for
the purpose of payment, redemption, exchange or registration of transfer or delivered in satisfaction in whole or in part of any sinking fund obligation shall, if surrendered to the Company or any agent of the Trustee or the Company under this
Indenture, be delivered to the Trustee and promptly cancelled by it, or, if surrendered to the Trustee, shall be promptly cancelled by it, and no Debt Securities shall be issued in lieu thereof except as expressly permitted by any of the provisions
of this Indenture. The Trustee shall dispose of cancelled Debt Securities in accordance with its customary procedures. 
 SECTION 3.11
Currency and Manner of Payments. 
 (a) With respect to Debt Securities denominated in Dollars or a Foreign Currency,
the following payment provisions shall apply: 
 (i) Except as provided in subparagraph (a)(ii) or in paragraph
(c) of this Section 3.11, payment of principal of and premium, if any, on any Debt Securities will be made at the offices established pursuant to Section 5.02 by delivery of a check in the currency in which the Debt
Security is denominated on the payment date against surrender of such Debt Security, and any interest on any Debt Security will be paid at such office by mailing a check in the currency in which the Debt Securities were issued to the Person entitled
thereto at the address of such Person appearing on the Debt Security Register. 
 (ii) Payment of the principal of and
premium, if any, and interest on such Debt Security may also, subject to applicable laws and regulations, be made at such other place or places as may be designated by the Company by any appropriate method (including, without limitation, by wire
transfer, CHIPS or the SWIFT system). 
 (b) Not later than the fourth Business Day after the Regular Record Date for such
Interest Payment Date, the paying agent will deliver to the Company a written notice specifying, in the currency in which each series of the Debt Securities are denominated, the respective aggregate amounts of principal of and premium, if any, and
interest on the Debt Securities to be made on such payment date, specifying the amounts so payable in respect of the Debt Securities. The failure of the paying agent to deliver such notice shall not relieve the Company from its obligation to make
all payments with respect to any Debt Security when due. 
 (c) If the Foreign Currency in which any of the Debt Securities
are denominated ceases to be used both by the government of the country which issued such currency and for the settlement of transactions by public institutions of or within the international banking community, then with respect to each date for the
payment of Foreign Currency occurring after the last date on which the Foreign Currency was so used (the “Conversion Date”), the Dollar shall be the currency of payment for use on each such date. The Dollar amount to be paid by the
Company to the Trustee and by the Trustee or any 

  

 24 

 
paying agent to the Holder of such Debt Securities with respect to such payment date shall be the Dollar Equivalent of the Foreign Currency as determined by
the Currency Determination Agent as of the second Business Day preceding the applicable payment date (the “Valuation Date”) in the manner provided in paragraph (d). 
 (d) The “Dollar Equivalent of the Foreign Currency” shall be determined by the Currency Determination Agent as of each
Valuation Date and shall be obtained by converting the specified Foreign Currency into Dollars at the Market Exchange Rate on the Valuation Date. 
 (e) The “Market Exchange Rate” shall mean, for any currency, the noon Dollar buying rate for that currency for cable transfers quoted in New York City on the Valuation Date as certified for customs
purposes (or, if not so certified, as otherwise determined) by the Federal Reserve Bank of New York. If such rates are not available for any reason with respect to one or more currencies for which an exchange rate is required, the Currency
Determination Agent shall use, in its sole discretion and without liability on its part, such quotation of the Federal Reserve Bank of New York as of the most recent available date, or, with the Company’s approval, quotations from one or more
major banks in New York City or in the country of issue of the currency in question, or such other quotations as the Currency Determination Agent shall deem appropriate and the Company shall approve. Unless otherwise specified by the Currency
Determination Agent, if there is more than one market for dealing in any currency by reason of foreign exchange regulations or otherwise, the market to be used in respect of such currency shall be that upon which a nonresident issuer of securities
designated in such currency would purchase such currency in order to make payments in respect of such securities. 
 All decisions and
determinations of the Currency Determination Agent regarding the Dollar Equivalent of the Foreign Currency and the Market Exchange Rate shall be in its sole discretion and shall, in the absence of manifest error, be conclusive for all purposes and
irrevocably binding upon the Company and all Holders of the Debt Securities. In the event that the Foreign Currency ceases to be used both by the government of the country which issued such currency and for the settlement of transactions by public
institutions of or within the international banking community, the Company, after learning thereof, will promptly give notice thereof to the Trustee (and the Trustee will promptly thereafter give notice in the manner provided in
Section 15.03 to the Holders) specifying the Conversion Date. 
 The Trustee shall be fully justified and protected in relying
on and acting upon the information so received by it from the Company or the Currency Determination Agent and shall not otherwise have any duty or obligation to determine such information independently. 
 If the principal of (and premium, if any) and interest on any Debt Securities is payable in a Foreign Currency and such Foreign Currency is not
available for payment due to the imposition of exchange controls or other circumstances beyond the control of the Company, then the Company shall be entitled to satisfy its obligations to Holders under this Indenture by making 

  

 25 

 
such payment in Dollars on the basis of the Market Exchange Rate for such Foreign Currency on the latest date for which such rate was established on or
before the date on which payment is due. Any payment made pursuant to this Section 3.11 in Dollars where the required payment is in a Foreign Currency shall not constitute a default or Event of Default under this Indenture. 

SECTION 3.12 CUSIP Numbers. The Company in issuing the Debt Securities may use “CUSIP” numbers (if then generally in use), and,
if so, the Trustee shall use “CUSIP” numbers in notices of redemption as a convenience to Holders; provided that any such notice may state that no representation is made as to the correctness of such numbers either as printed on the
Debt Securities or as contained in any notice of a redemption and that reliance may be placed only on the other identification numbers printed on the Debt Securities, and any such redemption shall not be affected by any defect in or omission of such
numbers. The Company will promptly notify the Trustee in writing of any change in the “CUSIP” numbers. 
 ARTICLE FOUR.
REDEMPTION OF DEBT SECURITIES; SINKING FUNDS 
 SECTION 4.01 Applicability of Article. The Company may reserve the right to
redeem and pay before Stated Maturity all or any part of the Debt Securities of any series, either by optional redemption, sinking fund (mandatory or optional) or otherwise, by provision therefor in the form of Debt Security for such series on such
terms as are specified in such form or the Board Resolution or Officers’ Certificate delivered pursuant to Section 3.01 or the indenture supplemental hereto as provided in Section 3.01 with respect to Debt Securities of
such series. Redemption of Debt Securities of any series shall be made in accordance with the terms of such Debt Securities and, to the extent that this Article does not conflict with such terms, in accordance with this Article. 
 SECTION 4.02 Notice of Redemption; Selection of Debt Securities. In case the Company shall desire to exercise the right to redeem all, or, as
the case may be, any part of a series of Debt Securities pursuant to Section 4.01, the Company shall fix a date for redemption and the Company, or, at the Company’s request, the Trustee in the name of and at the expense of the
Company, shall mail a notice of such redemption at least 30 and not more than 60 days prior to the date fixed for redemption to the Holders of Debt Securities so to be redeemed as a whole or in part at their last addresses as the same appear on the
Debt Securities Register. Such mailing shall be by first class mail. The notice if mailed in the manner herein provided shall be conclusively presumed to have been duly given, whether or not the Holder receives such notice. In any case, failure to
give such notice by mail or any defect in the notice to the Holder of any Debt Security designated for redemption as a whole or in part shall not affect the validity of the proceedings for the redemption of any other Debt Security. 
 Notice of redemption shall be given in the name of the Company and shall specify the date fixed for redemption, the Redemption Price at which Debt
Securities of any series are to be redeemed, the place of payment (which shall be at the offices or agencies to be maintained by the Company pursuant to Section 5.02), that payment of the Redemption Price will be made upon presentation
and surrender of such Debt Securities, that interest accrued to the date fixed 

  

 26 

 
for redemption will be paid as specified in said notice, that on and after said date interest thereon or on the portions thereof to be redeemed will cease to
accrue, and the Section of this Indenture pursuant to which Debt Securities will be redeemed. In case less than all Debt Securities of any series are to be redeemed, the notice of redemption shall also identify the particular Debt Securities to be
redeemed as a whole or in part and shall state that the redemption is for the sinking fund, if such is the case. In case any Debt Security is to be redeemed in part only, the notice of redemption shall state the portion of the principal amount
thereof to be redeemed and shall state that on and after the date fixed for redemption, upon surrender of such Debt Security, a new Debt Security or Debt Securities of such series in aggregate principal amount equal to the unredeemed portion thereof
will be issued without charge to the Holder. 
 If the Debt Securities of any series are to be redeemed, the Company shall give the Trustee
notice, at least fifteen (15) days (or such shorter period acceptable to the Trustee) in advance of the date notice of the redemption is to be given, as to the aggregate principal amount of Debt Securities to be redeemed. Unless otherwise
provided in the form of Debt Security of any series, Debt Securities may be redeemed in part in multiples equal to the minimum authorized denomination for Debt Securities of such series or any multiple thereof. Thereupon the Trustee shall select, in
such manner as in its sole discretion it shall deem appropriate, the Debt Securities or portions thereof to be redeemed, and shall as promptly as practicable notify the Company of the Debt Securities or portions thereof so selected. For all purposes
of this Indenture, unless the context otherwise requires, all provisions relating to the redemption of Debt Securities of any series shall relate, in the case of any Debt Security redeemed or to be redeemed only in part, to the portion of the
principal amount of such Debt Security which has been or is to be redeemed. 
 On or prior to the date fixed for redemption specified in the
notice of redemption given as provided in this Section 4.02, the Company will deposit with the Trustee or with the paying agent an amount of money in the currency in which the Debt Securities of such series are payable sufficient to
redeem on the date fixed for redemption all the Debt Securities so called for redemption at the appropriate Redemption Price, together with accrued interest to the date fixed for redemption. 
 The Trustee shall not mail any notice of redemption of any series of Debt Securities during the continuation of any default in payment of interest on
any series of Debt Securities when due or of any Event of Default, except that where notice of redemption with respect to any series of Debt Securities shall have been mailed prior to the occurrence of such default or Event of Default, the Trustee
shall redeem such Debt Securities provided funds are deposited with it for such purpose. 
 SECTION 4.03 Payment of Debt Securities
Called for Redemption. If notice of redemption has been given as herein provided, the Debt Securities or portions of Debt Securities with respect to which such notice has been given shall become due and payable on the date and at the place
stated in such notice at the applicable Redemption Price, together with interest accrued to the date fixed for redemption, and on and after said date (unless the Company shall default in the payment of such Debt Securities or portions thereof at the
Redemption Price, 

  

 27 

 
together with interest accrued to said date) interest on the Debt Securities or portions of Debt Securities so called for redemption shall cease to accrue,
and such Debt Securities and portions of Debt Securities shall be deemed not to be Outstanding hereunder and shall not be entitled to any benefit under this Indenture except to receive payment of the Redemption Price, together with accrued interest
to the date fixed for redemption. On presentation and surrender of such Debt Securities at the place of payment in said notice specified, the said Debt Securities or the specified portions thereof shall be paid and redeemed by the Company at the
applicable Redemption Price, together with interest accrued thereon to the date fixed for redemption; provided, however, that any installments of interest becoming due on the date fixed for redemption shall be payable to the Holders of such
Debt Securities, or one or more previous Debt Securities evidencing all or a portion of the same debt as that evidenced by such particular Debt Securities, registered as such on the relevant record dates according to their terms and the provisions
of Section 3.08. 
 Upon presentation and surrender of any Debt Security redeemed in part only, with, if the Company or the
Trustee so required, due endorsement by, or a written instrument of transfer in form satisfactory to the Company and the Trustee duly executed by, the Holder thereof or such Holder’s attorney duly authorized in writing, the Company shall
execute and the Trustee shall authenticate and deliver to the Holder thereof, at the expense of the Company, a new Debt Security or Debt Securities of the same series having the same interest rate and Stated Maturity and bearing interest from the
same date, of any authorized denominations as requested by such Holder, in aggregate principal amount equal to the unredeemed portion of the Debt Security so presented and surrendered. 
 SECTION 4.04 Exclusion of Certain Securities from Eligibility for Selection for Redemption. Debt Securities shall be excluded from
eligibility for selection for redemption if they are identified by registration and certificate number in a written statement signed by an authorized officer of the Company and delivered to the Trustee at least 45 days prior to the last date on
which notice of redemption may be given as being owned of record and beneficially by, and not pledged or hypothecated by, either (a) the Company or (b) an entity specifically identified in such written statement directly or indirectly
controlling or controlled by or under direct or indirect common control with the Company. 
 SECTION 4.05 Provisions with Respect to
any Sinking Funds. Unless the form or terms of any series of Debt Securities shall provide otherwise, in lieu of making all or any part of any mandatory sinking fund payment with respect to such series of Debt Securities in cash, the Company may
at its option (1) deliver to the Trustee for cancellation any Debt Securities of such series theretofore acquired by the Company, or (2) receive credit for any Debt Securities of such series (not previously so credited) acquired by the
Company and theretofore delivered to the Trustee for cancellation. Debt Securities so delivered or credited shall be credited at the applicable sinking fund Redemption Price with respect to the Debt Securities of such series. 
 On or before the 45th day next preceding each sinking fund Redemption Date, the Company will deliver to the Trustee a certificate signed by the Chief
Financial Officer, any Vice 

  

 28 

 
President, the Treasurer or any Assistant Treasurer of the Company specifying (i) the portion of the mandatory sinking fund payment to be satisfied by
deposit of cash in the currency in which the Debt Securities of such series are payable, by delivery of Debt Securities theretofore purchased or otherwise acquired by the Company (which Debt Securities shall accompany such certificate) and by credit
for Debt Securities acquired by the Company and theretofore delivered to the Trustee for cancellation redeemed by the Company and stating that the credit to be applied has not theretofore been so applied or applied in lieu of retiring Funded Debt
pursuant to Section 5.06 and (ii) whether the Company intends to exercise its right, if any, to make an optional sinking fund payment, and, if so, the amount thereof. Such certificate shall also state that no Event of Default has
occurred and is continuing. Such certificate shall be irrevocable and upon its delivery the Company shall be obligated to make the payment or payments therein referred to, if any, on or before the next succeeding sinking fund payment date. In case
of the failure of the Company on or before the 45th day next preceding each sinking fund Redemption Date to deliver such certificate (or to deliver the Debt Securities specified in this paragraph), the sinking fund payment due on the next succeeding
sinking fund payment date shall be paid entirely in cash (in the currency described above) and shall be sufficient to redeem the principal amount of Debt Securities as a mandatory sinking fund payment, without the option to deliver or credit Debt
Securities as provided in the first paragraph of this Section 4.05 and without the right to make an optional sinking fund payment as provided herein. 
 If the sinking fund payment or payments (mandatory or optional) with respect to any series of Debt Securities made in cash (in the currency described above) shall exceed the minimum authorized denomination set forth
in an Officers’ Certificate pursuant to Section 3.01 or the equivalent in the currency in which the Debt Securities of such series are payable (or a lesser sum if the Company shall so request), unless otherwise provided by the terms
of such series of Debt Securities, said cash shall be applied by the Trustee on the sinking fund Redemption Date with respect to Debt Securities of such series at the applicable sinking fund Redemption Price with respect to Debt Securities of such
series, together with accrued interest, if any, to the date fixed for redemption, with the effect provided in Section 4.03. The Trustee shall select, in the manner provided in Section 4.02, for redemption on such sinking fund
Redemption Date a sufficient principal amount of Debt Securities of such series to utilize said cash and shall thereupon cause notice of redemption of the Debt Securities of such series for the sinking fund to be given in the manner provided in
Section 4.02 (and with the effect provided in Section 4.03) for the redemption of Debt Securities in part at the option of the Company. Debt Securities of any series which are identified by registration and certificate number
in an Officers’ Certificate at least 45 days prior to the sinking fund Redemption Date as being beneficially owned by, and not pledged or hypothecated by, the Company or an entity directly or indirectly controlling or controlled by or under
direct or indirect common control with the Company shall be excluded from Debt Securities of such series eligible for selection for redemption. Any sinking fund moneys not so applied or allocated by the Trustee to the redemption of Debt Securities
of such series shall be added to the next cash sinking fund payment with respect to Debt Securities of such series received by the Trustee and, together with such payment, shall be applied in accordance with the provisions of this
Section 4.05. Any and all sinking fund moneys with respect to Debt Securities of any series held by the Trustee at the maturity of Debt Securities of 

  

 29 

 
such series, and not held for the payment or redemption of particular Debt Securities of such series, shall be applied by the Trustee, together with other
moneys, if necessary, to be deposited sufficient for the purpose, to the payment of the principal of the Debt Securities of such series at maturity. 
 The Trustee shall not convert any currency in which the Debt Securities of such series are payable for the purposes of such sinking fund application unless a Company Request is made, and any such conversion agreed to
in writing by the Trustee in response to such request shall be for the account and at the expense of the Company and shall not affect the Company’s obligation to pay the Holders in the currency to which such Holders are entitled. 
 On or before each sinking fund Redemption Date provided with respect to Debt Securities of any series, the Company shall pay to the Trustee in cash in
the currency described above a sum equal to all accrued interest, if any, to the date fixed for redemption on Debt Securities to be redeemed on such sinking fund Redemption Date pursuant to this Section 4.05. 
 ARTICLE FIVE. PARTICULAR COVENANTS OF THE COMPANY 
 SECTION 5.01 Payment of Principal, Premium and Interest. The Company will duly and punctually pay or cause to be paid (in the currency in which the Debt Securities of such series are payable) the principal
of and premium, if any, and interest on each of the Debt Securities at the place (subject to Section 3.03), at the respective times and in the manner provided in each series of Debt Securities and in this Indenture. 
 SECTION 5.02 Offices for Notices and Payments, etc. 
 (a) So long as the Debt Securities of any series remain Outstanding, the Company will maintain at the Place of Payment, an office or
agency where the Debt Securities may be presented for payment, an office or agency where the Debt Securities may be presented for registration of transfer and for exchange as in this Indenture provided, and an office or agency where notices and
demands to or upon the Company in respect of the Debt Securities or of this Indenture may be served and shall give the Trustee written notice thereof and any changes in the location thereof. In case the Company shall at any time fail to maintain any
such office or agency, or shall fail to give notice to the Trustee of any change in the location thereof, presentation and demand may be made and notice may be served in respect of the Debt Securities or of this Indenture at said office of the
Trustee. 
 (b) In addition to the office or agency maintained by the Company pursuant to Section 5.02(a), the
Company may from time to time designate one or more other offices or agencies where the Debt Securities may be presented for payment and presented for registration of transfer and for exchange in the manner provided in this Indenture, and the
Company may from time to time rescind such designations, as the Company may deem desirable or expedient; provided, however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain such
office and agency at the Place of Payment, for the purposes abovementioned. The Company will 

  

 30 

 
give to the Trustee prompt written notice of (i) any such designation or rescission thereof, and (ii) the location of any such office or agency
outside the Place of Payment and of any change of location thereof. 
 SECTION 5.03 Appointments to Fill Vacancies in Trustee’s
Office. The Company, whenever necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided in Section 8.10, a Trustee, so that there shall at all times be a Trustee hereunder. 
 SECTION 5.04 Provisions as to Paying Agent. 
 (a) (1) Whenever the Company shall have one or more paying agents for any series of Debt Securities other than the Trustee, it will, on or before each due date of the principal of (and premium, if any) or interest on
any Debt Securities of such series, deposit with a paying agent a sum sufficient to pay such amount becoming due, such sum to be held as provided by the Trust Indenture Act of 1939, and (unless such paying agent is the Trustee) the Company will
promptly notify the Trustee of its action or failure so to act. 
 (2) The Company will cause each paying agent other than the
Trustee to execute and deliver to the Trustee an instrument in which such paying agent shall agree with the Trustee, subject to the provisions of this Section, that such paying agent will: (i) comply with the provisions of the Trust Indenture
Act of 1939 applicable to it as a paying agent and (ii) during the continuance of any default by the Company (or any other obligor upon any series of Debt Securities) in the making of any payment in respect of the Debt Securities of such
series, upon the written request of the Trustee, forthwith pay to the Trustee all sums held in trust by such paying agent as such. 
 (b) If the Company shall act as its own paying agent, it will, on or prior to each due date of the principal of and premium, if any, or interest on Debt Securities of any series, set aside, segregate and hold in trust for the benefit of the
Holders of such Debt Securities a sum sufficient to pay such principal and premium, if any, or interest so becoming due and will notify the Trustee of any failure to take such action and of any failure by the Company (or by any other obligor on such
series of Debt Securities) to make any payment of the principal of and premium, if any, or interest on the Debt Securities when the same shall become due and payable. 
 (c) Anything in this Section 5.04 to the contrary notwithstanding, the Company may, at any time, for the purpose of obtaining
a satisfaction and discharge of this Indenture with respect to any or all series of Debt Securities then Outstanding, or for any other reason, pay or cause to be paid to the Trustee all sums held in trust by the Company, or any paying agent
hereunder, as required by this Section 5.04, such sums to be held by the Trustee upon the trusts herein contained. 
 (d) Anything in this Section 5.04 to the contrary notwithstanding, the agreement to hold sums in trust provided in this Section 5.04 is subject to Section 13.04. 
  

 31 

 SECTION 5.05 Limitation on Secured Debt. 
 (a) So long as the Debt Securities shall remain Outstanding, the Company will not at any time create, assume or guarantee, and will not
cause, suffer or permit a Restricted Subsidiary to create, assume or guarantee, any Secured Debt without making effective provision (and the Company covenants that in such case it will make or cause to be made effective provision) whereby the Debt
Securities then Outstanding subject to applicable priorities of payment shall be secured by such Security Interest equally and ratably with any and all other obligations and indebtedness which shall be so secured; provided, however,
that the foregoing covenants shall not be applicable to the following: 
 (i) (a) any Security Interest in property of
the Company or a Restricted Subsidiary securing indebtedness incurred by the Company or a Restricted Subsidiary prior to, at the time of, or within 180 days after the later of the acquisition, the completion of construction (including any
improvements on an existing property) or the commencement of commercial operation of such property, which indebtedness is incurred for the purpose of financing all or any part of the purchase price thereof or construction or improvements thereon; or
(b) the acquisition of property subject to any Security Interest upon such property existing at the time of acquisition thereof, whether or not assumed by the Company or such Restricted Subsidiary; or (c) any Security Interest existing on
the property or on the outstanding shares of capital stock or indebtedness of a Person at the time such Person shall become a Restricted Subsidiary; or (d) a Security Interest on property or shares of capital stock or indebtedness of a Person
existing at the time such Person is merged into or consolidated with the Company or a Restricted Subsidiary or at the time of a sale, lease or other disposition of the properties of a Person or firm as an entirety or substantially as an entirety to
the Company or a Restricted Subsidiary, provided, however, that no such Security Interest shall extend to any other Principal Property of the Company or such Restricted Subsidiary prior to such acquisition or to any other Principal
Property thereafter acquired other than additions to such acquired property; 
 (ii) Security Interests in property of the
Company or a Restricted Subsidiary in favor of the United States of America or any State thereof, or any department, agency or instrumentality or political subdivision of the United States of America or any State thereof, or in favor of any other
country, or any department, agency or instrumentality or political subdivision thereof (including, without limitation, Security Interests to secure indebtedness of the pollution control or industrial revenue bond type), in order to permit the
Company or a Restricted Subsidiary to perform any contract or subcontract made by it with or at the request of any of the foregoing, or to secure partial, progress, advance or other payments pursuant to any contract or statute or to secure any
indebtedness incurred for the purpose of financing all or any part of the purchase price or the cost of constructing or improving the property subject to such Security Interests; 
  

 32 

 (iii) Any Security Interest on any property or assets of any Restricted Subsidiary to
secure indebtedness owing by it to the Company or to a Restricted Subsidiary; 
 (iv) Mechanics’, materialmen’s,
carriers’ or other like liens arising in the ordinary course of business (including construction of facilities) in respect of obligations which are not due or which are being contested in good faith; 
 (v) Any Security Interest arising by reason of deposits with, or the giving of any form of security to, any governmental agency or any
body created or approved by law or governmental regulations, which is required by law or governmental regulation as a condition to the transaction of any business, or the exercise of any privilege, franchise or license and any Security Interest to
secure public or statutory obligations; 
 (vi) Security Interests for taxes, assessments or governmental charges or levies
not yet delinquent, or the Security Interests for taxes, assessments or government charges or levies already delinquent but the validity of which is being contested in good faith; 
 (vii) Security Interests (including judgment liens) arising in connection with legal proceedings so long as such proceedings are being
contested in good faith and, in the case of judgment liens, execution thereon is stayed; 
 (viii) Landlords’ liens on
fixtures located on premises leased by the Company or a Restricted Subsidiary in the ordinary course of business; 
 (ix)
Security Interests in connection with a Permitted Receivables Financing; or 
 (x) Any extension, renewal or replacement (or
successive extensions, renewals or replacements) in whole or in part of any Security Interest permitted by subsection (a) of this Section 5.05. 
 (b) Notwithstanding the provisions of subsection (a) of this Section 5.05, the Company and any one or more
Restricted Subsidiaries may without securing the Debt Securities issue, assume or guarantee Secured Debt which would otherwise be subject to the foregoing restrictions in an aggregate amount which, together with all other Secured Debt of the Company
and its Restricted Subsidiaries which would otherwise be subject to the foregoing restrictions (not including Secured Debt permitted to be secured under subsection (a) above) and the aggregate value of the Sale and Leaseback Transactions
(as defined in Section 5.06) in existence at such time (not including Sale and Leaseback 

  

 33 

 
Transactions the proceeds of which have been or will be applied in accordance with Section 5.06(b)), does not exceed 10% of Consolidated Net
Tangible Assets, determined as of a date not more than 90 days prior thereto. 
 (c) In the event that the Company shall
hereafter secure the Debt Securities of each series equally and ratably with any other obligation or indebtedness pursuant to the provisions of this Section 5.05, the Trustee is hereby authorized to enter into an indenture or agreement
supplemental hereto and to take such action, if any, as it may deem advisable to enable it to enforce effectively the rights of the Holders of the Debt Securities so secured, equally and ratably with such other obligation or indebtedness.

 SECTION 5.06 Sale and Leaseback Transactions. So long as the Debt Securities shall remain Outstanding, the Company will not,
and will not permit any Restricted Subsidiary to, sell or transfer (except to the Company or one or more Restricted Subsidiaries, or both) any Principal Property owned by it and in full operation for more than 180 days with the intention of taking
back a lease on such property (except a lease for a term of no more than three years entered into with the intent that the use by the Company or such Restricted Subsidiary of such property will be discontinued on or before the expiration of such
term) (herein referred to as a “Sale and Leaseback Transaction”) unless either (a) the Company or such Restricted Subsidiary would be entitled, pursuant to the provisions of Section 5.05 hereof, to incur Secured
Debt equal in amount to the amount realized or to be realized upon such sale or transfer secured by a Security Interest on the property to be leased without equally and ratably securing the Debt Securities, or (b) the Company or a Restricted
Subsidiary shall apply an amount equal to the value of the property so leased to the retirement (other than any mandatory retirement), within 120 days of the effective date of any such arrangement, of Funded Debt as shown on the most recent
consolidated balance sheet of the Company and which, in the case of such Funded Debt of the Company, is not subordinate and junior in right of payment to the prior payment of the Debt Securities; provided, however, that in lieu of
applying all or any part of such amount to such retirement, the Company may at its option (x) deliver to the Trustee Debt Securities theretofore purchased or otherwise acquired by the Company, or (y) receive credit for the Debt Securities
theretofore redeemed at its option. If the Company shall so deliver the Debt Securities to the Trustee (or receive credit for Debt Securities so delivered), the amount which the Company shall be required to apply to the retirement of indebtedness
pursuant to this Section 5.06 shall be reduced by an amount equal to the aggregate principal amount of such Debt Securities. The term “value” shall mean, with respect to a Sale and Leaseback Transaction, as of any
particular time, the amount equal to the greater of (i) the Capitalized Rent with respect thereto, or (ii) the fair value of such property at the time of entering into such Sale and Leaseback Transaction as determined by the Board of
Directors. 
 SECTION 5.07 Restrictions on Transfer of Principal Property to Unrestricted Subsidiaries. So long as the Debt
Securities of any series remain Outstanding, the Company will not itself, and will not cause, suffer or permit any Restricted Subsidiary to, transfer (whether by merger, consolidation or otherwise) any Principal Property to any Unrestricted
Subsidiary, unless it shall apply, within 180 days after the effective date of such transaction, or shall have 

  

 34 

 
committed within 180 days after such effective date to apply, an amount equal to the fair value of such Principal Property at the time of such transfer, as
determined by the Board of Directors, to (a) the acquisition, construction, development or improvement of properties or facilities which are, or, upon such acquisition, construction, development or improvement will be, a Principal Property or
Principal Properties or a part thereof, (b) the redemption of Debt Securities of any series in accordance with the provisions of Article Four or (c) the repayment of Funded Debt of the Company or of any Restricted Subsidiary (other than
any Funded Debt owed to any Restricted Subsidiary or any Funded Debt that is subordinate and junior in right of payment to the prior payment of the Debt Securities), or in part to such acquisition, construction, development or improvement and in
part to such redemption and/or repayment; provided that, in lieu of applying an amount equivalent to all or any part of such fair value to such redemption, the Company may, within 180 days after such transfer, deliver to the Trustee Debt
Securities (other than Debt Securities made the basis of a reduction in a mandatory sinking fund payment pursuant to Section 4.05) for cancellation and thereby reduce the amount to be applied to the redemption of the Debt Securities of
that series pursuant to clause (b) or clause (c) above, as the case may be, by an amount equivalent to the aggregate principal amount of the Debt Securities so delivered. Redemption of Debt Securities pursuant to this
Section 5.07 shall not be used as credits against mandatory sinking fund payments. 
 SECTION 5.08 Certificate to Trustee. So long as the Debt Securities of any series remain Outstanding, the Company will deliver to the Trustee on or before the thirtieth (30th) day after May 15 of each year an Officers’ Certificate stating that in the course of the performance by the signers of their duties as
officers of the Company, they would normally have knowledge of any default by the Company in the performance or fulfillment or observance of any covenants or agreements contained herein during the preceding fiscal year, stating whether or not they
have knowledge of any such default and, if so, specifying each such default of which the signers have knowledge and the nature thereof. The Officers’ Certificate need not comply with Section 15.05. 
 SECTION 5.09 Waivers of Covenants. Anything in this Indenture to the contrary notwithstanding, the Company may fail or omit, in respect of
any series of Debt Securities, and in any particular instance, to comply with a covenant, agreement or condition contained in Sections 5.02, 5.04 (other than in 5.04(a)(1) and (2)) to 5.08, inclusive, or
with any additional covenant, agreement or condition contained in a Board Resolution or Officers’ Certificate establishing such series of Debt Securities, any indenture supplemental hereto applicable to such series or any Debt Security of such
series if the Company shall have obtained and filed with the Trustee before or after the time for such compliance the consent in writing of the Holders of more than 50% in aggregate principal amount of the Debt Securities of the series affected by
such waiver at the time Outstanding, either waiving such compliance in such instance or generally waiving compliance with such covenant or condition, but no such waiver shall extend to or affect any obligation not expressly waived nor impair any
right consequent thereon and, until such waiver shall become effective, the obligations of the Company and the duties of the Trustee in respect of any such covenant or condition shall remain in full force and effect. 
  

 35 

 ARTICLE SIX. HOLDERS’ LISTS AND REPORTS BY THE COMPANY AND THE TRUSTEE 
 SECTION 6.01 Holders’ Lists. The Company covenants and agrees that it will furnish or cause to be furnished to the Trustee, not more
than 15 days after each Regular Record Date with respect to the Debt Securities of any series, and at such other times as the Trustee may request in writing, within 30 days after receipt by the Company of any such request, a list in such form as the
Trustee may reasonably require of the names and addresses of the Holders of Debt Securities of such series as of a date not more than 15 days prior to the time such information is furnished; provided, however, that no such list with respect
to any particular series of Debt Securities need be furnished at any such time if the Trustee is in possession thereof by reason of its acting as the Debt Security registrar for such series designated under Section 3.06 or otherwise.

 SECTION 6.02 Preservation and Disclosure of Lists. 
 (a) The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the
Holders of Debt Securities contained in the most recent list furnished to it as provided in Section 6.01 or received by the Trustee in the capacity of the Debt Security registrar (if so acting) under Section 3.06. The Trustee
may destroy any list furnished to it as provided in Section 6.01 upon receipt of a new list so furnished. 
 (b)
The rights of Holders to communicate with other Holders with respect to their rights under this Indenture or under the Debt Securities of any series or of all Debt Securities, and the corresponding rights and duties of the Trustee, shall be as
provided by the Trust Indenture Act of 1939. 
 (c) Every Holder of Debt Securities, by receiving and holding the same, agrees
with the Company and the Trustee that neither the Company nor the Trustee nor any agent of either of them shall be held accountable by reason of any disclosure of information as to names and addresses of Holders made pursuant to the Trust Indenture
Act of 1939. 
 SECTION 6.03 Reports by the Company. The Company agrees to file with the Trustee and the Commission, and transmit
to Holders, such information, documents and other reports, and such summaries thereof, as may be required pursuant to the Trust Indenture Act of 1939 at the times and in the manner provided pursuant to such Act; provided that any such
information, documents or reports required to be filed with the Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, shall be filed with the Trustee within 15 days after the same is so required to be
filed with the Commission. Delivery of such reports, information and documents to the Trustee is for informational purposes only and the Trustee’s receipt thereof shall not constitute constructive notice of any information contained therein or
determinable from information contained therein, including the Company’s compliance with any of its covenants hereunder (as to which the Trustee is entitled to rely exclusively on Officers’ Certificates). 
  

 36 

 SECTION 6.04 Reports by the Trustee. 
 (a) The Trustee shall transmit to Holders such reports concerning the Trustee and its actions under this Indenture as may be required
pursuant to the Trust Indenture Act of 1939 at the times and in the manner provided pursuant thereto. The interval between transmissions of reports to be transmitted at intervals shall be twelve months or such shorter time required by the Trust
Indenture Act of 1939. If the Trust Indenture Act of 1939 does not specify the date on which a report is due, the such report shall be due on May 15 of each year following the first issuance of Debt Securities. 
 (b) A copy of each such report shall, at the time of such transmission to Holders, be filed by the Trustee with each stock exchange upon
which Debt Securities of any series are listed, with the Commission and with the Company. The Company will notify the Trustee, in writing, when the Debt Securities of any series are listed on any stock exchange. 
 SECTION 6.05 Statement by Officers as to Default. The Company shall deliver to the Trustee, promptly after and in any event within five
business days after one or more of the officers of the Company described in the definition of “Officers’ Certificate” becomes aware of the occurrence of any Event of Default or an event which, with notice or the lapse of time or both,
would constitute an Event of Default, an Officers’ Certificate setting forth the details of such Event of Default or default and the action which the Company proposes to take with respect thereto. 
 ARTICLE SEVEN. REMEDIES OF THE TRUSTEE AND HOLDERS ON EVENT OF DEFAULT 
 SECTION 7.01 Events of Default. “Event of Default”, with respect to any series of Debt Securities, wherever used herein,
means any one of the following events (whatever the reason for such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment, decree or order of any court or any order, rule or
regulation of any administrative or governmental body), unless such event is either inapplicable to such series or it is specifically deleted or modified in the Board Resolution, Officers’ Certificate or supplemental indenture under which such
series of Debt Securities is issued or in the form of Debt Security for such series: 
 (a) default in the payment of any
installment of interest upon any Debt Security of such series as and when the same shall become due and payable, and continuance of such default for a period of 30 days; or 
 (b) default in the payment of the principal of and premium, if any, on any Debt Security of such series as and when the same shall become
due and payable either at maturity, upon redemption, by declaration of acceleration or otherwise; or 
  

 37 

 (c) default in the payment or satisfaction of any sinking fund payment or analogous
obligation, if any, with respect to the Debt Securities of such series as and when the same shall become due and payable by the terms of the Debt Securities of such series, and continuance of such default for a period of 30 days; or 
 (d) failure on the part of the Company duly to observe or perform any of the covenants, warranties or agreements on the part of the
Company in respect of the Debt Securities of such series in this Indenture (other than a covenant, warranty or agreement a default in whose performance or whose breach is elsewhere in this Section specifically dealt with) continued for a period of
60 days after the date on which written notice of such failure, specifying such failure and requiring the same to be remedied, shall have been given to the Company by the Trustee, by registered mail, or to the Company and the Trustee by the Holders
of at least 25% in aggregate principal amount of the Outstanding Debt Securities of such series; or 
 (e) the uncured or
unwaived failure on the part of the Company to make payment of principal of or interest on any other obligation for borrowed money of the Company, including with respect to any other series of Debt Securities, beyond any period of grace with respect
thereto if the aggregate principal amount (or, in the case of Original Issue Discount Debt Securities, such portion of the principal amount as may be specified in the terms of such indebtedness as due and payable upon acceleration) of any such
obligation in respect of which principal or interest is and remains in default is in excess of $60,000,000; provided, however, that subject to the provisions of Section 7.08 and Section 8.01 the Trustee shall not be
charged with knowledge of any such default unless written notice thereof shall have been given to the Trustee by the Company, by the holders or an agent of the holders of any such indebtedness, by the trustee then acting under any indenture or other
instrument under which such default shall have occurred, or by the Holders of not less than 25% in aggregate principal amount of such series of Debt Securities at the time Outstanding; or 
  

 38 

 (f) a decree or order by a court having jurisdiction in the premises shall have been
entered adjudging the Company a bankrupt or insolvent, or approving as properly filed a petition seeking reorganization of the Company under the Federal bankruptcy laws or any other similar applicable Federal or state law, and such decree or order
shall have continued undischarged and unstayed for a period of 60 days; or a decree or order of a court having jurisdiction in the premises for the appointment of a receiver or liquidator or trustee or assignee or other similar official in
bankruptcy or insolvency of the Company or of all or substantially all of its property, or for the winding up or liquidation of its affairs, shall have been entered, and such decree or order shall have continued undischarged and unstayed for a
period of 60 days; or 
 (g) the Company shall institute proceedings to be adjudicated a voluntary bankrupt, or shall consent
to the filing of a bankruptcy proceeding against it, or shall file a petition or answer or consent seeking an arrangement or a reorganization under the Federal bankruptcy laws or any other similar applicable Federal or state law, or shall consent to
the filing of any such petition, or shall consent to the appointment of a receiver or liquidator or trustee or assignee or other similar official in bankruptcy or insolvency of it or of all or substantially all of its property, or shall make an
assignment for the benefit of creditors generally, or shall admit in writing its inability to pay its debts generally as they become due; or 
 (h) any other Event of Default provided in the Board Resolution, Officers’ Certificate or supplemental indenture under which such series of Debt Securities is issued or in the form of Debt Security for such
series. 
 In the case of each and every Event of Default, so long as such Event of Default with respect to any series of Debt Securities for which there are
Debt Securities Outstanding occurs and is continuing (other than an Event of Default specified in clause (f) or (g) of Section 7.01) and shall not have been remedied or waived to the extent permitted by the terms
of this Indenture, unless the principal of all of the Debt Securities of such series shall have already become due and payable, either the Trustee or the Holders of not less than 25% in aggregate principal amount of the Outstanding Debt Securities
of such series, by notice in writing to the Company (and to the Trustee if given by Holders), may declare the principal (or, if the Debt Securities of that series are Original Issue Discount Debt Securities, such portion of the principal amount as
may be specified in the terms of that series) of all the Debt Securities of such series and the interest accrued thereon to be due and payable immediately, and upon any such declaration the same shall become and shall be immediately due and payable,
anything in this Indenture or in the Debt Securities of such series contained to the contrary notwithstanding. If an Event of Default specified in clause (f) or (g) of Section 7.01 occurs and is continuing, then
the principal amount of (or, if the Debt Securities of that series are Original Issue Discount Debt Securities, such portion of the principal amount as may be specified in the terms thereof as due and payable upon acceleration) and any accrued and
unpaid interest on that series shall immediately become due and payable without any declaration or other act on the part of the Trustee or any Holder. This provision, however, is subject to the condition that if, at any time after the principal of
the Debt 

  

 39 

 
Securities of such series shall have been so declared due and payable, and before any judgment or decree for the payment of the moneys due shall have been
obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay in the currency in which the Debt Securities of such series are payable all matured installments of interest upon all of the
Debt Securities and the principal of and premium, if any, on any and all Debt Securities of such series which shall have become due otherwise than by such declaration (with interest on overdue installments of interest to the extent that payment of
such interest is enforceable under applicable law and on such principal and premium, if any, at the rate borne by the Debt Securities of such series or as otherwise provided in the form of Debt Security for such series, to the date of such payment
or deposit) and the expenses of the Trustee (subject to Section 8.06), and any and all defaults under this Indenture, other than the nonpayment of principal of and accrued interest on Debt Securities of such series which shall have
become due by such declaration, shall have been cured or shall have been waived in accordance with Section 7.07 or provision deemed by the Trustee to be adequate shall have been made therefor—then and in every such case the Holders
of at least a majority in aggregate principal amount of the Debt Securities of such series then Outstanding, by written notice to the Company and to the Trustee, may rescind and annul such declaration and its consequences; but no such rescission and
annulment shall extend to or shall affect any subsequent default, or shall impair any right consequent thereon. 
 In case the Trustee or
any Holders shall have proceeded to enforce any right under this Indenture and such proceedings shall have been discontinued or abandoned because of such rescission and annulment or for any other reason or shall have been determined adversely to the
Trustee, then and in every such case the Company, the Trustee and the Holders shall be restored respectively to their several positions and rights hereunder, and all rights, remedies and powers of the Company, the Trustee and the Holders shall
continue as though no such proceeding had been taken. 
 SECTION 7.02 Payment of Debt Securities Upon Default; Suit Therefor. The
Company covenants that (a) in case default shall be made in the payment of any installment of interest upon any Debt Security of any series as and when the same shall become due and payable, and such default shall have continued for a period of
30 days, or (b) in case default shall be made in the payment of the principal of and premium, if any, on any Debt Security of any series as and when the same shall have become due and payable, whether at maturity of the Debt Security or upon
redemption or by declaration or otherwise or (c) in case default shall be made in the making or satisfaction of any sinking fund payment or analogous obligation with respect to the Debt Securities of any series when the same becomes due by the
terms of the Debt Securities of any series—then, upon demand of the Trustee, the Company will pay to the Trustee, for the benefit of the Holders (or Holders of Debt Securities of any such series in the case of clause (c) above), the
whole amount that then shall have become due and payable on any such Debt Security (or Debt Securities of any such series in the case of clause (c) above) for principal and premium, if any, or interest, or both, as the case may be, with
interest upon the overdue principal and premium, if any, and (to the extent that payment of such interest is enforceable under applicable law) upon the overdue installments of interest at the rate borne by the Debt Securities 

  

 40 

 
of such series or as otherwise provided in the form of Debt Security of such series; and, in addition thereto, such further amount as shall be sufficient to
cover the costs and expenses of collection, including a reasonable compensation to the Trustee, its agents, attorneys and counsel, and any expenses or liabilities incurred and advances made by the Trustee, except compensation or advances arising, or
expenses or liabilities incurred, as a result of the Trustee’s negligence or bad faith. 
 Until such demand is made by the Trustee,
the Company may pay the principal of and premium, if any, and interest on the Debt Securities of any series to the Persons entitled thereto, whether or not the principal of and premium, if any, and interest on the Debt Securities of such series are
overdue. 
 In case the Company shall fail forthwith to pay such amounts upon such demand, the Trustee, in its own name and as trustee of an
express trust, shall be entitled and empowered to institute any actions or proceedings at law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceeding to judgment or final decree, and may enforce
any such judgment or final decree against the Company or any other obligor on such Debt Securities and collect, in the manner provided by law out of the property of the Company or any other obligor on such Debt Securities wherever situated, the
moneys adjudged or decreed to be payable. If any Event of Default with respect to any series of Debt Securities occurs and is continuing, the Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders of
Debt Securities of such series by such appropriate judicial proceedings as the Trustee shall deem necessary to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this Indenture or in aid of the
exercise of any power granted herein, or to enforce any other proper remedy. 
 In case there shall be pending proceedings for the
bankruptcy or for the reorganization of the Company or any other obligor on the Debt Securities of any series under the Federal bankruptcy laws or any other applicable law, or in case a receiver or trustee shall have been appointed for the property
of the Company or such other obligor, or in the case of any other similar judicial proceedings relative to the Company or other obligor upon the Debt Securities of any series, or to the creditors or property of the Company or such other obligor, the
Trustee, irrespective of whether the principal of the Debt Securities of such series shall then be due and payable as therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have made any demand pursuant to the
provisions of this Section 7.02, shall be entitled and empowered by intervention in such proceedings or otherwise, (a) to file and prove a claim or claims for the whole amount of principal and interest owing and unpaid in respect of
the Debt Securities of such series, and, in case of any judicial proceedings, to file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the Trustee and of the Holders of the Debt
Securities of such series allowed in such judicial proceedings relative to the Company or any other obligor on such Debt Securities, its or their creditors, or its or their property, (b) unless prohibited by applicable law and regulations, to
vote on behalf of the Holders of any Debt Securities of any series in any election of a trustee or a standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency 

  

 41 

 
proceedings or person performing similar functions in comparable proceedings, and (c) to collect and receive any moneys or other property payable or
deliverable on any such claims, and to distribute the same after the deduction of its charges and expenses; and any receiver, assignee or trustee in bankruptcy or reorganization is hereby authorized by each of the Holders of the Debt Securities of
such series to make such payments to the Trustee, and, in the event that the Trustee shall consent to the making of such payments directly to such Holders, to pay to the Trustee such amount as shall be sufficient to cover reasonable compensation to
the Trustee, its agents, attorneys and counsel, and all other expenses and liabilities incurred and advances made by the Trustee except compensation or advances arising, or expenses or liabilities incurred, as a result of the Trustee’s own
negligence or willful misconduct. 
 Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept,
or adopt on behalf of any Holder any plan or reorganization, arrangement, adjustment or composition affecting the Debt Securities or the rights of any Holder thereof, or to authorize the Trustee to vote in respect of the claim of any Holder (except,
as aforesaid, for the election of a trustee in bankruptcy or other Person performing similar functions) in any such proceeding. 
 All
rights of action and of asserting claims under this Indenture, or under any of the Debt Securities of any series, may be enforced by the Trustee without the possession of any of such Debt Securities, or the production thereof on any trial or other
proceeding relative thereto, and any such suit or proceeding instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment shall be for the ratable benefit of the Holders of the Debt
Securities of such series in respect of which such judgment has been recovered. 
 In any proceedings brought by the Trustee (and also any
proceedings involving the interpretation of any provision of this Indenture to which the Trustee shall be a party), the Trustee shall be held to represent all the Holders of the Debt Securities in respect to which such action was taken, and it shall
not be necessary to make any Holders of such Debt Securities parties to any such proceedings. 
 SECTION 7.03 Application of Moneys
Collected by Trustee. Any moneys collected by the Trustee pursuant to Section 7.02 shall be applied in the order following, at the date or dates fixed by the Trustee for the distribution of such moneys, upon presentation of the Debt
Securities of such series, and stamping thereon the payment, if only partially paid, and upon surrender thereof, if fully paid: 
 FIRST: To the payment of costs and expenses of collection and reasonable compensation to the Trustee, its agents, attorneys and counsel, and of all other expenses and liabilities incurred, and all advances made, by the Trustee except
compensation or advances arising, or expenses or liabilities incurred, as a result of its own negligence or willful misconduct, and any other amounts owing the Trustee under Section 8.06; 
  

 42 

 SECOND: In case the principal of the Debt Securities of such series shall not have
become due and be unpaid, to the payment of interest on such Debt Securities, in the order of the maturity of the installments of such interest, with interest (to the extent that such interest has been collected by the Trustee) upon the overdue
installments of interest at the rate borne by such Debt Securities, such payments to be made ratably to the Persons entitled thereto; 
 THIRD: In case the principal of the Debt Securities of such series shall have become due, by declaration or otherwise, to the payment of the whole amount then owing and unpaid upon such Debt Securities for principal
and premium, if any, and interest, with interest on the overdue principal and premium, if any, and (to the extent that such interest has been collected by the Trustee) upon overdue installments of interest at the rate borne by such Debt Securities;
and in case such moneys shall be insufficient to pay in full the whole amounts so due and unpaid upon such Debt Securities, then, to the payment of such principal and premium, if any, and interest without preference or priority of principal and
premium, if any, over interest, or of interest over principal and premium, if any, or of any installment of interest over any other installment of interest, or of any Debt Security of such series over any other such Debt Security, such payments to
be made ratably to the Persons entitled thereto; 
 FOURTH: To the payment of any surplus then remaining to the Company, its
successors or assigns, or as a court of competent jurisdiction shall direct. 
 SECTION 7.04 Proceedings by Holders. No Holder of
any Debt Security of any series shall have any right by virtue of or by availing of any provision of this Indenture to institute any suit, action or proceeding in equity or at law or in bankruptcy or otherwise upon or under or with respect to this
Indenture or for the appointment of a receiver or trustee, or for any other remedy hereunder, unless such Holder previously shall have given to the Trustee written notice of default and of the continuance thereof, as hereinbefore provided, and
unless also the Holders of not less than 25% in aggregate principal amount of the Debt Securities of such series then Outstanding shall have made written request upon the Trustee to institute such action, suit or proceeding in its own name as
Trustee hereunder and shall have offered to the Trustee such indemnity as it may require against the costs, expenses and liabilities to be incurred therein or thereby, and the Trustee for 60 days after its receipt of such notice, request and offer
of indemnity, shall have neglected or refused to institute any such action, suit or proceeding (and no direction inconsistent with such written request shall have been given to the Trustee pursuant to Section 7.07), it being understood
and intended, and being expressly covenanted by the taker and Holder of every Debt Security of every series with every other taker and Holder and the Trustee, that no one or more Holders of Debt Securities shall have any right in any manner whatever
by virtue of or by availing of any provision of this Indenture to affect, disturb or prejudice the rights of any other Holder of such Debt Securities, or to obtain or seek to obtain priority over or preference to any other such Holder, or to enforce
any right under this Indenture, except in the manner herein provided and for the equal, ratable and common benefit of all Holders of Debt Securities. 
  

 43 

 SECTION 7.05 Proceedings by Trustee. In case of an Event of Default hereunder the Trustee may
in its discretion proceed to protect and enforce the rights vested in it by this Indenture by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and enforce any of such rights, either by suit in equity or by
action at law or by proceeding in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement contained in this Indenture or in aid of the exercise of any power granted in this Indenture, or to enforce any other legal
or equitable right vested in the Trustee by this Indenture or by law. 
 SECTION 7.06 Remedies Cumulative and Continuing. All
powers and remedies given by this Article Seven to the Trustee or to the Holders shall, to the extent permitted by law, be deemed cumulative and not exclusive of any thereof or of any other powers and remedies available to the Trustee or the
Holders, by judicial proceedings or otherwise, to enforce the performance or observance of the covenants and agreements contained in this Indenture, and no delay or omission of the Trustee or of any Holder to exercise any right or power accruing
upon any default occurring and continuing as aforesaid shall impair any such right or power, or shall be construed to be a waiver of any such default or an acquiescence therein; and, subject to the provisions of Section 7.04, every power
and remedy given by this Article Seven or by law to the Trustee or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders. 
 SECTION 7.07 Direction of Proceedings and Waiver of Defaults by Majority of Holders. The Holders of a majority in aggregate principal amount
of the Outstanding Debt Securities of any series shall have the right to direct the time, method, and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred on the Trustee with respect
to the Debt Securities by this Indenture; provided, however, that (subject to the provisions of Section 8.01) the Trustee shall have the right to decline to follow any such direction if the Trustee shall determine upon advice of
counsel that the action or proceeding so directed may not lawfully be taken or would be materially and unjustly prejudicial to the rights of Holders not joining in such direction or if the Trustee in good faith by a trust committee of directors or
trustees and/or Responsible Officers shall determine that the action or proceeding so directed would involve the Trustee in personal liability or if the Trustee in good faith shall so determine that the actions or forebearances specified in or
pursuant to such direction would be unduly prejudicial to the interests of Holders of the Debt Securities of all series not joining in the giving of said direction, it being understood that (subject to Section 8.01) the Trustee shall
have no duty to ascertain whether or not such actions or forebearances are duly prejudicial to such Holders. The Trustee may take any other action deemed proper by the Trustee not inconsistent with such direction. The Holders of a majority in
aggregate principal amount of the Outstanding Debt Securities of any series may on behalf of the Holders of all the Debt Securities of such series waive any past default or Event of Default hereunder and its consequences except a default in the
payment of principal of or premium, if 

  

 44 

 
any, or interest on such Debt Securities, or a default in the making of any sinking fund payment with respect to such Debt Securities. Upon any such waiver
the Company, the Trustee and the Holders of such Debt Securities shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other default or Event of Default or impair any
right consequent thereon. Whenever any default or Event of Default shall have been waived as permitted by this Section 7.07, said default or Event of Default shall for all purposes of the Debt Securities and this Indenture be deemed to
have been cured and to be not continuing. 
 This Section 7.07 shall be in lieu of Sections 316(a)(1)(A) and 316(a)(1)(B) of the
Trust Indenture Act of 1939 and such Sections 316(a)(1)(A) and Section 316(a)(1)(B) are hereby expressly excluded from this Indenture, as permitted by the Trust Indenture Act of 1939. 
 SECTION 7.08 Notice of Defaults. The Trustee shall give the Holders notice of any default hereunder as and to the extent provided by the
Trust Indenture Act of 1939; provided, however, that in the case of any default of the character specified in Section 7.01(d), no such notice to Holders shall be given until at least 60 days after the occurrence thereof.
For the purpose of this Section, the term “default” means any event which is, or after notice or lapse of time or both would become, an Event of Default. 
 SECTION 7.09 Undertaking to Pay Costs. In any suit for the enforcement of any right or remedy under this Indenture, or in any suit against the Trustee for any action taken, suffered or omitted by it as
Trustee, a court may require any party litigant in such suit to file an undertaking to pay the costs of such suit, and may assess costs against any such party litigant, in the manner and to the extent provided in the Trust Indenture Act of 1939;
provided that neither this Section nor the Trust Indenture Act of 1939 shall be deemed to authorize any court to require such an undertaking or to make such an assessment in any suit instituted by the Company, and any provision of the Trust
Indenture Act of 1939 to such effect is hereby expressly excluded from this Indenture, as permitted by the Trust Indenture Act of 1939. This Section does not apply to a suit by the Trustee, a suit by a Holder pursuant to Section 7.10
hereof or a suit by Holders of more than 10% in principal amount of the then Outstanding Debt Securities. 
 SECTION 7.10
Unconditional Right of Holders to Receive Principal, Premium and Interest. Notwithstanding any other provision in this Indenture, the Holder of any Debt Security shall have the rights, which are absolute and unconditional, to receive payment
of the principal of, premium, if any, and (subject to Section 3.08) interest on such Debt Security on the respective Stated Maturities expressed in such Debt Security (or in the case of redemption or repayment, on the date for redemption
or repayment, as the case may be) and to institute suit for the enforcement of any such payment, and such rights shall not be impaired without the consent of such Holder. 
  

 45 

 ARTICLE EIGHT. CONCERNING THE TRUSTEE 
 SECTION 8.01 Duties and Responsibilities of Trustee. The duties and responsibilities of the Trustee shall be as provided by the Trust
Indenture Act of 1939. Notwithstanding the foregoing, no implied covenants or obligations, except as provided by the Trust Indenture Act of 1939, shall be read into this Indenture against the Trustee, and no provision of this Indenture shall require
the Trustee to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its duties hereunder, or in the exercise of any of its rights or powers, if it shall have reasonable grounds for believing that
repayment of such funds or adequate indemnity against such risk or liability is not reasonably assured to it. Whether or not therein expressly so provided, every provision of this Indenture relating to the conduct or affecting the liability of or
affording protection to the Trustee shall be subject to the provisions of this Section. 
 (a) Except during the continuance
of an Event of Default, in the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee and
conforming to the requirements of this Indenture; but in the case of any such certificates or opinions which by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to
determine whether or not they conform to the requirements of this Indenture (but need not confirm or investigate the accuracy of mathematical calculations or other facts stated therein). 
 (b) In case an Event of Default has occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by
this Indenture, and use the same degree of care and skill in their exercise, as a prudent person would exercise or use under the circumstances in the conduct of his or her own affairs. 
 (c) No provision of this Indenture shall be construed to relieve the Trustee from liability for its own negligent action, its own
negligent failure to act, or its own willful misconduct, except that 
 (i) this clause (c) shall not be construed
to limit the effect of clause (a) of this Section; 
 (ii) the Trustee shall not be liable for any error of
judgment made in good faith by a Responsible Officer, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; and 
 (iii) the Trustee shall not be liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the Holders of a majority in principal amount of the Outstanding
Debt Securities of any series, relating to the time, method and place of conducting any proceeding for any remedy available to the Trustee, or exercising any trust or power conferred upon the Trustee, under this Indenture with respect to the Debt
Securities of such series. 
  

 46 

 SECTION 8.02 Reliance on Documents, Opinions, etc. Subject to the provisions of
Section 8.01, 
 (a) the Trustee may conclusively rely and shall be protected in acting or refraining from acting
upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note or other paper document believed by it to be genuine and to have been signed or presented by the proper party
or parties; 
 (b) any request, direction, order or demand of the Company mentioned herein shall be sufficiently evidenced by
an Officers’ Certificate (unless otherwise evidence in respect thereof be herein specifically prescribed); and any resolution of the Board of Directors may be evidenced to the Trustee by a copy thereof certified by the Secretary or an Assistant
Secretary of the Company; 
 (c) the Trustee may consult with counsel of its selection and the advice of such counsel or any
Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with such advice or Opinion of Counsel; 
 (d) the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request, order
or direction of any of the Holders, pursuant to the provisions of this Indenture, unless such Holders shall have offered to the Trustee security or indemnity satisfactory to the Trustee against the costs, expenses and liabilities which may be
incurred therein or thereby; 
 (e) the Trustee shall not be liable for any action taken, suffered or omitted by it in good
faith and believed by it to be authorized or within the discretion or rights or powers conferred upon it by this Indenture; 
 (f) prior to the occurrence of an Event of Default with respect to the Debt Securities of any series and after the curing or waiving of all Events of Default with respect to such Debt Securities, the Trustee shall not be bound to make any
investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, bond, debenture, note, or other paper or document, but the Trustee, in its discretion,
may make such further inquiry or investigation as it may see fit, and, if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by
agent or attorney at the sole cost of the Company and shall incur no liability or additional liability of any kind by reason of such inquiry or investigation; 
 (g) the Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder either directly or by or through agents
or attorneys, and the Trustee shall not be liable or responsible for any willful misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder; 
  

 47 

 (h) the Trustee shall not be deemed to have knowledge of any default or Event of Default
unless a Responsible Officer of the Trustee has actual knowledge thereof or unless written notice of any event which is in fact such a default or Event of Default is received by the Trustee at the Corporate Trust Office of the Trustee, and such
notice references the Debt Securities and this Indenture; 
 (i) whenever in the administration of this Indenture the Trustee
shall deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad faith on its part,
conclusively rely upon an Officers’ Certificate; 
 (j) in no event shall the Trustee be responsible or liable for
special, indirect, or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of
action; 
 (k) the rights, privileges, protections, immunities and benefits given to the Trustee, including, without
limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Trustee in each of its capacities hereunder, and each agent, custodian and other Person employed to act hereunder; and 
 (l) the Trustee may request that the Company deliver a certificate setting forth the names of individuals and/or titles of officers
authorized at such time to take specified actions pursuant to this Indenture. 
 SECTION 8.03 No Responsibility for Recitals,
etc. The recitals contained herein and in the Debt Securities (except in the Trustee’s certificate of authentication) shall be taken as the statements of the Company, and the Trustee assumes no responsibility for the correctness of the
same. The Trustee makes no representations as to the validity or sufficiency of this Indenture or of the Debt Securities of any series. The Trustee represents that it is duly authorized to execute and deliver this Indenture and perform its
obligations hereunder. Neither the Trustee nor the Authenticating Agent shall be accountable for the use or application by the Company or any Debt Securities or the proceeds of any Debt Securities authenticated and delivered by the Trustee in
conformity with the provisions of this Indenture. 
 SECTION 8.04 Trustee and Agents May Own Debt Securities. The Trustee, any
paying agent, or any agent of the Trustee or the Company under this Indenture, in its individual or any other capacity, may become the owner or pledgee of Debt Securities of any series with the same rights it would have if it were not Trustee or
such agent and, subject to Sections 8.08 and 8.13, if operative, may otherwise deal with the Company and receive, collect, hold, and retain collections from the Company with the same rights it would have if it were not the Trustee
or such agent. 
  

 48 

 SECTION 8.05 Moneys to be Held in Trust. Subject to the provisions of
Section 13.04, all moneys received by the Trustee shall, until used or applied as herein provided, be held in trust for the purposes for which they were received, but need not be segregated from other funds except to the extent required
by law. Neither the Trustee nor any paying agent shall be under any liability for interest on any moneys received by it hereunder except such as it may agree with the Company to pay thereon. So long as no Event of Default with respect to the Debt
Securities of any series shall have occurred and be continuing, all interest allowed on any such moneys shall be paid from time to time upon the written order of the Company, signed by its President, its Chief Financial Officer, any Vice President,
its Treasurer or an Assistant Treasurer. 
 SECTION 8.06 Compensation and Expenses of Trustee. The Company covenants and agrees
to pay to the Trustee from time to time, and the Trustee shall be entitled to, reasonable compensation (which shall not be limited by any provision of law in regard to the compensation of a trustee of an express trust), and the Company will pay or
reimburse the Trustee upon its request for all expenses, disbursements and advances incurred or made by the Trustee in accordance with any of the provisions of this Indenture (including the reasonable compensation and the expenses and disbursements
of its counsel and all persons not regularly in its employ and any amounts paid by the Trustee to any Authenticating Agent pursuant to Section 8.14) except any such expense, disbursement or advance as may arise from its negligence or bad
faith. The Company also covenants to indemnify the Trustee for, and to hold it harmless against, any loss, liability, claim, damage or expense incurred without negligence or willful misconduct on the part of the Trustee and arising out of or in
connection with the acceptance or administration of this trust, or the performance of its duties hereunder, including the current payment of all costs and expenses of defending itself against any claim of liability in the premises. The obligations
of the Company under this Section 8.06 to compensate and indemnify the Trustee and to pay or reimburse the Trustee for expenses, disbursements and advances shall constitute additional indebtedness hereunder and shall survive the
termination and discharge of this Indenture. Such additional indebtedness shall be secured by a lien prior to that of the Debt Securities upon all property and funds held or collected by the Trustee as such, except funds held in trust for the
benefit of the Holders of particular Debt Securities. When the Trustee incurs expenses or renders services in connection with an Event of Default, the expenses (including the reasonable charges and expenses of its counsel) and the compensation for
the services are intended to constitute expenses of administration under any applicable Federal or state bankruptcy, insolvency or other similar law. 
 SECTION 8.07 Officers’ Certificate as Evidence. Subject to the provisions of Section 8.01, whenever in the administration of the provisions of this Indenture the Trustee shall deem it
necessary or desirable that a matter be proved or established prior to taking or omitting any action hereunder, such matter (unless other evidence in respect thereof be herein specifically prescribed) may, in the absence of negligence or willful
misconduct on the part of the Trustee, be deemed to be conclusively proved and established by an Officers’ Certificate delivered to the Trustee, and such Officers’ Certificate, in the absence of negligence or willful misconduct on the part
of the Trustee, shall be full warrant to the Trustee for any action taken or omitted by it under the provisions of this Indenture upon the faith thereof. 
  

 49 

 SECTION 8.08 Conflicting Interest of Trustee. If the Trustee has or shall acquire any
conflicting interest within the meaning of the Trust Indenture Act of 1939, the Trustee shall either eliminate such conflicting interest or resign in the manner provided by, and subject to the provisions of, the Trust Indenture Act of 1939 and this
Indenture. 
 SECTION 8.09 Eligibility of Trustee. There shall at all times be a Trustee with respect to each series of Debt
Securities hereunder which shall be a Person organized and doing business under the laws of the United States or any state or territory thereof or of the District of Columbia authorized under such laws to exercise trust powers, having a combined
capital and surplus of at least $50,000,000, subject to supervision or examination by Federal, state, territorial, or District of Columbia authority and willing to act as Trustee hereunder. If such Person publishes reports of condition at least
annually, pursuant to law or to the requirements of the aforesaid supervising or examining authority, then for the purposes of this Section 8.09, the combined capital and surplus of such Person shall be deemed to be its combined capital
and surplus as set forth in its most recent report of condition so published. In case at any time the Trustee with respect to any series of Debt Securities shall cease to be eligible in accordance with the provisions of this
Section 8.09, such Trustee shall resign immediately in the manner and with the effect specified in Section 8.10. 
 SECTION 8.10 Resignation or Removal of Trustee. 
 (a) The Trustee may at any time resign with respect to
any series of Debt Securities by giving written notice by first class mail of such resignation to the Company and to the Holders of such series of Debt Securities at their addresses as they shall appear on the Debt Security Register. Upon receiving
such notice of resignation, the Company shall promptly appoint a successor trustee with respect to such series by written instrument, in duplicate, executed by order of the Board of Directors, one copy of which instrument shall be delivered to the
resigning Trustee and one copy to the successor trustee. If no successor trustee with respect to such series shall have been so appointed and have accepted appointment within 60 days after the mailing of such notice of resignation to the Holders,
the resigning Trustee may petition at the expense of the Company any court of competent jurisdiction for the appointment of a successor trustee, or any Holder of such series of Debt Securities who has been a bona fide Holder of a Debt Security or
Debt Securities of such series for at least six months may, subject to the provisions of Section 7.09, on behalf of such Holder and all others similarly situated, petition any such court for the appointment of a successor trustee with
respect to such series. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, appoint such successor trustee. 
 (b) In case at any time any of the following shall occur— 
 (i) the Trustee shall fail
to comply with the provisions of Section 8.08 after written request therefor by the Company or by any Holder who has been a bona fide Holder of a Debt Security or Debt Securities of such series for at least six months, unless the
Trustee’s duty to resign is stayed in accordance with the provisions of Section 310(b) of the Trust Indenture Act of 1939, or 
  

 50 

 (ii) the Trustee shall cease to be eligible in accordance with the provisions of
Section 8.09 and shall fail to resign after written request therefor by the Company or by any such Holder of a note of such series, or 
 (iii) the Trustee shall become incapable of acting with respect to any series of Debt Securities, or shall be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or
any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation or liquidation, 
 then, in any such case, the Company may remove the Trustee with respect to such series and appoint a successor trustee for such series by written instrument, in duplicate, executed on instruction of the President, the Chief Financial
Officer, the Treasurer, any Vice President or the General Counsel of the Company, one copy of which instrument shall be delivered to the Trustee so removed and one copy to the successor trustee, or, subject to the provisions of
Section 7.09, any Holder who has been a bona fide Holder of a Debt Security or Debt Securities of such series for at least six months may, on behalf of such Holder and all others similarly situated, petition any court of competent
jurisdiction for the removal of the Trustee and the appointment of a successor trustee with respect to such series. Such court may thereupon, after such notice, if any, as it may deem proper and prescribe, remove such Trustee and appoint such
successor trustee. 
 (c) The Holders of a majority in aggregate principal amount of the Outstanding Debt Securities of any
series may at any time remove the Trustee with respect to such series by delivering to the Trustee so removed, to the successor trustee so appointed and to the Company the evidence provided for in Section 9.01 of the action in that
regard taken by the Holders, and nominate a successor Trustee which shall be deemed appointed as successor Trustee unless within ten days after such nomination the Company objects thereto, in which case the Trustee so removed or any Holder of a Debt
Security or Debt Securities of such series, upon the terms and conditions and otherwise as in subsection (a) of this Section 8.10 provided, may petition any court of competent jurisdiction for an appointment of a successor
Trustee with respect to such series. 
 (d) Any resignation or removal of the Trustee with respect to all or any series of
Debt Securities and any appointment of a successor Trustee pursuant to any of the provisions of this Section 8.10 shall become effective upon acceptance of appointment by the successor Trustee as provided in Section 8.11.

 SECTION 8.11 Acceptance by Successor Trustee. Any successor Trustee appointed as provided in Section 8.10 shall
execute, acknowledge and deliver to the Company and to its predecessor Trustee an instrument accepting such appointment hereunder, and thereupon the resignation or removal of the predecessor Trustee shall become effective with respect to all or any
series as to which it is resigning as Trustee, and such successor Trustee, 

  

 51 

 
without any further act, deed or conveyance, shall become vested with all the rights, powers, duties and obligations of its predecessor hereunder with
respect to all or any such series, with like effect as if originally named as Trustee herein with respect to all or any such series; nevertheless, on the written request of the Company or of the successor Trustee, the Trustee ceasing to act shall,
upon payment of any amounts then due it pursuant to the provisions of Section 8.06, execute and deliver an instrument transferring to such successor Trustee all the rights and powers of the Trustee with respect to all or any such series
so ceasing to act. Upon request of any such successor Trustee, the Company shall execute any and all instruments in writing for more fully and certainly vesting in and confirming to such successor Trustee all such rights and powers. Any Trustee
ceasing to act shall, nevertheless, retain a lien upon all property or funds held or collected by such Trustee with respect to all or any series as to which it is resigning as Trustee, to secure any amounts and shall be entitled to any indemnities
then due it pursuant to the provisions of Section 8.06. 
 No successor Trustee shall accept appointment as provided in this
Section 8.11 unless at the time of such acceptance such successor Trustee shall be qualified under the provisions of Section 8.08 and eligible under the provisions of Section 8.09. 
 Upon acceptance of appointment by a successor Trustee with respect to all or any series of Debt Securities as provided in this Section 8.11,
the Company shall mail notice of the succession of such Trustee hereunder to the Holders of Debt Securities of such series at their addresses as they shall appear on the Debt Security Register. If the Company fails to mail such notice within ten
days after acceptance of appointment by the successor Trustee, the successor Trustee shall cause such notice to be mailed at the expense of the Company. 
 In case the appointment hereunder of a successor Trustee with respect to the Debt Securities of one or more (but not all) series, the Company, the retiring Trustee and each successor Trustee with respect to the Debt
Securities of any applicable series shall execute and deliver an indenture supplemental hereto which shall contain such provisions as shall be deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the retiring
Trustee with respect to the Debt Securities of any series as to which the retiring Trustee is not retiring shall continue to be vested in the retiring Trustee, and shall add to or change any of the provisions of this Indenture as shall be necessary
to provide for or facilitate the administration of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in such supplemental indenture shall constitute such Trustees co-trustees of the same trust and that each
such Trustee shall be Trustee of a trust or trusts hereunder separate and apart from any trust or trusts hereunder administered by any other such Trustee. 
 SECTION 8.12 Succession by Merger, etc. Subject to Sections 8.08 and 8.09, any Person into which the Trustee may be merged or converted or with which it may be consolidated, or any Person
resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any Person succeeding to the trust business of the Trustee, shall be the successor of the Trustee hereunder without the execution or filing of any paper
or any further act on the part of any of the parties hereto. 
  

 52 

 In case at the time any successor to the Trustee shall succeed to the trusts created by this Indenture
any of the Debt Securities shall have been authenticated but not delivered, any such successor to the Trustee may adopt the certificate of authentication of any predecessor Trustee, and deliver such Debt Securities so authenticated; and in case at
that time any of the Debt Securities shall not have been authenticated, any successor to the Trustee may authenticate such Debt Securities either in the name of such successor Trustee or, if such successor Trustee is a successor by merger,
conversion or consolidation, the name of any predecessor hereunder; and in all such cases such certificate shall have the full force which it is anywhere in the Debt Securities or in this Indenture provided that the certificate of the Trustee shall
have. 
 SECTION 8.13 Limitation on Rights of Trustee as a Creditor. If and when the Trustee shall be or become a creditor of the
Company (or any other obligor upon the Debt Securities), the Trustee shall be subject to the provisions of the Trust Indenture Act of 1939 regarding the collection of claims against the Company (or any such other obligor). 
 SECTION 8.14 Authenticating Agents. There may be an Authenticating Agent or Authenticating Agents appointed by the Trustee from time to time
with power to act on its behalf and subject to its direction in the authentication and delivery of any series of Debt Securities issued upon original issuance, exchange, transfer or redemption thereof as fully to all intents and purposes as though
such Authenticating Agent (or Authenticating Agents) had been expressly authorized to authenticate and deliver such Debt Securities, and Debt Securities so authenticated shall be entitled to the benefits of this Indenture and shall be valid and
obligatory for all purposes as though authenticated by the Trustee hereunder. For all purposes of this Indenture, the authentication and delivery of Debt Securities by any Authenticating Agent pursuant to this Section 8.14 shall be
deemed to be the authentication and delivery of such Debt Securities “by the Trustee”, and whenever this Indenture provides that “the Trustee shall authenticate and deliver” Debt Securities or that Debt Securities “shall
have been authenticated and delivered by the Trustee”, such authentication and delivery by any Authenticating Agent shall be deemed to be authentication and delivery by the Trustee. Any such Authenticating Agent shall at all times be a Person
organized and doing business under the laws of the United States of America or of any State or Territory or the District of Columbia, with a combined capital and surplus of at least $50,000,000 and authorized under such laws to act as an
authenticating agent, duly registered to act as such, if and to the extent required by applicable law and subject to supervision or examination by Federal or State authority. If such Person publishes reports of its condition at least annually
pursuant to law or the requirements of such authority, then for the purposes of this Section 8.14 the combined capital and surplus of such Person shall be deemed to be its combined capital and surplus as set forth in its most recent
report of condition so published. If at any time an Authenticating Agent shall cease to be eligible in accordance with the provisions of this Section 8.14, or to be duly registered if and to the extent required by applicable law and
regulations, it shall resign immediately in the manner and with the effect herein specified in this Section 8.14. 
 Whenever
reference is made in this Indenture to the authentication and delivery of Debt Securities of any series by the Trustee or the Trustee’s certificate of authentication, such 

  

 53 

 
reference shall be deemed to include authentication and delivery on behalf of the Trustee by its Authenticating Agent appointed with respect to the Debt
Securities of such series and a certificate of authentication executed on behalf of the Trustee by its Authenticating Agent appointed with respect to the Debt Securities of such series. 
 Any Person into which any Authenticating Agent may be merged or converted or with which it may be consolidated, or any Person resulting from any merger,
consolidation or conversion to which any Authenticating Agent shall be a party, or any Person succeeding to the authenticating agency business of any Authenticating Agent, shall be the successor of such Authenticating Agent hereunder, if such
successor Person is otherwise eligible under this Section 8.14, without the execution or filing of any paper or any further act on the part of the parties hereto or such Authenticating Agent or such successor Person. 
 In case at the time such successor to any such agency shall succeed to such agency any of the Debt Securities shall have been authenticated but not
delivered, any such successor to such Authenticating Agent may adopt the certificate of authentication of any predecessor Authenticating Agent and deliver such Debt Securities so authenticated; and in case at that time any of the Debt Securities
shall not have been authenticated, any successor to any Authenticating Agent may authenticate such Debt Securities either in the name of any predecessor hereunder or in the name of the successor Authenticating Agent; and in all cases such
certificate shall have the full force which it has anywhere in the Debt Securities or in this Indenture provided that the certificate of the predecessor Authenticating Agent shall have had such force; provided, however, that the right to
adopt the certificate of authentication of any predecessor Authenticating Agent or to authenticate Debt Securities in the name of any predecessor Authenticating Agent shall apply only to its successor or successors by merger, conversion or
consolidation. 
 Any Authenticating Agent may at any time resign as Authenticating Agent with respect to any series of Debt Securities by
giving written notice of resignation to the Trustee and to the Company. The Trustee may at any time terminate the agency of any Authenticating Agent with respect to any series of Debt Securities by giving written notice of termination to such
Authenticating Agent and to the Company. Upon receiving such a notice of resignation or upon such a termination, or in case at any time Authenticating Agent shall cease to be eligible under this Section 8.14, the Trustee may, and shall,
upon written request of the Company, promptly use its best efforts to appoint a successor Authenticating Agent. 
 Upon the appointment, at
any time after the original issuance of any of the Debt Securities, of any successor, additional or new Authenticating Agent, the Trustee shall give written notice of such appointment to the Company and shall at the expense of the Company mail
notice of such appointment to all Holders of Debt Securities of such series as the names and addresses of such Holders appear on the Debt Security Register. 
 Any successor Authenticating Agent with respect to any series of Debt Securities upon acceptance of its appointment hereunder shall become vested with all the rights, powers 

  

 54 

 
and duties of its predecessor hereunder, with like effect as though originally named as an Authenticating Agent herein with respect to such series. No
successor Authenticating Agent shall be appointed unless eligible under the provisions of this Section 8.14 and duly registered if and to the extent required under applicable law and regulations. 
 Any Authenticating Agent by the acceptance of its appointment with respect to any series of Debt Securities shall be deemed to have agreed with the
Trustee that: it will perform and carry out the duties of an Authenticating Agent as herein set forth with respect to such series, including among other things the duties to authenticate and deliver Debt Securities when presented to it in connection
with exchanges, registrations of transfer or redemptions thereof; it will keep and maintain, and furnish to the Trustee from time to time as requested by the Trustee appropriate records of all transactions carried out by it as Authenticating Agent
and will furnish the Trustee such other information and reports as the Trustee may reasonably require; it is eligible for appointment as Authenticating Agent under this Section 8.14 and will notify the Trustee promptly if it shall cease
to be so qualified; and it will indemnify the Trustee against any loss, liability or expense incurred by the Trustee and will defend any claim asserted against the Trustee by reason of any acts or failures to act of the Authenticating Agent with
respect to such series but it shall have no liability for any action taken by it at the specific written direction of the Trustee. 
 The
Company agrees to pay to each Authenticating Agent from time to time reasonable compensation and expenses for its services, and the Trustee shall have no liability for such payments. 
 The provisions of Sections 8.02(a), (b), (c), (e) and (f), 8.03, 8.04, 8.06 (insofar as it
pertains to indemnification), 9.01, 9.02 and 9.03 shall bind and inure to the benefit of each Authenticating Agent to the same extent that they bind and inure to the benefit of the Trustee. 
  

 55 

 If an appointment with respect to one or more series is made pursuant to this Section 8.14,
the Debt Securities of such series may have endorsed thereon, in addition to the Trustee’s certificate of authentication, an alternate certificate of authentication in the following form: 
 This is one of the Debt Securities of the series designated herein issued under the within-mentioned Indenture. 
  

											
	[                                       
                             ], as Trustee	  		 	[                                       
                             ], as Trustee
	  
 By:
	 	  
	  	 	By:	 	  

		 	Authorized Signatory	  	 		 	as Authenticating Agent
		 		  	OR	 		 		 	
						
	Dated:	 		  		 		 	By:	 	  

		 		  		 		 		 	Authorized Signatory
						
		 		  		 		 	Dated:	 	

 ARTICLE NINE. CONCERNING THE HOLDERS 
 SECTION 9.01 Action by Holders. Whenever in this Indenture it is provided that the Holders of a specified percentage in aggregate principal
amount of the Debt Securities of any series may take any action (including the making of any demand or request, the giving of any notice, consent or waiver or the taking of any other action) the fact that at the time of taking any such action the
Holders of such specified percentage of such series have joined therein may be evidenced (a) by any instrument or any number of instruments of similar tenor executed by Holders of such series in person or by agent or proxy appointed in writing,
or (b) by the record of the Holders of such series voting in favor thereof at any meeting of such Holders duly called and held in accordance with the provisions of Article Ten, or (c) by a combination of such instrument or
instruments and any such record of such a meeting of Holders of such series. 
 SECTION 9.02 Proof of Execution by Holders.
Subject to the provisions of Sections 8.01, 8.02 and 10.05, proof of the execution of any instrument by a Holder or such Holder’s agent or proxy shall be sufficient if made in accordance with such reasonable rules and
regulations as may be prescribed by the Trustee or in such manner as shall be satisfactory to the Trustee. The ownership of Debt Securities shall be provided by the Debt Security Register or by a certificate of the Debt Security registrar with
respect to a series of Debt Securities. The record of any Holders’ meeting shall be proved in the manner provided in Section 10.06. 
 SECTION 9.03 Who Are Deemed Absolute Owners. The Company, the Trustee with respect to a series of Debt Securities, and any agent of the Trustee or the Company under this Indenture may deem the Person in
whose name such Debt Security shall be registered upon the Debt Security Register to be, and may treat such Person as, the absolute owner of such Debt Security (whether or not such Debt Security shall be overdue and notwithstanding any notation of
ownership or other writing thereon made by anyone other than the Company, the Trustee or any such agent) for the purpose of receiving payment of or on account of the principal of and premium, if any, and interest on such Debt Security and for all
other purposes; and neither the 

  

 56 

 
Company nor the Trustee nor any such agent shall be affected by any notice to the contrary. All such payments so made to any Holder for the time being or
upon such Holder’s order shall, to the extent of the sum or sums so paid, be effectual to satisfy and discharge the liability for moneys payable upon any such Debt Security. 
 SECTION 9.04 Company-Owned Debt Securities Disregarded. In determining whether the Holders of the requisite aggregate principal amount of
Debt Securities of any series have concurred in any direction or consent under this Indenture, Debt Securities of such series which are owned by the Company or any other obligor on the Debt Securities of such series or by any Person directly or
indirectly controlling or controlled by or under direct or indirect common control with the Company or any other obligor on such Debt Securities shall be disregarded and deemed not to be Outstanding for the purpose of any such determinations;
provided, however, that for the purposes of determining whether the Trustee shall be protected in relying on any such direction or consent only such Debt Securities which the Trustee knows are so owned shall be so disregarded. Debt Securities
so owned which have been pledged in good faith may be regarded as Outstanding notwithstanding this Section 9.04 if the pledgee shall establish to the satisfaction of the Trustee the right of the pledgee to vote such Debt Securities and
that the pledgee is not a Person directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any such other obligor. Upon request of the Trustee, the Company shall furnish to the Trustee
promptly an Officers’ Certificate listing and identifying all Debt Securities of a series, if any, known by the Company to be owned or held by or for the account of the Company or any other obligor on such Debt Securities or by any Person
directly or indirectly controlling or controlled by or under direct or indirect common control with the Company or any other obligor on such Debt Securities; and, subject to the provisions of Section 8.01, the Trustee shall be entitled
to accept such Officers’ Certificates as conclusive evidence of the facts therein set forth and of the fact that all such Debt Securities not listed therein are Outstanding for the purpose of any such determination. 
 SECTION 9.05 Revocation of Consents; Future Holders Bound. At any time prior to (but not after) the evidencing to the Trustee, as provided in
Section 9.01, of the taking of any action by the Holders of the percentage in aggregate principal amount of the Debt Securities of any series specified in this Indenture in connection with such action, any Holder of a Debt Security which
is shown by the evidence to be included in the Debt Securities the Holders of which have consented to or are bound by consents to such action, may, by filing written notice with the Trustee at the Corporate Trust Office and upon proof of holding as
provided in Section 9.02, revoke such action so far as concerns such Debt Security. Except as aforesaid any such action taken by the Holder of any Debt Security shall be conclusive and binding upon such Holder and upon all future Holders
and owners of such Debt Security and of any Debt Security issued on transfer thereof or in exchange or substitution therefor, irrespective of whether or not any notation in regard thereto is made upon any such Debt Security. Any action taken by the
Holders of the percentage in aggregate principal amount of the Debt Securities specified in this Indenture in connection with such action shall be conclusively binding upon the Company, the Trustee and the Holders of all of the Debt Securities
affected by such action. 
  

 57 

 ARTICLE TEN. HOLDERS’ MEETINGS 
 SECTION 10.01 Purposes of Meetings. A meeting of Holders of the Debt Securities of all or any series may be called at any time and from time
to time pursuant to the provisions of this Article Ten for any of the following purposes: 
 (a) to give any notice to the
Company or to the Trustee with respect to such series, or to give any directions to the Trustee, or to consent to the waiving of any default hereunder and its consequences, or to take any other action authorized to be taken by Holders pursuant to
any of the provisions of Article Seven; 
 (b) to remove the Trustee and nominate a successor trustee pursuant to
the provisions of Article Eight; 
 (c) to consent to the execution of an indenture or indentures supplemental
hereto pursuant to the provisions of Section 11.02; or 
 (d) to take any other action authorized to be taken by
or on behalf of the Holders of any specified aggregate principal amount of the Debt Securities of all or any series, as the case may be, under any other provision of this Indenture or under applicable law. 
 SECTION 10.02 Call of Meetings by Trustee. The Trustee may at any time call a meeting of Holders of Debt Securities of all or any series to
take any action specified in Section 10.01, to be held at such time and at such place as the Trustee shall determine. Notice of every meeting of the Holders of Debt Securities of all or any series, setting forth the time and place of
such meeting and in general terms the action proposed to be taken at such meeting, shall be mailed by the Trustee to Holders of Debt Securities of each series that may be affected by the action proposed to be taken at such meeting at their addresses
as they shall appear on the Debt Security Register. Such notice shall be mailed not less than 20 nor more than 90 days prior to the date fixed for the meeting. 
 SECTION 10.03 Call of Meetings by Company or Holders. In case at any time the Company, pursuant to a resolution by the Board of Directors, or the Holders of at least 10% in aggregate principal amount of
the Debt Securities then Outstanding of each series that may be affected by the action proposed to be taken shall have requested the Trustee to call a meeting of such Holders, by written request setting forth in reasonable detail the action proposed
to be taken at the meeting, and the Trustee shall not have mailed the notice of such meeting within 20 days after receipt of such request, then the Company or such Holders may determine the time and place for such meeting and may call such meeting
to take any action authorized in Section 10.01, by mailing notice thereof as provided in Section 10.02. 
 SECTION 10.04 Qualifications for Voting. To be entitled to vote at any meeting of Holders of Debt Securities a person shall (a) be a Holder of one or more Debt Securities of a series affected by the action proposed to be
taken or (b) be a Person appointed by an instrument 

  

 58 

 
in writing as proxy by a Holder of one or more such Debt Securities. The rights of Holders of Debt Securities to have their votes counted shall be subject to
the provisions in the definition of “Outstanding” in Section 1.01. The only Persons who shall be entitled to be present or to speak at any meeting of Holders of Debt Securities shall be the Persons entitled to vote at such
meeting and their counsel, any representatives of the Trustee and its counsel and any representatives of the Company and its counsel. 
 SECTION 10.05 Regulations. Notwithstanding any other provisions of this Indenture, the Trustee may make such reasonable regulations as it may deem advisable for any meeting of Holders of Debt Securities, in regard to proof of
the holding of Debt Securities and of the appointment of proxies, and in regard to the appointment and duties of inspectors of votes, the submission and examination of proxies, certificates and other evidence of the right to vote, and such other
matters concerning the conduct of the meeting as it shall think fit. Except as otherwise permitted or required by any such regulation, the holding of Debt Securities shall be proved in the manner specified in Section 9.02 and the
appointment of any proxy shall be proved in the manner specified in said Section 9.02 or by having the signature of the Person executing the proxy witnessed or guaranteed by any bank, broker or trust company. 
 The Trustee shall, by an instrument in writing, appoint a temporary chairman of the meeting, unless the meeting shall have been called by the Company or
by Holders of Debt Securities as provided in Section 10.03, in which case the Company or the Holders of Debt Securities calling the meeting, as the case may be, shall in like manner appoint a temporary chairman. A permanent chairman and
a secretary of the meeting shall be elected by vote of the Holders of a majority in aggregate principal amount of the Debt Securities represented at the meeting and entitled to vote. 
 Subject to the provisions of Section 9.04, at any meeting each Holder of a Debt Security of a series entitled to vote at such meeting or
proxy shall be entitled to one vote for each $1,000 principal amount of Debt Securities of such series held or represented by such Holder; provided, however, that no vote shall be cast or counted at any meeting in respect of any Debt Security
challenged as not Outstanding and ruled by the chairman of the meeting to be not Outstanding. The chairman of the meeting shall have no right to vote except as a Holder of Debt Securities of such series or proxy therefor. Any meeting of Holders of
Debt Securities duly called pursuant to the provisions of Section 10.02 or 10.03 may be adjourned from time to time and the meeting may be held as so adjourned without further notice. 
 At any meeting of Holders of Debt Securities, the presence of Persons holding or representing Debt Securities in an aggregate principal amount
sufficient to take action upon the business for the transaction of which such meeting was called shall be necessary to constitute a quorum; but, if less than quorum be present, the Persons holding or representing a majority of the Debt Securities
represented at the meeting may adjourn such meeting with the same effect, for all intents and purposes, as though a quorum had been present. 
  

 59 

 SECTION 10.06 Voting. The vote upon any resolution submitted to any meeting of Holders of
Debt Securities shall be by written ballots on which shall be subscribed the signatures of the Holders of Debt Securities entitled to vote at such meeting or of their representatives by proxy, and the letter or letters, serial number or numbers or
other distinguishing marks of the Debt Securities held or represented by each such Holder. The permanent chairman of the meeting shall appoint two inspectors of votes who shall count all votes cast at the meeting for or against any resolution and
who shall make and file with the secretary of the meeting their verified written reports in duplicate of all votes cast at the meeting. A record in duplicate of the proceedings of each meeting of Holders of Debt Securities shall be prepared by the
secretary of the meeting and there shall be attached to said record the original reports of the inspectors of votes on any vote by ballot taken thereat and affidavits by one or more persons having knowledge of the facts setting forth a copy of the
notice of the meeting and showing that said notice was mailed as provided in Section 10.02. The record shall be signed and verified by the affidavits of the permanent chairman and secretary of the meeting and one of the duplicates shall
be delivered to the Company and the other to the Trustee to be preserved by the Trustee, the latter to have attached thereto the ballots voted at the meeting. Any record so signed and verified shall be conclusive evidence of the matters therein
stated. 
 SECTION 10.07 No Delay of Rights by Meeting. Nothing in this Article Ten contained shall be deemed or
construed to authorize or permit, by reason of any call of a meeting of Holders of Debt Securities of any or all series or any rights expressly or impliedly conferred hereunder to make such call, any hindrance or delay in the exercise of any right
or rights conferred upon or reserved to the Trustee or to the Holders of Debt Securities under any of the provisions of this Indenture or of the Debt Securities. 
 ARTICLE ELEVEN. SUPPLEMENTAL INDENTURES 
 SECTION 11.01 Supplemental Indentures without
Consent of Holders. The Company, when authorized by a Board Resolution, and the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto (which shall conform to the provisions of the Trust Indenture
Act of 1939 as in force at the date of the execution thereof) for one or more of the following purposes: 
 (a) to evidence
the succession of another Person to the Company, or successive successions, and the assumption by the successor Person of the covenants, agreements and obligations of the Company pursuant to Articles Five and Twelve hereof;

 (b) to add to the covenants of the Company such further covenants, restrictions, conditions or provisions as the Board of
Directors shall consider to be for the protection of the Holders of Debt Securities of any or all series, and to make the occurrence, or the occurrence and continuance, of a default in any of such additional covenants, restrictions, conditions or
provisions a default or an Event of Default with respect to such series permitting the enforcement of all or any of the several remedies provided in this Indenture as herein set forth; provided, however, that in respect of any such additional

  

 60 

 
covenant, restriction or condition, such supplemental indenture may provide for a particular period of grace after default (which period may be shorter or
longer than that allowed in the case of other defaults) or may provide for an immediate enforcement upon such default or may limit the remedies available to the Trustee upon such default; 
 (c) to cure any ambiguity or to correct or supplement any provision contained herein or in any supplemental indenture which may be
defective or inconsistent with any other provision contained herein or in any supplemental indenture or to make any changes hereto that are required by law; 
 (d) to secure the Debt Securities of all series in accordance with the provisions of Section 5.05; 
 (e) to convey, transfer, assign, mortgage or pledge any property to or with the Trustee; 
 (f) to make such other provisions in regard to matters or questions arising under this Indenture as shall not adversely affect the
interests of the Holders of the Debt Securities; 
 (g) to evidence and provide for the acceptance of appointment by another
Person as a successor Trustee hereunder with respect to one or more series of Debt Securities and to add to or change any of the provisions of this Indenture as shall be necessary to provide for or facilitate the administration of the trusts
hereunder by more than one Trustee, pursuant to Section 8.11; 
 (h) to modify, amend or supplement this Indenture
in such a manner as to permit the qualification of any indenture supplemental hereto under the Trust Indenture Act of 1939 as then in effect, except that nothing herein contained shall permit or authorize the inclusion in any indenture supplemental
hereto of the provisions referred to in Section 316(a)(2) of the Trust Indenture Act of 1939; 
 (i) to provide for the
issuance under this Indenture of Debt Securities in coupon form (including Debt Securities registrable as to principal only) and to provide for exchangeability of such Debt Securities with Debt Securities of the same series issued hereunder in fully
registered form and to make all appropriate changes for such purpose; 
 (j) to change or eliminate any of the provisions of
this Indenture, provided, however, that any such change or elimination shall become effective only when there is no Debt Security Outstanding of any series created prior to the execution of such supplemental indenture which is entitled to the
benefit of such provision; or 
 (k) to establish any additional form of Debt Security, as permitted by
Section 2.02, and to provide for the issuance of any additional series of Debt Securities, as permitted by Section 3.01, and to set forth the terms thereof. 
  

 61 

 The Trustee is hereby required to join with the Company in the execution of any such supplemental indenture, to make any
further appropriate agreements and stipulations which may be therein contained and to accept the conveyance, transfer, assignment, mortgage or pledge of any property thereunder, but the Trustee shall not be obligated to enter into any such
supplemental indenture which affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise. Any supplemental indenture authorized by the provisions of this Section 11.01 may be executed by the Company and
the Trustee without the consent of the Holders of any of the Debt Securities at the time Outstanding, notwithstanding any of the provisions of Section 11.02. 
 SECTION 11.02 Supplemental Indentures with Consent of Holders. With the consent (evidenced as provided in Section 9.01) of the Holders of greater than 50% in aggregate principal amount of the
Outstanding Debt Securities of each series affected by such supplemental indenture (all such Holders voting as a single class), by act of said Holders delivered to the Company and the Trustee, the Company, when authorized by a Board Resolution, and
the Trustee may from time to time and at any time enter into an indenture or indentures supplemental hereto for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this Indenture or of any
supplemental indenture or of modifying in any manner the rights of the Holders of the Debt Securities of each series under this Indenture; provided, however, that no such supplemental indenture shall, without the consent of the Holders of all
of the Outstanding Debt Securities of each series affected, (i) extend the fixed maturity of any Debt Security of such series, or reduce the rate or extend the time of payment of interest thereon, or reduce the principal amount thereof or any
premium thereon, or make the principal thereof or interest or premium thereon payable in any coin or currency other than that provided in the Debt Securities of such series or (ii) reduce the aforesaid percentage of Debt Securities of a series,
the Holders of which are required to consent (a) to any such supplemental indenture, (b) to rescind and annul a declaration that any Debt Securities of such series are due and payable as a result of the occurrence of an Event of Default,
(c) to waive any past default under the Indenture and its consequences or (d) to waive compliance with Sections 5.02, 5.04 (other than 5.04(a)(1) and (2)) to 5.08, inclusive, or with any
additional covenant, agreement or condition contained in a Board Resolution or Officers’ Certificate establishing such series of Debt Securities, any indenture supplemental hereto applicable to such series or any Debt Security of such series.

 Upon the request of the Company, accompanied by a copy of a Board Resolution certified by its Secretary or Assistant Secretary
authorizing the execution of any such supplemental indenture, and upon the filing with the Trustee of evidence of the consent of Holders of Debt Securities as aforesaid, the Trustee shall join with the Company in the execution of such supplemental
indenture unless such supplemental indenture affects the Trustee’s own rights, duties or immunities under this Indenture or otherwise, in which case the Trustee may in its discretion, but shall not be obligated to, enter into such supplemental
indenture. 
  

 62 

 It shall not be necessary for the consent of the Holders of Debt Securities under this
Section 11.02 to approve the particular form of any proposed supplemental indenture, but it shall be sufficient if such consent shall approve the substance thereof. 
 SECTION 11.03 Effect of Supplemental Indentures. Upon the execution of any supplemental indenture pursuant to the provisions of this
Article Eleven, this Indenture shall be and be deemed to be modified and amended in accordance therewith and the respective rights, limitation of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company
and the Holders of Debt Securities shall thereafter be determined, exercised and enforced hereunder subject in all respects to such modifications and amendments and all the terms and conditions of any such supplemental indenture shall be and be
deemed to be part of the terms and conditions of this Indenture for any and all purposes. 
 SECTION 11.04 Notation on Debt
Securities. Debt Securities authenticated and delivered after the execution of any supplemental indenture pursuant to the provisions of this Article Eleven may bear a notation in form approved by the Trustee as to any matter provided
for in such supplemental indenture. If the Company or the Trustee shall so determine, new Debt Securities of any series so modified as to conform, in the opinion of the Trustee and the Board of Directors to any modification of this Indenture
contained in any such supplemental indenture may be prepared and executed by the Company, authenticated by the Trustee and delivered in exchange for the Outstanding Debt Securities of such series. 
 SECTION 11.05 Evidence of Compliance of Supplemental Indenture to be Furnished Trustee. The Trustee, subject to the provisions of
Sections 8.01 and 8.02, shall receive, and shall be fully protected in relying upon, an Officers’ Certificate and an Opinion of Counsel as conclusive evidence that any supplemental indenture executed pursuant hereto complies
with the requirements of this Article Eleven and is authorized and permitted by this Indenture. 
 ARTICLE TWELVE. CONSOLIDATION, MERGER,
SALE AND CONVEYANCE 
 SECTION 12.01 Company May Consolidate, etc., on Certain Terms. Nothing contained in this Indenture or
in any of the Debt Securities shall prevent any consolidation or merger of the Company with or into any other Person (whether or not affiliated with the Company), or successive consolidations or mergers in which the Company or its successor or
successors shall be a party or parties, or shall prevent any sale, conveyance or lease of all or substantially all of the property of the Company to any other Person (whether or not affiliated with the Company) authorized to acquire and operate the
same; provided, however, and the Company hereby covenants and agrees, that any such consolidation, merger, sale, conveyance (excluding any pledge) or lease shall be upon the condition that (a) immediately after such consolidation,
merger, sale, conveyance or lease the entity (whether the Company or such other Person) formed by or surviving any such consolidation or merger, or to which such sale, conveyance or lease shall have been made, shall not be in default in the
performance or observance of any of the terms, covenants and conditions of this Indenture to be kept or 

  

 63 

 
performed by the Company; (b) the Person (if other than the Company) formed by or surviving any such consolidation or merger or to which such sale,
conveyance or lease shall have been made, shall be a Person organized under the laws of the United States of America or any state thereof; and (c) the due and punctual payment of the principal of and premium, if any, and interest on all of the
Debt Securities, according to their tenor, and the due and punctual performance and observance of all of the covenants and conditions of this Indenture to be performed or observed by the Company, shall be expressly assumed, by supplemental indenture
satisfactory in form to the Trustee, executed and delivered to the Trustee by the Person (if other than the Company) formed by such consolidation, or into which the Company shall have been merged, or by the Person which shall have acquired or leased
such property. 
 SECTION 12.02 Successor Entity to be Substituted. In case of any such consolidation, merger, sale, conveyance
(excluding any pledge) or lease and upon the assumption by the successor Person, by supplemental indenture, executed and delivered to the Trustee and satisfactory in form to the Trustee, of the due and punctual payment of the principal of and
premium, if any, and interest on all of the Debt Securities and the due and punctual performance and observance of all of the covenants and conditions of this Indenture to performed or observed by the Company, such successor Person shall succeed to
and be substituted for the Company, with the same effect as if it had been named herein as the party of the first part, and (except in the event of a conveyance by way of lease) the predecessor entity shall be relieved of any further obligation
under this Indenture and the Debt Securities. Such successor Person thereupon may cause to be signed, and may issue either in its own name or in the name of Harley-Davidson, Inc. any or all of the Debt Securities issuable hereunder which theretofore
shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such successor Person instead of the Company and subject to all the terms, conditions and limitations in this Indenture prescribed, the Trustee shall
authenticate and shall deliver any Debt Securities which previously shall have been signed and delivered by the officers of the Company to the Trustee for authentication, and any Debt Securities which such successor Person thereafter shall cause to
be signed and delivered to the Trustee for that purpose. All the Debt Securities of each series so issued shall in all respects have the same legal rank and benefit under this Indenture as the Debt Securities of such series theretofore or thereafter
issued in accordance with the terms of this Indenture as though all of such Debt Securities had been issued at the date of the execution hereof. In case of any such consolidation, merger, sale, conveyance or lease such changes in phraseology and
form (but not in substance) may be made in the Debt Securities thereafter to be issued as may be appropriate. 
 SECTION 12.03
Opinion of Counsel to Be Given Trustee. The Trustee, subject to Sections 8.01 and 8.02, shall be provided with an Opinion of Counsel as conclusive evidence that any such consolidation, merger, sale or conveyance and any
such assumption complies with the provisions of this Article Twelve and that all conditions precedent herein provided relating to such transactions have been complied with. 
  

 64 

 ARTICLE THIRTEEN. SATISFACTION AND DISCHARGE OF INDENTURE 
 SECTION 13.01 Satisfaction, Discharge and Defeasance of Debt Securities of any Series. The Company shall be deemed to have paid and
discharged the entire indebtedness on all the Debt Securities of a series, the provisions of this Indenture (except as to (x) the rights of Holders of Debt Securities of such series to receive, from the money, in the currency required, and
Government Obligations deposited with the Trustee pursuant to Section 13.02(a) or the interest and principal received by the Trustee in respect of such Government Obligations, payment of the principal of (and premium, if any) and any
installment of principal of (and premium, if any) or interest on such Debt Securities on the Stated Maturities thereof or upon the Redemption Dates for Debt Securities required to be redeemed pursuant to any mandatory sinking fund or analogous
provisions relating to Debt Securities of that series or pursuant to any call for redemption relating to Debt Securities of that series, (y) the Company’s rights and obligations with respect to such Debt Securities under
Sections 3.06, 3.07, 13.03 and 13.04, 5.02, 5.04, 6.01, 8.06, 8.10, 8.11 and, to the extent applicable to such series, Article Four, so long as the principal of (and
premium, if any) and interest on the Debt Securities of such series remain unpaid and, thereafter, only the Company’s rights and obligations under Sections 5.04, 8.06, 13.03 and 13.04, and (z) the rights,
powers, trusts, duties and immunities of the Trustee with respect to the Debt Securities of such series) as it relates to such Debt Securities shall no longer be in effect, and the Trustee, at the expense of the Company, shall, upon Company Request,
execute proper instruments acknowledging the same if: 
 (a) (1) all Debt Securities of such series therefore
authenticated and delivered (other than (i) Debt Securities which have been destroyed, lost or stolen and which have been replaced or paid as provided in Section 3.07 and (ii) Debt Securities for whose payment money has
theretofore been deposited in trust or segregated and held in trust by the Company and thereafter repaid to the Company or discharged from such trust, as provided in Sections 13.03 and 13.04) have been delivered to the Trustee for
cancellation; (2) the Company has paid or caused to be paid in the currency required all other sums payable under this Indenture in respect of the Debt Securities of such series; and (3) the Company has delivered to the Trustee an
Officers’ Certificate, an Opinion of Counsel and a written opinion of independent public accountants, each stating that all conditions precedent herein provided for relating to the satisfaction of the entire indebtedness of all Debt Securities
of any such series and the discharge of the Indenture as it relates to such Debt Securities have been complied with; or 
 (b)
(1) all Debt Securities of such series not theretofore delivered to the Trustee for cancellation (i) have become due and payable, or (ii) will become due and payable at their Stated Maturity within one year, or (iii) are to be
called for redemption within one year under arrangements satisfactory to the Trustee for the giving of notice of redemption by the Trustee in the name, and at the expense of the Company; (2) the condition described in paragraph
(a) of Section 13.02 has been satisfied; and (3) the conditions described in paragraphs (a)(2) and (a)(3) of this Section 13.01 have been satisfied; or 
  

 65 

 (c) (1) the conditions referred to in paragraphs (b)(2) and (b)(3) of
this Section 13.01 have been satisfied; (2) no Event of Default or event which with notice or lapse of time would become an Event of Default shall have occurred and be continuing on the date of the deposit referred to in
paragraph (a) of Section 13.02 or on the ninety-first day after the date of such deposit; provided, however, that should that condition fail to be satisfied on or before such ninety-first day, the Trustee shall
promptly, upon satisfactory receipt of evidence of such failure, return such deposit to the Company; (3) the Company has either (i) delivered to the Trustee an opinion of counsel of a nationally-recognized independent tax counsel to the
effect that Holders of the Debt Securities of such series will not recognize income, gain or loss for Federal income tax purposes as a result of such deposit and the satisfaction, discharge and defeasance contemplated by this
paragraph (c) of this Section 13.01 and will be subject to Federal income tax on the same amounts and in the same manner and at the same times as would have been the case if such deposit and defeasance had not occurred or
(ii) the Company shall have received from, or there shall have been published by, the United States Internal Revenue Service a ruling to the effect stated in subsection (i) of this Section 13.01(c)(3); and (4) the
Company has received an Opinion of Counsel to the effect that the satisfaction, discharge and defeasance contemplated by this Section 13.01 will not result in the delisting of the Debt Securities of that series from any
nationally-recognized securities exchange on which they are listed. 
 SECTION 13.02 Defeasance of Debt Securities of any Series.
The provisions of this Indenture (except as to (x) the rights of Holders of Debt Securities of any series to receive, from the money, in the currency required, and Government Obligations deposited with the Trustee pursuant to
paragraph (a) below or the interest and principal received by the Trustee in respect of such Government Obligations, payment of the principal of (and premium, if any) and any installment of principal of (and premium, if any) or interest
on such Debt Securities on the Stated Maturities thereof or upon the Redemption Dates for Debt Securities required to be redeemed pursuant to any mandatory sinking or analogous provisions relating to Debt Securities of that series or pursuant to any
call for redemption relating to Debt Securities of that series, (y) the Company’s rights and obligations with respect to such Debt Securities under Sections 3.06, 3.07, 13.03, 13.04, Article Seven
(other than subsections (d) and (e) of Section 7.01), Sections 5.01, 5.02, 5.04, 6.01, 8.06, 8.10, 8.11 and, to the extent applicable to such series, Article
Four, so long as the principal of (and premium, if any) and interest on the Debt Securities of such series remain unpaid and, thereafter, only the Company’s rights and obligations under Sections 5.04, 8.06, 13.03
and 13.04, and (z) the rights, powers, trusts, duties and immunities of the Trustee with respect to the Debt Securities of such series) as it relates to Debt Securities of any series shall no longer be in effect, and the Trustee, at the
expense of the Company shall, upon Company Request, execute proper instruments acknowledging the same if: 
 (a) the Company
has deposited or caused to be deposited with the Trustee as trust funds in trust for the purpose (A) the Dollars or Foreign Currency, as applicable, in an amount, or (B) Government Obligations which through the payment of interest and
principal in respect thereof in accordance with their terms will provide on or before the due date of any payment in respect of such series of Debt Securities in an amount, or (C) a 

  

 66 

 
combination thereof, sufficient, after payment of all Federal, state and local taxes in respect thereof payable by the Trustee, in the opinion of a
nationally-recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, to pay and discharge (i) the principal of (and premium, if any) and each installment of principal (and premium,
if any) and interest on the Outstanding Debt Securities of that series on the Stated Maturity of such principal or installment of principal or interest and (ii) any mandatory sinking fund payments or analogous payments or payments pursuant to
any call for redemption applicable to Debt Securities of such series on the day on which such payments are due and payable in accordance with the terms of the Indenture and such Debt Securities; 
 (b) no Event of Default or event which with notice or lapse of time would become an Event of Default shall have occurred and be continuing
on the date of such deposit; 
 (c) the interest of the Holders in such deposit shall have been duly perfected under the
applicable provisions of the Uniform Commercial Code; and 
 (d) the Company has delivered to the Trustee an Officers’
Certificate and an Opinion of Counsel, each stating that all conditions precedent herein provided for relating to the defeasance contemplated by this Section have been complied with. 
 SECTION 13.03 Application of Trust Funds; Indemnification. 
 (a) Subject to the provisions of Section 13.04, all money and Government Obligations deposited with the Trustee pursuant to
Section 13.01 or 13.02 and all money received by the Trustee in respect of Government Obligations deposited with the Trustee, shall be held in trust and applied by it, in accordance with the provisions of the Debt Securities and
this Indenture, to the payment, either directly or through any paying agent (including the Company acting as its own paying agent) as the Trustee may determine, to the Persons entitled thereto, of the principal (and premium, if any) and interest for
whose payment such money and Government Obligations have been deposited with or received by the Trustee as contemplated by Section 13.01 or 13.02. 
 (b) The Company shall pay and shall indemnify the Trustee against any tax, fee or other charge imposed on or assessed against Government
Obligations deposited pursuant to Section 13.01 or 13.02 or the interest and principal received in respect of such obligations, other than any such tax, fee or other charge payable by or on behalf of Holders. The Company shall be
entitled to prompt notice of an assessment or the commencement of any proceeding for which indemnification may be sought hereunder and, at its election, to contest such assessment or to participate in, assume the defense of, or settle such
proceeding. 
 (c) The Trustee shall deliver or pay to the Company from time to time upon Company Request any Government
Obligations or money held by it as provided in 

  

 67 

 
Section 13.01 or 13.02 which, in the opinion of a nationally-recognized firm of independent public accountants expressed in a written
certification thereof delivered to the Trustee, are then in excess of the amount thereof which then would have been required to be deposited for the purpose for which such obligations or money were deposited or received. 
 (d) If the Trustee is unable to apply any money or Government Obligations in accordance with this Section 13.03 by reason of
any legal proceeding or by reason of any order or judgment of any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the Company’s obligations under this Indenture and the Debt Securities, if any,
of such series shall be revived and reinstated as though no deposit had occurred pursuant to Section 13.01 or Section 13.02, as the case may be, until such time as the Trustee is permitted to apply all such money or
Government Obligations in accordance with this Section 13.03; provided, however, that if the Company has made any payment of interest on or principal of (and premium, if any) on any Debt Securities, if any, of such series because
of the reinstatement of its obligations, the Company shall be subrogated to the rights of the Holders of such series of Debt Securities, if any, to receive such payment from the money or Government Obligations held by the Trustee. 
 SECTION 13.04 Return of Unclaimed Moneys. Any moneys deposited with or paid to the Trustee or any paying agent for payment of the principal
of and premium, if any, or interest on Debt Securities and not applied but remaining unclaimed by the Holders of Debt Securities for two years after the date upon which the principal of and premium, if any, or interest on such Debt Securities, as
the case may be, shall have become due and payable, shall be repaid to the Company by the Trustee or such paying agent on written demand; and the Holder of any of the Debt Securities entitled to receive such payment shall thereafter look only to the
Company for any payment thereof. 
 ARTICLE FOURTEEN. IMMUNITY OF INCORPORATORS, STOCKHOLDERS, ETC. 
 SECTION 14.01 Indenture and Debt Securities Solely Obligations of the Company. No recourse under or upon any obligation, covenant or
agreement of this Indenture, any supplemental indenture, or of any Debt Security, or for any claim based thereon or otherwise in respect thereof, shall be had against any incorporator, organizer, stockholder, member, owner, officer, director,
manager or employee, as such, past, present or future, of the Company or any Subsidiary or of any predecessor or successor Person, either directly or through the Company, whether by virtue of any constitution, statute or rule of law, or by the
enforcement of any assessment or penalty or otherwise; it being expressly understood that this Indenture and the obligations issued hereunder are solely obligations of the Company, and that no such personal liability whatever shall attach to, or is
or shall be incurred by, any incorporator, organizer, stockholder, member, owner, officer, director, manager or employee, as such, of the Company or of any predecessor or successor Person, or any of them, because of the creation of the indebtedness
hereby authorized, or under or by reason of the obligations, covenants or agreements contained in this Indenture, or in any of the Debt Securities or implied thereby; and 

  

 68 

 
that any and all such personal liability, either at common law or in equity or by constitution or statute of, and any and all such rights and claims against,
every such incorporator, organizer, stockholder, member, owner, officer, director, manager or employee, as such, because of the creation of the indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements
contained in this Indenture or in any of the Debt Securities or implied thereby, are hereby expressly waived and released as a condition of, and as a consideration for, the execution of this Indenture and the issue of such Debt Securities.

 ARTICLE FIFTEEN. MISCELLANEOUS PROVISIONS 
 SECTION 15.01 Provisions Binding on Successors of the Company. All of the covenants, stipulations, promises and agreements in this Indenture contained by the Company shall bind its successors and assigns
whether so expressed or not. 
 SECTION 15.02 Indenture for Sole Benefit of Parties and Holders of Debt Securities. Nothing in
this Indenture or in the Debt Securities, expressed or implied, shall give or be construed to give to any Person, firm or corporation, other than the parties hereto, any agent of the Trustee or the Company under this Indenture and the Holders of the
Debt Securities, any legal or equitable right, remedy or claim under or in respect of this Indenture, or under any covenant, condition or provision herein contained; all such covenants, conditions and provisions being, subject to the provisions of
Articles Twelve and Fourteen, for the sole benefit of the parties hereto, any agent of the Trustee or the Company under this Indenture and the Holders of the Debt Securities. 
 SECTION 15.03 Addresses for Notices, etc. Any notice or demand which by any provision of this Indenture is required or permitted to be given
or served by the Trustee or by the Holders of Debt Securities on the Company may be given or served by being deposited, registered or certified mail postage prepaid, in a post office letter box in the United States or by facsimile transmission
addressed (until another address is filed by the Company with the Trustee) to the Company, 3700 West Juneau Avenue, Milwaukee, Wisconsin 53208, Attention: Treasurer, facsimile no. (414) 343-4990, with a copy to the Company, 3700 West Juneau
Avenue, Milwaukee, Wisconsin 53208, Attention: General Counsel, facsimile no. (414) 343-4089. Any notice, direction, request or demand by any Holder of a Debt Security or the Company to or upon the Trustee shall be deemed to have been
sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust Office. Any notice, report or other instrument required by any of the provisions of this Indenture to be given by the Trustee to the Holders of Debt
Securities of any or all series shall be deemed to have been sufficiently given, for all purposes, when mailed by first class mail. 
 SECTION 15.04 New York Contract. Pursuant to New York General Obligations Law 5–1401, this Indenture and the Debt Securities shall be governed by and construed in accordance with the laws of the State of New York applicable
to agreements made or instruments entered into and, in each case, performed in such state. 
  

 69 

 SECTION 15.05 Evidence of Compliance with Conditions Precedent. Upon any Company request to
the Trustee to take any action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an Officers’ Certificate stating that all conditions precedent, if any (including any covenant, compliance with which
constitutes a condition precedent) provided for in this Indenture relating to the proposed action have been complied with and an Opinion of Counsel stating that, in the opinion of such counsel, all such conditions precedent have been complied with,
except that in the case of any such application or demand as to which the furnishing of such document is specifically required by any provision of this Indenture relating to such particular application or demand, no additional certificate or opinion
need be furnished. 
 Each certificate or opinion provided for in this Indenture and delivered to the Trustee with respect to compliance
with a condition or covenant provided for in this Indenture shall include (1) a statement that the Person making such certificate or opinion has read such covenant or condition; (2) a brief statement as to the nature and scope of the
examination or investigation upon which the statements or opinions contained in such certificate or opinion are based; (3) a statement that, in the opinion of such Person, such Person has made such examination or investigation as is necessary
to enable such Person to express an informed opinion as to whether or not such covenant or condition has been complied with; and (4) a statement as to whether or not, in the opinion of such Person, such condition or covenant has been complied
with. 
 SECTION 15.06 Legal Holidays. In any case where the date of maturity of interest on or principal of or premium, if any,
on any series of Debt Securities or the date fixed for redemption of any Debt Security or Debt Securities will be a legal holiday or a day on which banking institutions are legally authorized or obligated to close in New York or any other location
where a paying agent appointed pursuant to Section 5.02 is located, then payment of such interest on or principal of and premium, if any, on such Debt Securities need not be made by such paying agent on such date but may be made by such
paying agent on the next succeeding business day that is not a day in such location that is either a legal holiday or a day on which banking institutions are legally authorized or obligated to close, with the same force and effect as if made on such
date of maturity or the date fixed for redemption and no interest shall accrue for the period from and after such prior date. 
 SECTION 15.07 Trust Indenture Act of 1939 to Control. If any provision hereof limits, qualifies or conflicts with the duties imposed by any of Sections 310 through 317 of the Trust Indenture Act of 1939, by the operation of
Section 318(c) thereof, such imposed duties shall control, except as, and to the extent, expressly excluded from this Indenture, as permitted by the Trust Indenture Act of 1939. If any provision of this Indenture modifies or excludes any
provision of the Trust Indenture Act of 1939 that may be so modified or excluded, the latter provision shall be deemed to apply to this Indenture as so modified or to be excluded, as the case may be. 
  

 70 

 SECTION 15.08 Table of Contents, Headings, etc. The table of contents and the titles and
headings of the articles and sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way modify or restrict any of the terms or provisions hereof. 
 SECTION 15.09 Determination of Principal Amount. In determining whether the Holders of the requisite principal amount of Outstanding Debt
Securities of any series have given any request, demand, authorization, direction, notice, consent or waiver hereunder, or whether sufficient funds are available for redemption or for any other purpose, (i) the principal amount of an Original
Issue Discount Debt Security that shall be deemed to be Outstanding for such purposes shall be the amount of the principal thereof that would be due and payable as of the date of such determination upon a declaration of acceleration of the maturity
thereof pursuant to Section 7.01, (ii) the principal amount of any Debt Securities denominated in a Foreign Currency that shall be deemed to be Outstanding for such purposes shall be determined by converting the Foreign Currency
into Dollars at the Market Exchange Rate as of the date of such determination and (iii) the principal amount of any Indexed Debt Security that shall be deemed to be Outstanding for such purposes shall be the amount of the principal face amount
of such Indexed Debt Security at original issuance, unless otherwise provided in or pursuant to this Indenture. 
 SECTION 15.10
Execution in Counterparts. This Indenture may be executed in any number of counterparts, each of which shall be an original and such counterparts shall together constitute but one and the same instrument.
[                    ] hereby accepts the trusts in this Indenture declared and provided, upon the terms and conditions hereinabove set forth.

 SECTION 15.11 Waiver of Jury Trial. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT
PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE OR THE DEBT SECURITIES. 
 SECTION 15.12 Force Majeure. In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or
indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or
malfunctions of utilities, communications or computer (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as
soon as practicable under the circumstances. 
 [Remainder of Page Intentionally Left Blank] 
  

 71 

 IN WITNESS WHEREOF, the undersigned have executed this Indenture as of the date first set forth above.

  

			
	HARLEY-DAVIDSON, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	[                                       
                             ]
		
	By:	 	  

	Name:	 	
	Title:	 	

 Signature Page to Indenture

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00150-of-00352.parquet"}]]